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ABSTRACT 
 
INJECTABLE HYDROGELS FOR LOCAL PROTEIN DELIVERY TO ENGINEER 
MYOCARDIAL REMODELING 
 
Brendan P. Purcell 
Jason A. Burdick, PhD 
 
 The endogenous tissue remodeling events that occur following a 
myocardial infarction (MI) are inadequate to maintain left ventricular (LV) 
function, and the progression towards heart failure is often inevitable.  Our 
increased understanding of protein regulators of post MI remodeling provides the 
opportunity to intervene and engineer tissue remodeling through exogenous 
protein delivery.  The global hypothesis of this dissertation was that the local 
delivery of therapeutic proteins (SDF-1! and TIMP-3) from injectable hyaluronic 
acid (HA) hydrogels attenuates adverse post MI remodeling processes by 
providing sustained concentrations of bioactive signals within the remodeling 
myocardium. 
 To test this hypothesis, HA based hydrogels were designed with 
crosslinking chemistries to allow hydrogel formation and protein encapsulation in 
situ upon injection through a syringe, negatively charged polymer backbones to 
bind encapsulated proteins through electrostatic interactions and sustain protein 
release, and degradable crosslinks to release proteins in a controlled fashion.  
Using these injectable hydrogel systems, adverse post MI remodeling events 
were attenuated following experimental MI in animals by enhancing endogenous 
cell homing to the myocardium through SDF-1! delivery and inhibiting matrix 
metalloproteinase activity through TIMP-3 delivery.   
Our results demonstrate the utility of implantable biomaterials to localize 
and sustain biological signals to engineer tissue remodeling processes, and 
provide insight into novel biological therapeutics to treat LV remodeling following 
MI. 
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CHAPTER 1 
 
Introduction 
 
1.1. Significance 
The loss of functional tissue following a myocardial infarction (MI) is 
detrimental to heart function. Over 3 million people in the United States currently 
suffer from heart failure caused by MI1 and more than 1 million MIs occur each 
year2.   These troubling statistics amount to an economic burden of over $30 
billion in the United States2.  Current clinical treatments for MI include coronary 
stents and bypass surgeries to overcome the blocked artery and reperfuse the 
ischemic tissue.  In addition, current pharmacological treatments lessen the 
workload of the injured heart.  While these treatments delay the onset of heart 
failure following MI, they do little to alter the tissue remodeling process initiated 
after coronary artery occlusion.  The changes in myocardial tissue structure 
during post MI remodeling cause global changes to left ventricle (LV) geometry, 
compromise LV function, and lead to the progression of heart failure. 
Unfortunately, whole organ-transplants remain the only current treatment for 
patients with end-stage heart failure, and these are severely limited by the low 
number of donor hearts. 
 
1.2. Post MI remodeling 
An MI occurs when arterial blood flow to the myocardium is interrupted, 
typically by a ruptured atherosclerotic plaque in the coronary arteries. The lack of 
oxygen supply (hypoxia) to the highly aerobic myocardium following coronary 
artery occlusion induces the expression of proteins active in tissue remodeling.  
These include surface adhesion molecules and soluble factors that activate the 
coronary endothelium and signal the infiltration of endogenous cells3-6.  Within 
the first few hours post MI, neutrophils accumulate in the ischemic myocardium 
and release ROS and proteolytic enzymes that damage both vasculature and 
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parenchymal cells in the myocardium6-9. In addition, marrow derived monocytes 
infiltrate the myocardium and differentiate into macrophages upon adherence to 
the damaged ECM10, 11.  These matured macrophages phagocytize necrotic 
cells, provide a major source of proteases, and secrete growth factors to activate 
fibroblast proliferation10.  Proliferating fibroblasts within the MI region also 
express a number of proteins and proteolytic enzymes that contribute to tissue 
remodeling12-15.  Together, proteins expressed from both recruited cells and cells 
native to the myocardium orchestrate the post MI remodeling process that occurs 
locally in the MI region of the myocardium.  While there are potentially hundreds 
of proteins that contribute to tissue remodeling post MI, the following two sections 
will highlight two families of proteins that are particularly important post MI and 
the focus of the research that follows. 
 
1.3. Matrix metalloproteinases (MMPs) 
The abundance of protease activity in the setting of MI contributes to ECM 
degradation, instability in the MI region, and myocardial expansion.  A family of 
proteolytic enzymes that contribute to MI expansion are the MMPs16, 17.  MMPs 
hydrolyze peptide bonds with a high level of amino acid specificity and regulation.  
Under normal physiological conditions, MMP activity is precisely controlled to 
maintain a low level of structural protein, cell receptor, and growth factor 
turnover.  However, following a stimulus such as an injury, there is a loss of 
control over MMP activity which causes maladaptive changes to tissue 
architectures and functions, often resulting in the progression of disease18.  For 
example, MMP dysregulation has been observed in patients during post MI 
remodeling and heart failure19, 20.  Specifically, MMP expression was upregulated 
following MI, while the expression of endogenous tissue inhibitors of MMPs 
(TIMPs) was not.  Subsequent clinical studies quantified MMP/TIMP levels in the 
circulation and found that plasma levels of MMPs increased following MI without 
a concomitant increase in plasma TIMPs.  In particular, plasma TIMP-3 levels 
significantly decreased in the early post MI period, at a time when maximal MMP 
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induction and release was occurring 21-26.  This prolonged MMP/TIMP 
dysregulation was correlated with myocardial expansion in patients following MI.  
Further, regional MMP/TIMP expression has been quantified in the myocardium 
following experimental MI in pigs27, 28,17,29-31.  LV samples were harvested 8 
weeks following induced MI, and immunoblotting revealed a significant induction 
of the representative classes of MMPs whereas the relative levels of the 4 TIMPs 
(TIMP-1,2,3,4) were decreased or remained the same following MI.  Further, to 
quantify MMP activity within the remote, border and MI regions, a fluorogenic-
microdialysis assay was developed and revealed that induction of MMP activity is 
highly localized to the MI region29-31. 
 
1.4. Stromal cell-derived factor-1 alpha (SDF-1!)  
 SDF-1! chemokine mediates steady state homing of progenitor cells to 
the bone marrow by binding to the CXCR4 receptor, but is also expressed by 
endothelial cells in ischemic tissue through activation of hypoxia inducible 
transcription factors32, 33.  SDF-1! expression is upregulated in the myocardium 
during the first few days following MI, but is quickly downregulated34-36.  Separate 
studies have shown a concomitant increase in CXCR4+ circulating cells during 
the first few days following MI suggesting that these cells are mobilized and 
respond to the myocardial SDF-1! homing signal37-39.  In addition, the mobilized 
CXCR4+ cells express cardiac specific markers suggesting that the SDF-
1!/CXCR4 homing axis contributes to myocardial repair following MI37-40.  The 
importance of this homing axis in post MI remodeling was shown by systemic 
administration of a pharmacological CXCR4 antagonist41.  A single dose of the 
antagonist following MI increased progenitor cell numbers in the circulation and 
in the heart, promoted myocardial vascularity, reduced fibrosis, and improved 
cardiac function and survival.  Continuous antagonist infusion increased 
circulating progenitor cell numbers, but blocked their engraftment in the 
myocardium, leading to worsened outcomes.  Therefore, enhancing endogenous 
cell homing involves both mobilizing cells from their native niche and sustaining 
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local signals to promote their engraftment in the myocardium.  Sustaining SDF-
1! levels in the myocardium through exogenous delivery of recombinant SDF-1! 
has been shown to increase myocardial c-kit+ and CXCR4+ progenitor cells 
densities, increased vascular structures and improved cardiac function36, 42, 43.  
 
1.5. Engineered proteins 
Collectively, endogenous protein expression following MI is inadequate to 
prevent maladaptive changes to myocardial tissue structure, which ultimately 
cause a gradual loss of LV function.  However, our increased understanding of 
these protein regulators provides an opportunity to intervene and engineer tissue 
remodeling through exogenous delivery of protein based therapeutics.  Delivery 
of proteins over small pharmaceutical drugs has several advantages including 
the highly specific functions of proteins that cannot be mimicked by chemical 
compounds, and the well-tolerated immunological response to proteins because 
of their natural amino acid composition44.  In addition, advances in genetic 
engineering and chemical ligation technologies have allowed for large-scale 
production of proteins for therapeutic use.   
Recombinant proteins are produced by isolating a human gene for the 
protein of interest, then expressing the gene in a cell culture platform using 
recombinant DNA technology45.  A variety of cell types have been used for 
recombinant protein production including bacteria, yeast, insect cells, and 
mammalian cells46-48.  In addition, transgenic animals and plants have been used 
for recombinant protein production.  This technique has proven to be a powerful 
way to produce many of the thousands of sequenced human proteins in large 
quantities, as primary sources of human tissues are limited.  In addition, while 
protein sequences are often conserved between species, isolation of proteins for 
therapeutic use from animal sources can be problematic.  Tissue extraction and 
purification processes are difficult and costly, and the purified product still carries 
the risk of disease and immunological rejection in humans44.  While more efficient 
and less expensive than extraction of proteins from tissues, recombinant proteins 
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for therapeutic use are still very expensive, with estimates up to $100,000 per 
patient per year for some disease treatments49.   
As an alternative to cell-based protein production, where the cell is used 
as a factory to synthesize proteins with its innate machinery, chemical synthesis 
technologies have been developed to produce proteins through purely synthetic 
routes50.  For example, solid-phase peptide synthesis (SPPS) grows a 
polypeptide chain from a functionalized polymer resin by utilizing protecting 
groups to couple amino acids from C to N terminus, one at a time.  The N-
terminal amine of the growing polypeptide chain is deprotected and then reacted 
with the activated carboxylic acid of an N-protected amino acid.  The coupling 
reactions are forced to completion by using an excess of activated soluble amino 
acid to improve yield of the final polypeptide chain.  The solid-phase is then 
washed of excess amino aicds and the coupling reaction repeated for 
subsequent amino acids.  Following completion of polypeptide synthesis, the 
polypeptide is cleaved from the polymer solid-phase and isolated for use.  SPPS 
is typically limited to proteins that are shorter than approximately 30kDa.  SPPS 
synthesis can proceed rapidly in an automated fashion, and produces large 
yields of purified product50.  Longer proteins can be achieved using chemical 
ligation techniques to couple two SPPS synthesized proteins together51.  One 
major advantage to SPPS over recombinant technologies is the ease with which 
proteins of almost any desired sequence can be generated.  SPPS is commonly 
used to generate minimal peptide sequences designed from protein active sites 
in order to study protein interactions or to provide simpler mimics of the full-
length protein for therapeutic use.  
 
1.6. Limitations of protein therapeutics  
 These advances in protein engineering have led to more than 130 peptide 
or protein drugs approved for clinical use by the US Food and Drug 
Administration (FDA), and many more are in development44.  While proteins 
continue to be a major focus of drug development efforts, significant challenges 
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remain in maximizing their efficacy towards treating disease.  Specifically, short 
half-lives and rapid clearance of systemically delivered proteins require frequent 
dosage to maintain protein concentrations within the therapeutic window to 
effectively treat the patient.  In addition, diseases local to a specific organ (e.g., 
MI) present a challenge to provide physiologic concentrations of the protein in the 
organ, while limiting systemic actions of the protein.   One attractive way to 
overcome these challenges is the use of a device that encapsulates proteins and 
protects them from degradation and rapid clearance, while releasing physiologic 
protein concentrations locally, and in a sustained fashion.  
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CHAPTER 2 
 
Research Overview 
 
2.1. Objectives 
 As discussed in the Introduction to this dissertation (Chapter 1), there is a 
pressing need for treatment strategies that attenuate adverse left ventricular (LV) 
remodeling following myocardial infarction (MI).  Injectable hydrogels are 
developing as a unique therapeutic platform to treat patients with MI, through a 
range of both biochemical and biomechanical signaling.  Additionally,  
recombinant and chemically synthesized proteins offer an attractive source of 
biological therapeutics to modulate post MI tissue remodeling processes; 
however, their short half-lives in blood plasma and ubiquitous involvement in 
normal biological processes throughout the body make continuous, systemic 
delivery of the drugs problematic.   
 With this in mind, the goal of my dissertation work has been to develop 
hydrogels that can be injected onto or into the myocardium to encapsulate and 
sustain the release of protein therapeutics locally following MI.  Generally, 
injectable hydrogel systems were designed using a hyaluronic acid (HA) 
backbone to mimic a hydrated tissue-like environment.  These HA-based 
hydrogels were engineered for (1) injectability through formation of covalent 
bonds on or within myocardial tissue, (2) controlled degradation through either 
hydrolytic or enzymatic means, and (3) interactions with proteins through charge 
association, all features to alter the local release and presentation of 
therapeutics.  More specifically, HA hydrogels were designed that form in vivo 
through either free-radical polymerization of methacrylate groups initiated with 
photo or re-dox mechanisms or via formation of a hydrozone bond through the 
combination of polymers with aldehyze or hydrazide functionality.  Next, 
degradation was mediated through crosslinks that contained either hydrolytically 
degradable ester bonds for passive degradation or the incorporation of matrix 
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metalloproteinase (MMP) cleavable peptides for cell-mediated degradation.  
Finally, many proteins interact natively with HA due to charge interactions and 
these responses were enhanced by the incorporation of sulfated polysaccharides 
or by directly adding sulfate groups to HA.    
Two proteins were chosen for delivery based on their roles in post MI 
remodeling and their natural association with polysaccharides in the ECM; (1) 
stromal-derived factor-1 alpha (SDF-1!) is a chemokine that regulates trafficking 
of cells between the bone marrow and ischemic tissues, as well as promotes 
angiogenic responses and enhances cell viability and (2) tissue inhibitor of matrix 
metalloproteinase-3 (TIMP-3) is a protease inhibitor that regulates MMP activity 
by forming a non-covalent complex with MMPs.  Delivery of each molecule was 
investigated separately to determine efficacy of each therapeutic strategy (i.e., 
cell recruitment and MMP inhibition). In all studies, experiments were pursued 
both in vitro, to illustrate the release behavior and activity of either SDF-1! or 
TIMP-3, and in vivo, to illustrate the influence of local release on LV remodeling 
and cardiac function in animal models. 
 
2.2. Specific Aims and Hypotheses 
The global hypothesis of this dissertation was that the local delivery of 
therapeutic proteins (SDF-1! and TIMP-3) from injectable HA hydrogels 
modulates post MI remodeling processes by providing sustained concentrations 
of bioactive signals within the remodeling myocardium.  To test this hypothesis, 
five specific aims were identified and completed.   
 
Specific Aim 1: Demonstrate that local SDF-1! delivery from HA hydrogels 
homes mobilized bone marrow derived cells (BMCs) to the heart post MI. 
Specific Hypothesis 1:  Epicardial delivery of SDF-1! from adherent HA 
hydrogels will enhance engraftment of mobilized BMCs in the heart.  
HA was modified with hydroxyethylmethacrylate (HEMA) groups to allow free-
radical initiated crosslinking of hydrolytically degradable macromers for 
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encapsulation and delivery of SDF-1!.  A visible light photo-initiator system was 
utilized to form hydrogels in the presence of light, which allowed in situ formation 
of HA gels on the epicardial surface of the myocardium through light exposure.  
SDF-1! binding affinity to HA macromers, along with photo-encapsulated SDF-
1! release kinetics and hydrogel degradation was quantified in vitro.  In addition, 
the activity of released molecules was assessed using BMCs in an in vitro 
chemotaxis assay.  After demonstrating sustained release of active molecules in 
vitro, a mouse MI model (collaboration with Dr. Kenneth Margulies, UPenn) was 
developed to quantify and track systemically infused BMCs with epicardial 
delivery of SDF-1! from adherent HA hydrogel patches.  The experiments were 
designed to demonstrate the utility of HA hydrogels to localize and sustain SDF-
1! release and provide proof-of-concept that this system promotes endogenous 
BMC homing to the heart following MI. 
 
Specific Aim 2: Assess the therapeutic benefit of an engineered SDF-1! 
analogue (ESA) delivery from injectable HA hydrogels post MI. 
Specific Hypothesis 2:  ESA delivery from injectable HA hydrogels will attenuate 
post MI remodeling by providing a sustained homing signal within the 
myocardium. 
To expand on the work of Aim 1 that investigated the ability of local delivery of 
SDF-1! from degradable HA hydrogels to effectively home BMCs to the heart, 
these hydrogels were utilized for encapsulation and delivery of ESA, a truncated 
version of SDF-1! produced via chemical peptide synthesis (collaboration with 
Dr. Joseph Woo, UPenn).  For therapeutic assessment, a redox-initiator system 
was used to form hydrogels within the myocardium via injection through a 
syringe.  Kinetics of hydrogel formation was quantified using rheometry to ensure 
rapid gelation in situ for maximal ESA encapsulation.  Release kinetics of 
encapsulated ESA and hydrogel degradation were quantified in vitro, along with 
released molecule activity using BMCs in a chemotaxis assay.  After 
demonstrating sustained release of active molecules in vitro, encapsulated ESA 
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release was quantified in vivo using ESA labeled with a near-infrared tag and 
delivery from injectable HA hydrogels in a rat model of MI.  Functional 
assessment of ESA delivery from HA hydrogels post MI was compared to MI only 
and hydrogel alone controls using echocardiography and hemodynamic analysis.  
In addition, myocardial tissue structure was analyzed with immunohistochemistry 
to provide a mechanistic understanding of any observed improvements in LV 
function.  
 
Specific Aim 3: Investigate the effect of local TIMP-3 release from injectable 
HA hydrogels on MMP activity and LV remodeling following MI. 
Specific Hypothesis 3: Local delivery of TIMP-3 from injectable HA hydrogels will 
reduce myocardial expansion and attenuate global LV remodeling through MMP 
inhibition within the MI region. 
HEMA modified HA macromers, along with the redox-initiator system used in Aim 
2 were used for encapsulation and delivery of TIMP-3 in this Aim.  TIMP-3 
binding to HA macromers was quantified as in Aim 1, and TIMP-3 release from 
redox-initiated hydrogels along with hydrogel degradation was quantified in vitro.  
In order to investigate the effects of TIMP-3 delivery post MI, a pig MI model 
(collaboration with Dr. Frank Spinale, University of South Carolina, and Dr. 
Robert Gorman, UPenn) was used to quantify regional MMP activity, infarct 
expansion, and LV function after injection.  These metrics were compared 
between hydrogel/TIMP-3 group and control groups of MI only and hydrogel 
alone, and biochemical analysis of tissues from all groups was analyzed with 
immunohistochemistry and for the expression of a range of genes involved in the 
remodeling process to investigate the biological effects of TIMP-3 delivery.      
 
Specific Aim 4: Develop sulfated HA macromers to incorporate high TIMP-3 
binding affinity into injectable HA hydrogels. 
Specific Hypothesis 4:  Incorporation of sulfate groups into HA macromers will 
enhance binding of TIMP-3 and therefore allow control of TIMP-3 delivery from 
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injectable HA hydrogels. 
HEMA modified HA macromers used in Aims 1-3 were synthetically sulfated 
using a method that maintains reactive group chemistry to allow incorporation of 
sulfated HA into injectable HA hydrogels.  Sulfate content, charge, and TIMP-3 
binding of HA macromers were analyzed before and after sulfation reaction and 
compared to the naturally sulfated heparin.  Sulfated HA macromers were mixed 
with unsulfated HA macromers and hydrogel crosslinking was quantified with 
rheometry and compared to hydrogels consisting of only unsulfated HA 
macromers to confirm covalent incorporation of sulfated HA macromers.  Further, 
TIMP-3 or bovine serum albumin (BSA) was encapsulated into the hydrogels and 
protein release along with hydrogel degradation were analyzed with incorporation 
of sulfated HA to investigate the influence of sulfation on protein release from HA 
hydrogels.  
 
Specific Aim 5: Engineer injectable HA hydrogels with MMP sensitive 
degradation for localized TIMP-3 delivery as a function of MMP expression 
within the MI region. 
Specific Hypothesis 5: Incorporation of MMP-sensitive crosslinks will permit 
TIMP-3 release based on local MMP concentrations and alter LV remodeling 
when injected into infarct tissue. 
Based on our results in Aim 3 using HEMA modified HA hydrogels with hydrolytic 
degradation and therefore passive rTIMP-3 release to inhibit MMP activity post 
MI, we designed injectable HA hydrogels that degrade and release rTIMP-3 in 
direct proportion to local MMP activity.  To accomplish this, hydrogels were 
developed with MMP degradable crosslinks that form stable networks in the 
absence of MMP activity, but degrade in the presence of MMP-2 and MMP-9.  
Based on our results in Aim 4 on sulfated polymers that bind and immobilize 
TIMP-3 within hydrogels, dextran sulfate was also incorporated into HA 
hydrogels for this Aim in order to limit passive TIMP-3 release.  Further, polymers 
were modified with complimentary reactive groups to form hydrogels rapidly upon 
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injection through a dual-barrel syringe without the need for free-radical initiators, 
using hydrazone chemistry (formation through reaction of hydrazide and 
aldehyde containing polymers).  TIMP-3 binding to sulfated polymers was 
quantified in vitro and compared to unsulfated HA and sulfated heparin controls.  
Hydrogel crosslinking was quantified using rheometry and MMP mediated 
hydrogel degradation was quantified in vitro.  TIMP-3 release from the hydrogels 
was quantified and the effect of TIMP-3 encapsulation on MMP mediated 
hydrogel degradation was investigated in vitro.  After demonstrating MMP-
triggered release of encapsulated TIMP-3 in vitro, the injectable hydrogel system 
was applied in the pig MI model used in Aim 3 and the same outcomes were 
pursued to assess therapeutic efficacy of this unique delivery approach. 
 
2.3. Chapter Outline 
An extensive review of the use of injectable hydrogels for treating MI will 
be presented first in Chapter 3.  Next, each Specific Aim of this dissertation will 
constitute its own chapter consisting of introduction, methods, results, and 
discussion sections in the following order:  Specific Aim 1 - Chapter 4, Specific 
Aim 2 - Chapter 5, Specific Aim 3 - Chapter 6, Specific Aim 4 - Chapter 7, 
Specific Aim 5 - Chapter 8. Finally, the conclusions related to each Specific Aim 
along with any limitations of the studies will follow in Chapter 9. 
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CHAPTER 3 
 
Injectable acellular hydrogels for cardiac repair: a review 
 
(Adapted from : E. Tous*, B.P. Purcell*, J.L. Ifkovits, J.A. Burdick, J Cardiovasc 
Transl Res, 2011, 4:528-542 *Authors contributed equally) 
 
3.1. Introduction  
Left ventricular (LV) remodeling caused by a myocardial infarction (MI) is 
responsible for almost 70% of the 5 million cases of heart failure that have 
occurred in the United States in recent years1.  Early infarct expansion or 
stretching has been associated with poor long-term prognosis2-4 and has been 
identified as the mechanical phenomenon that initiates and sustains the process 
of adverse post-MI LV remodeling that leads to heart failure5-10.  Infarct 
expansion causes abnormal stress distributions in myocardial regions outside the 
infarction, especially in the adjacent borderzone (BZ) region, putting this region at 
a mechanical disadvantage.  With time, increased regional stress is the impetus 
for several maladaptive biologic processes, such as myocyte apoptosis and 
matrix metalloproteinase activation that inherently alter the contractile properties 
of normally perfused myocardium11-13.  Once initiated, these maladaptive 
processes lead to a heart failure phenotype that is difficult to reverse by medical 
or surgical means. 
Previous work has demonstrated that the use of ventricular restraints, 
such as polymeric meshes wrapped around the heart or sutured to the surface of 
the infarcted myocardium, reduces infarct expansion by mechanically stabilizing 
the heart and forcing it to maintain its original shape, thus limiting long-term 
global LV remodeling in large animal models10,14-17  However, these approaches 
are limited by the invasive procedure in which they are applied and clinical 
adoption has not occurred.  In order to circumvent the invasive surgical 
placement of restraining devices early post-MI, our group and others have begun 
to explore the use of injectable materials, and specifically hydrogels, to limit 
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infarct expansion and normalize the regional stress distribution18-35. 
Hydrogels are water-swollen polymer networks that exhibit many tissue-
like properties and have been explored for numerous tissue engineering and 
drug delivery applications36-38.  Hydrogels can form through numerous 
techniques, including via self-assembly, through non-covalent interactions with 
ionic species, through covalent crosslinking via chemical reaction, and through 
thermal transitions that lead to gelation36-38.  These techniques are advantageous 
as they could potentially translate to catheter delivery for minimally-invasive, 
percutaneous therapies.  Hydrogels are finding application in cardiac therapy 
alone as a means for thickening and stabilizing the myocardium via tissue 
bulking, as well as for the delivery of a wide variety of therapies, such as cells 
and growth factors39, 40.  This review will specifically focus on the application of 
hydrogels for (1) tissue bulking and (2) molecule delivery approaches that may 
translate quickly to the clinic since difficulties related to finding an adequate cell 
source for transplantation are eliminated.   
 
3.2. Injectable Hydrogels as Bulking Agents 
Over the past decade it has become clear that the mechanical changes 
that occur after MI must be considered when developing post-MI therapies35,41,42.  
MI leads to extracellular matrix (ECM) breakdown and results in geometric 
changes in both the infarcted and healthy myocardium.  LV dilation results in 
stretched cardiomyocytes in the border zone (BZ) and healthy myocardium, 
which subsequently lose the ability to efficiently contract43.  Globally, this is 
manifested as a shift to a more spherical shape and a reduction in the transmural 
wall thickness.  The Law of Laplace (Eq. 3.1) illustrates how the resulting dilation 
(increased radius) and thinning of the myocardium post-MI leads to increased 
stress; where stress (T) is directly proportional to pressure (P) and the radius of 
curvature (R), and inversely to the thickness of the myocardial wall (h).   
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                                                                                           (Eq. 3.1) 
As mentioned above, past strategies to attenuate LV expansion have included 
surgeries to reconstruct the dilated ventricle and restraints placed around the 
myocardium or infarct to physically prevent dilation16,44-47.  Injectable hydrogels 
may present a material system that is applied in a non-invasive manner (liquid to 
solid transition) and leads to limited LV expansion.  In this section we will review 
common natural and synthetic hydrogels that have been investigated to this end, 
as well as comment on the underlying mechanisms of therapy.  The reader 
should refer to Table 3.1 throughout this section, which summarizes the various 
materials that have been investigated in animal models of MI.   
Table 3.1. Summary of injectable hydrogels and their assessment in animal models of MI. 
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Natural Hydrogels 
Christman and colleagues pioneered the field of acellular injectable 
biomaterials by exploring the effects of fibrin glue as a bulking agent18,23,34,49.   
Fibrin has natural binding domains for soluble growth factors and cellular integrin 
receptors, motivating its use for wound healing applications.  Although fibrin is 
commonly utilized for these biological properties, it can also be used as a 
mechanical support for the myocardium18,29,34,49.  Specifically, fibrin forms a 
crosslinked 3-D hydrogel in the myocardium upon injection with a dual-barreled 
syringe.  One barrel contains fibrinogen and aprotinin, a fibrinolysis inhibitor, and 
the second barrel contains thrombin, factor XIIIa, and CaCl218,23,29,49.  Following a 
similar mechanism to that involved in the normal clotting cascade in vivo, when 
fibrinogen and thrombin are mixed, fibrinogen is converted to fibrin which self 
assembles and is crosslinked via the factor XIIIa. 
Christman et al. injected these fibrin hydrogels into the ischemic LV one 
week following induced MI in rats (reperfusion- MI model) and animals were 
sacrificed 5 weeks later.  Echocardiograph and explant data showed that fibrin is 
capable of maintaining fractional shortening (FS) and preserving infarct scar 
thickness after the material was resorbed18.  In later studies, using the same 
model, Christman et al. demonstrated the ability of fibrin to substantially 
decrease infarct size and increase arteriole density in the infarct area compared 
to control BSA injections49.  These results imply that in addition to its bulking 
effects, fibrin may also elicit a bioactive response that influences LV remodeling.   
Significant increases in neovasculature formation (capillary density) following 
fibrin injection in rat models of MI were later confirmed by Huang et al.23.   
Natural materials that are relatively bioinert such as alginate have also 
been explored as injectable hydrogels to treat MI.  Alginate is a linear seaweed-
derived copolymer consisting of linked !-D-mannuronate (M) and "-L-guluronate 
(G) residues and can be crosslinked into hydrogels with the addition of divalent 
cations 57. Unlike fibrin, alginate must be modified with adhesive peptides to 
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facilitate cell binding.  Both non-modified alginate and alginate modified with 
adhesive peptides such as Arg-Gly-Asp (RGD) or Tyr-Ile-Gly-Ser-Arg (YIGSR) 
have been explored as bulking agents26,31,34,50,51 and comparisons have been 
performed between the two31,50.  Yu et al. compared modified alginate to non-
modified alginate using a rat reperfusion-MI model with injections 5 weeks post-
MI, more indicative of a chronic response50.  Five weeks after hydrogel injections, 
both alginate groups improved FS, reduced LV dimensions and significantly 
increased myocardial wall thickness compared to control BSA injections.  
Although both non-modified and modified groups also increased the number of 
arterioles in the infarct area, modified alginate resulted in higher densities, 
indicating the ability of adhesive peptide modifications to promote angiogenesis 
following MI.  Tsur-Gang et al. also observed improved geometry and function 
following injection of non-modified alginate hydrogels; however, they observed 
conflicting data with modified alginate hydrogels31. Specifically, modified alginate 
showed a reduced benefit compared to non-modified alginate in terms of LV 
diastolic and systolic dimension (LVDD and LVSD), LV diastolic and systolic 
areas (LVDA and LVSA), FS, and fractional area change, although no significant 
differences in relative scar thickness or blood vessel densities were observed.   
Utilizing a large animal swine model, Mukherjee et al. injected composite 
hydrogels containing both fibrin and alginate to prevent geometric LV 
remodeling29.  One week post-MI, 200µL injections (25 total) were applied to the 
infarct area via a double barreled injection device; one component was 
comprised of fibrinogen, fibronectin, factor XIII, plasminogen and gelatin-grafted 
alginate dissolved in an aprotinin solution, while the second consisted of 
thrombin and 40mM CaCl2.  Therapeutic outcomes included increased posterior 
wall thickness 1 week post injection and a reduction in infarct expansion 21 and 
28 days post-MI; however, no functional improvements were observed.  Other 
interesting findings included a significant reduction of soluble collagen in the 
treatment groups, suggesting that collagen was less vulnerable to protease 
degradation.  This observation was supported by a significant decrease in 
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protease levels (e.g., MMP-2) in the composite hydrogel injection group, which 
could favor infarct stiffening and, thus, attenuate maladaptive remodeling in the 
future. 
Chitosan is a linear polysaccharide that is biocompatible and 
biodegradable and therefore has been used in a wide variety of tissue 
engineering applications58.  Chitosan hydrogels can be formed upon mixing 
commercially produced chitosan with a glycerol phosphate and glyoxal solution.  
These gels exhibit a thermoresponsive gelation that is tuned to occur at 37°C by 
changing the glyoxal concentration, while hydrogel degradation is controlled by 
the degree of deacetylation59,60.  In a rat infarct model, a thermally responsive 
chitosan was injected 1 week post-MI28.  Four weeks after hydrogel injection, the 
myocardium thickness was significantly increased compared to PBS controls, 
even though the amount of chitosan present in the myocardium after 4 weeks 
had substantially decreased due to hydrogel degradation.  There were also 
significant improvements in infarct size, FS, ejection fraction (EF), end systolic 
diameter (ESD), end diastolic diameter (EDD), and microvessel density.  
Although the material was not completely degraded at the end of this study, like 
fibrin, this is an example of a degradable material that was effective in not only 
preserving thickness but also function.   
Hyaluronic acid (HA) is a polysaccharide that is abundant in the body and 
can play several biological roles that include angiogenesis, cell migration, and 
scar reduction depending on its molecular weight and the addition of function 
groups allows for tunability in material properties61-66.  In one example, acrylated-
HA was mixed with a thiol-terminated PEG crosslinker (PEG-SH4) and 
crosslinked via Michael-type addition; the mixture was injected into a rat MI 
model 2 weeks post-MI33.  Four weeks after treatment, heart function was 
evaluated; HA treatment led to significantly decreased infarct size, increased EF 
and increased arteriole and capillary density.  Interestingly, results showed 
significant increases in infarct thickness while histology showed complete 
degradation of the HA gels. Improvements in this work were attributed to the 
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biological role of HA, which like fibrin has proven to play a large role in wound 
healing applications.  Additional work with engineered HA hydrogels will be 
discussed in a section below on modulating hydrogel properties. 
Collagen is a natural ECM protein that has been applied for LV remodeling 
therapies due to the ability to inject as a liquid, which subsequently gels at 
37°C19,23.  Collagen injections in 1 week old rat infarcts substantially increased 
infarct thickness, stroke volume (SV) and EF compared to saline inject controls; 
there was also a trend for improved end systolic volume (ESV)19.  While this 
study did not show any evidence of angiogenesis or cell infiltration, Huang et al, 
using a reperfused model, were able to demonstrate both increased 
angiogenesis and myofibroblast infiltration in the infarct zone compared to 
controls23.  Contradicting results may be attributed to variables in methodology 
(Table 1) or differences in collagen types and concentrations used.  Dai et al. 
used a mixture of collagen I (95%) and collagen III (5%) at 65 mg/mL, while 
Huang et al. used a collagen I at 1 mg/mL.  As an alternative to hydrogels 
composed solely of isolated collagen, Matrigel is commercially available hydrogel 
derived from the ECM that is primarily composed of collagen, but also contains 
numerous other molecules derived from the basement membrane.  Studies with 
Matrigel alone in a mouse model showed trends towards increased scar 
thickening and improved function compared to infarct controls25; thickening and 
improved EDD were also observed in a rat model54. In addition, studies by Huang 
et al. showed significantly increased capillary density with Matrigel injection23.  
Extracellular matrix (ECM) components isolated from healthy myocardium 
have been recently explored to treat MI.  Singelyn et al., decellularized and 
solubilized the ECM from pig hearts for use as an injectable scaffold30.  The 
isolated ECM material maintained a complex composition including collagen and 
glyocosaminoglycan content and exhibited a natural thermoresponsive behavior 
as it self-assembled into a nanofibrous gel at 37°C from a liquid precursor at 
25°C.  Interestingly, the cocktail of isolated ECM components stimulated the 
migration of human coronary artery endothelial cells (HCAEC) and rat aortic 
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smooth muscle cells (RASMC) in vitro.  For in vivo application, 90 µL hydrogels 
were successfully pushed through a catheter into the non-infarcted myocardium 
of rats where they induced a significant increase in arteriole formation 11 days 
post-injection. In later work, Seif-Naraghi et al. isolated both porcine and human 
pericardial ECM (PPM and HPM respectively) to evaluate their potential as 
autologous scaffolds for treating MI55.  Similarly, these gels polymerized under 
thermal stimulation and maintained native components of the pericardial ECM.  
While in vitro results demonstrated that PPM was more effective in promoting 
migration of HCAEC, RASMC, and rat epicardial cells (RECs) compared to HPM, 
in vivo data 2 weeks post injection (90 µL) indicated that both PPM and HPM 
similarly promoted neovascularization (76 ±13 arterioles per mm2 and 51±42 
arterioles per mm2, respectively).  Interestingly, stem cell evaluation revealed that 
although very slight, c-kit+ cells were present within the injection regions, eluding 
to a role in endogenous homing of these materials.  These studies demonstrate 
that providing cardiac-specific cues to the injured myocardium via decellularized 
ECM injectable hydrogels provides a useful strategy to promote cardiac-specific 
tissue formation. 
 
Synthetic Hydrogels 
Natural materials may provide numerous important cellular-interactive 
cues (e.g., adhesion and cell-mediated degradation), but are generally limited in 
the extent that their properties can be adjusted (ie: mechanics, degradation, and 
viscosity).  In contrast, synthetic materials provide additional potential in 
engineering a variety of gelation mechanisms and physical properties. One 
synthetic thermosensitive polymer, comprised of dextran (Dex) grafted 
poly(caprolactone)-2-hydroxyethyl methacrylate (PCL-HEMA) and copolymerized 
with poly(N-isopropylacrylamide) (PNIPAAm) termed Dex-PCL-HEMA/PNIPAAm, 
was developed to gel in situ.  Material injections were performed 4 days post-MI 
in a rabbit model and resulted in significant reductions in infarct scar and 
improvement in EF and LV end diastolic and systolic diameter (LVEDD and 
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LVSD) compared to PBS control injections when assessed 30 days after 
injection32.  Significant thickening was observed despite no histological evidence 
of material remaining.   
Similarly, Fujimoto et al. synthesized a biodegradable, temperature 
responsive hydrogel composed of N-PNIPAAm, acrylic acid, and hydroxyethyl 
methacrylate-poly(trimethylene carbonate) (poly(NIPAAm-co-AAc-co-
HEMAPTMC)) with slower degradation than the previously discussed polymer 
(Figure 3.1)22. Like Dex-PCL-HEMA/PNIPAAm, poly(NIPAAm-co-AAc-co-
HEMAPTMC) was engineered to undergo gelation at body temperature.  In this 
particular study, a hydrogel with a maximum tensile strength of 6.1 kPa and 
complete hydrogel degradation after 5 months was evaluated for its efficacy in 
preventing LV remodeling in a rat MI model.  The polymer was injected two 
weeks post-MI; after 8 weeks the myocardium thickness, EDA and fractional area 
change were significantly improved compared to PBS injection controls.  
 
Figure 3.1. In vivo application of injectable synthetic polymers.  Chemical structure of 
poly(NIPAAm-co-AAc-co-HEMAPTMC) (a), representative images of PBS (b) and gel  (c) injected 
hearts at 8 weeks, and hematoxylin and eosin stained section of PBS control (d) and gel 
treatment (e) hearts at 8 weeks.  Scale bar: 5 mm in (b,c), 500 µm in (d,e). Figure adapted from 
22. 
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Another synthetic material consisting of !cyclodextrin (!-CD) and poly(ethylene 
glycol) (MPEG-PCL-PEG) triblock polymer that has the ability to gel in situ has 
also demonstrated therapeutic benefits when injected to target LV 
remodeling24,32.  Degradation can be controlled by the PCL block and hydrogels 
were formed upon mixing the linear MPEG-PCL-MPEG polymer with !-CD. 
When injected 5 minutes post-MI in a rat model, the hydrogel-treated groups 
showed a significant reduction in infarct size, LVEDD, LVESD, and an increase in 
FS compared to PBS inject controls.  No increase in neovascularization was 
observed32.  In 1 week old infarcts in a rabbit model, significant improvements in 
thickness, infarct size, LVEDD, LVESD, and EF were observed with no increase 
in microvessel density24. 
The aforementioned synthetic materials have all been degradable.  In 
contrast, a non-degradable vinyl sulfone derivatized PEG (PEG-VS) has also 
been investigated to treat MI21.  PEG-based hydrogels are bioinert and can be 
tailored to have high mechanical properties. PEG-VS was polymerized upon 
combination with dithiothreitol (DTT) and injected into a rat MI model 2 minutes 
post-MI.  PEG-VS significantly increased the wall thickness at 4 weeks, and 
although no longer significant, was still thicker than saline controls at 13 weeks.  
Despite PEG-VS thickening the myocardial wall, echocardiograph analysis 
showed significant improvements in EDD only 4 weeks after MI; this was not 
maintained at 13 weeks.  FS was also not improved in treatment groups.  Here, 
in this small animal model, it is observed that prolonged material presence (or 
stabilization) is not sufficient to attenuate LV remodeling.   
 
Limitations of Experimental Assessment of Bulking Agents 
From the above reviewed results, it is clear that bulking agents may 
attenuate remodeling post-MI; however, the mechanism involved in their success 
still remains to be elucidated.  If anything, these results reveal the complexity in 
the material interaction with the myocardial tissue, including both the biological 
(e.g., material remodeling, inflammatory response) and mechanical (e.g., stress 
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reduction) responses.  Variable results from these studies indicate that material 
thickness21,26,29,34, infarct size34, and/or increased angiogenesis19,24,56 do not 
necessarily correlate directly with improved heart function.  However, 
discrepancies in results could be due to inconsistencies in methodology (Table 
3.1) (e.g., animal models, infarct, amount of material injected, timing of injection) 
and material properties and their importance should be considered when 
investigating LV remodeling.  Specifically, several animal models have been 
used to study the efficacy of bulking agents.  The most popular model is by far 
the rat model, possibly due to costs and ease of implementation; however, this 
model has several limitations.  The most obvious is the lack of clinical relevance 
associated with a small animal model, as well as infarct consistency.  In the 
clinical setting, factors such as the LV volume and structure, material injection 
volume, and method for injection will be very different than in the rat.   
Material injection of bulking studies has been performed as early as 
immediately post-MI21,25 as late at 8 weeks post-MI26.  In separate studies with 
fibrin, injection at 1 week was more effective in improving myocardium function18 
versus injection 5 weeks post-MI34. Utilizing a permanent ligation rat model, 
Landa et al. directly compared injections into new (1 week post-MI) and old (2 
months post-MI) infarcts and demonstrated the efficacy of alginate in both 
(although to different extents)26. Recent infarcts resulted in improvements in wall 
thickening and LV dilation; while older infarcts also showed improvements, 
results were more pronounced, implying that post-MI therapies are more effective 
when applied early in the LV remodeling process, potentially before irreversible 
processes have occurred.  Similar to injection time, data collection time points 
are also important to consider. The longest study evaluated in this review was 3 
months post treatment21 and 4 months post-MI26.   
 
Material Optimization: Theoretical Evaluation 
Theoretical models have implied that material properties, specifically 
mechanics and volume, are important to consider when selecting the type of 
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bulking agent to ameliorate dilation and increased stress in the myocardial 
wall35,67-69.  Using a finite element (FE) model to simulate the effects of injecting a 
non-contractile material into the myocardium, Wall et al. showed that bulking the 
myocardium was sufficient to attenuate post-MI geometric changes and, thus, 
decrease stress in the myocardial wall35.  More specifically, they demonstrated 
that injections of 4.5% of the LV wall volume and 20% of the stiffness of the 
natural myocardium into the BZ were able to decrease the fiber stress by 20% 
compared to control simulations with no injections.  Other approaches have 
validated the importance of infarct compliance using FE, as well as lump-
parameter models; results reveal similar overall beneficial outcomes35,67,68.   FE 
models have also been employed to evaluate the effects of material volume and 
distribution in the myocardium and showed that they influence the extent of 
remodeling (Figure 3.2)35,69.  After testing several injection patterns it was 
determined that the maximum number of injections leads to the highest reduction 
in fiber stress69.  These simulations provide insight to the relevance of bulking 
material properties, specifically mechanics and volume distribution, and present 
more evidence to pursue injectable material therapies to control LV remodeling.   
 
Figure 3.2.  Finite element (FE) model of injected polymeric materials.  Reference FE model 
for infarcted canine heart (a) and modified FE model with polymeric inclusion injection pattern into 
dilated LV (b) can be used to assess the effects of material volume and distribution on myofiber 
stress.  Figure adapted from69.  
 28 
Material Optimization: Comparing Different Materials 
Only two studies have directly compared different materials and their 
efficacy in preventing LV remodeling23,34.   Utilizing an infarct-reperfusion rat 
model, Yu et al. compared non-modified alginate to fibrin with injections applied 5 
weeks post-MI34.  Two days after injection, both materials were similarly effective 
in improving FS, LV dimensions and wall thickness.  However, 5 weeks post 
injection, alginate demonstrated greater improvements than fibrin in FS, LV 
dimensions, and wall thickness.  This could be attributed to the extended 
presence of alginate in the myocardium while fibrin was no longer detectable; 
however, fibrin treatment did result in thicker myocardial walls when compared to 
BSA control injections.  Interestingly, while unable to promote cell adhesion, 
alginate, like fibrin, resulted in significantly higher arteriole density.  Despite 
alginate’s superiority in long-term functional outcomes, fibrin treatment groups 
had significantly smaller infarcts compared to controls. This comparison 
highlights potential differences in the efficacy of material stabilization in 
preventing LV remodeling, due to differences in material degradation and 
biological activity.  In another study, Huang et al. compared the extent of 
angiogenesis between fibrin, collagen and Matrigel post-MI and determined that 
while all three polymers significantly increased capillary density, only collagen 
significantly increased the degree of myofibroblast infiltration23.   
 
Material Optimization: Comparing Properties 
Few studies have experimentally evaluated the role of material properties 
(e.g., volume and mechanics) on LV remodeling.  A review of injectable materials 
illustrates that a wide range of volumes have been injected as bulking agents 
(Table 3.1).  As a single example of differences in injected volumes, Leor et al. 
injected an alginate-calcium solution into the LAD 4 days post-MI via a coronary 
catheter in swine51.  During this time post MI, the vasculature of the infarcted 
myocardium is leaky, allowing the alginate mixture to be delivered to the infarct 
site.  Due to inadequate levels of calcium in the vasculature, the alginate solution 
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does not crosslink until released into the myocardium where levels of calcium 
suffice to stimulate gelation.  Various volumes of 1, 2 and 4 mL were injected; 2 
and 4 mL injections led to superior LVDA and LVSA with 2 mL injections resulting 
in significant thickening (despite material degradation) and more pronounced 
trends for functional improvements.  These findings illustrate the importance of 
injection volume in stabilizing the myocardial wall69.  Other parameters, such as 
number and pattern of injections, although relevant through theoretical analysis69, 
have yet to be investigated in a clinically relevant model. 
The influence of material properties may also be an important parameter 
to control, yet few studies have investigated this, particularly in a controlled 
manner.  This may be due to limitations in material systems where various 
important properties can be decoupled.  For example, fibrin properties can be 
varied by adjusting the concentration of fibrinogen and thrombin70 and Martens et 
al. adjusted these parameters to optimize fibrin viscosity and gelation for catheter 
delivery71.  Similarly, alginate properties can be adjusted by varying weight 
percent and the ratio of M and G units 72.  However, in both of these systems 
viscosity may be changed during injection and lead to differences in not only final 
mechanics, but also material dispersion and biomaterial concentration.   
A recent study by Ifkovits et al. was the first to explore how the mechanical 
properties of injectable materials influence LV remodeling (Figure 3.3)53.  A highly 
modified HA polymer (methacrylated HA, MeHA) with a high compressive 
modulus (43 kPa) was directly compared to lower modified MeHA with a low 
compressive modulus (7.7 kPa).  This study demonstrated that although both 
materials similarly thickened, or bulked, the infarcted myocardial wall, high MeHA 
was able to also decrease infarct size and dilation as well as improve function 
under stress compared to the infarct control.  This provides evidence that the 
mechanical properties of the injectable material are important to consider for 
attenuating LV remodeling.  Studies with tunable injectable materials will broaden 
the understanding of factors, such as mechanics and degradation that should be 
regarded to target LV remodeling via bulking agents.  
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Figure 3.3.  Injectable hyaluronic acid hydrogel.  Chemical structure of methacrylated 
hyaluronic acid (a), schematic of gel formation process where functional macromers react via a 
radical polymerization to form a gel (b), and a representative Masson’s Trichrome stain of the gel 
in myocardium 8 week post-MI (c). G=Gel, Scale Bar, 50 µm. Figure adapted from53. 
 
Likewise, the biological activity of materials cannot be overlooked.   A study by 
Ryan et al. injected a biocompatible dermal and soft tissue filler (Radiesse) 
composed of calcium hydroxyapatite microspheres suspended in an aqueous gel 
carrier of water, glycerin, and carboxymethylcellulose.  The uncrosslinked gel 
carrier allows endogenous cells to access the encapsulated microspheres to 
promote collagen synthesis73.  Radiesse was injected into the myocardium 45 
minutes after ligation in an ovine MI model and analyzed at 4 weeks; injection 
resulted in a thickened myocardial wall, increased global EF and reduced LV end 
systolic volumes compared to controls.  Unlike the previously mentioned 
hydrogel systems that directly bulk the myocardium through hydrogel 
crosslinking, this approach provides an effective means to induce tissue bulking 
by promoting the biological response to materials for attenuated LV remodeling 
and preserved cardiac function52, 74-78.  
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3.3. Injectable Hydrogels for Molecule Delivery 
In addition to mechanically supporting the injured myocardium as 
described above, injectable hydrogels provide a water-swollen matrix to 
encapsulate therapeutic molecules for targeted molecule delivery to the 
myocardium following MI.  Exogenous delivery of therapeutic molecules including 
growth factors, cytokines and DNA plasmids can be used to manipulate 
endogenous post-MI remodeling processes; however, the high rates of diffusion 
and short half-life during which these molecules retain their biological activity in 
vivo make successful application of these molecules to treat MI difficult79.  To this 
end, injectable hydrogels provide a useful platform to sustain the release of 
therapeutic molecules in the setting of MI.  Molecules are encapsulated in the 
hydrogel matrix and released locally over time to sustain target levels of the 
molecule in the myocardium while preventing detrimental systemic effects.  The 
pioneering work of Dr. Robert Langer and Dr. Judah Folkman showed that 
polymer matrices can be used to sustain the release of encapsulated molecules 
for up to 100 days80.  Molecule release from these hydrogels exhibited an initial 
‘burst release’ in which molecule release rates are rapid, followed by sustained 
released profiles with slower release rates (Figure 3.4).  This initial burst release 
was significantly decreased with higher polymer concentrations (i.e., higher 
polymer-to-water ratios) and the overall release kinetics were unique for each 
polymer-molecule combination.  Polymer-molecule interactions, polymer 
hydrophobicity, and hydrogel degradation all influence the diffusion of 
encapsulated molecules in the hydrogel matrix and therefore determine 
encapsulated molecule release kinetics81.  The following sections will review the 
range of combinations of therapeutic molecules and injectable hydrogel 
formulations that have been applied to treat MI. 
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Figure 3.4.  Representative release behavior from injectable hydrogels.  Molecules are 
mixed into a hydrogel precursor solution (a), encapsulated after hydrogel formation upon injection 
(b), and are released from the network through both diffusion (c) and degradation (d) 
mechanisms.  Molecule release from these systems can be controlled through polymer 
concentration, crosslink density and by incorporating affinity between the encapsulated molecule 
and hydrogel (e).  Release profiles are unique for each polymer-molecule combination and are 
therefore often determined experimentally.     
 
Anti-apoptotic Molecules  
In order to attenuate the loss of viable myocardium following MI, protective 
growth factors have been delivered locally from injectable hydrogels to the at-risk 
myocardium.  Ruvinov et al. developed alginate hydrogel microparticles with 
sulfate group modifications to affinity-bind encapsulated insulin-like growth factor-
1 (IGF-1) and hepatocyte growth factor (HGF) for sustained molecule release in 
the setting of MI82.  IGF-1 has been shown to be cytoprotective and HGF has 
been shown to be pro-angiogenic and anti-fibrotic; therefore, this group 
hypothesized that delivery of both of these molecules following MI would have an 
additive effect on preserving the viability and structure of the myocardium.  
Modifying hydrogels with negatively charged groups is a common way to mimic 
the natural affinity of glycosaminoglycans (GAGs) for proteins in order to localize 
and sustain the release of exogenously delivered proteins. In this particular 
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system, the modified alginate microparticles exhibited a dual release behavior 
with distinct release kinetics for IGF-1 and HGF (IGF-1 release was faster than 
HGF release), indicating a difference in the affinity of each molecule for the 
sulfate group modifications (Figure 3.5).  Importantly, the molecules released 
from the microparticles remained active (confirmed in vitro with cell culture 
assays) and were protected by protease degradation when bound to the sulfate 
modified alginate (as evidenced by mass spectroscopy).  When injected 1 week 
after induced MI in rats, the alginate microparticles facilitated significant 
improvements in IGF-1/HGF mediated repair compared to IGF-1/HGF injected in 
saline and alginate microparticles injected without growth factors.  These 
improvements include reductions in fibrotic area (collagen staining), apoptotic 
cells (caspase-3 expression), and increases in vessel densities and areas (!-
SMA expression), proliferating cardiomyocytes (Ki67 expression), and evidence 
of cardiogenesis (GATA4 expression) 4 weeks following injection.  
 
Figure 3.5.  Molecule release from affinity-binding alginate hydrogels.  Release kinetics of 
IGF-1 and HGF from the same hydrogel (a) and from separate hydrogels (b).  Cumulative protein 
released (%) = (cumulative released protein up to each time point/total protein recovered from the 
hydrogel) ! 100. Residual protein entrapped in the hydrogels at the end of the study was 
recovered with sodium citrate treatment. Figure adapted from82. 
 
In addition to GAG affinities, the natural affinity of streptavidin for biotin 
has been exploited to sustain the release of IGF-1 from injectable hydrogels20.  
Davis et al., biotinylated self-assembling (SA) oligopeptides and IGF-1 to form a 
streptavidin-biotin complex upon mixing the biotinylated oligopeptides and IGF-1 
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with tetravalent streptavidin.  The oligopeptides were designed with alternating 
hydrophilic and hydrophobic amino acids in order to “self-assemble” into 
nanofibrous hydrogels upon exposure to physiologic pH and osmolarity.  IGF-1 
release from the hydrogels was sustained for up to 84 days in vivo after injection 
into the myocardium or rats.  Tethering IGF-1 to the peptide scaffold using the 
streptavidin-biotin strategy had significant effects on improving cardiomyocyte 
survival in vitro (cardiomyocyte [3H]phenylalanine incorporation) and in vivo 
(caspase-3 cleavage of implanted neonatal cardiac myocytes) confirming the 
activity of released IGF-1.  Combining the IGF-1/SA peptide hydrogels with 
neonatal cardiac myocytes significantly improved functional outcomes post MI, 
however the contribution of the IGF-1/SA peptide hydrogels alone was not 
investigated.  
These self-assembling peptide hydrogels have also been explored to 
deliver platelet derived growth factor (PDGF) to prevent cardiomyocyte apoptosis 
post MI83.  The amphiphilic nature of the oligopeptides provided sustained 
release of PDGF through weak molecular interactions between the oligopeptides 
and PDGF.  PDGF release was sustained from hydrogels for 14 days following 
injection into the myocardium of rats.  The released PDGF activated its receptor 
(PDGFR-!) in cardiomyocytes adjacent to the injection areas and attenuated 
cardiomyocyte death (caspase-3 cleavage) 14 days after induced MI and 
PDGF/SA peptide hydrogel injection.  In addition, global LV geometry and LV 
function (fractional shortening) was preserved 14 days following MI with the 
PDGF/SA peptide hydrogels.  A subsequent study confirmed the therapeutic 
benefit of these PDGF releasing hydrogels84.  LV geometry and function 
(hemodynamic parameters) and myocardial tissue structure (vascular density, 
regional blood flow, and infarct size) were significantly improved 4 months 
following induced MI in rats with injection of the PDGF/SA peptide hydrogels.  
Importantly, the locally delivered PDGF did not have adverse systemic effects 
(pulmonary hypertension) as confirmed by no observed change in pulmonary 
artery thickness.  
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Another group of proteins that can recover cell viability during periods of 
environmental stress, the heat shock family of proteins, have also been delivered 
in the setting of MI using injectable hydrogels.  Lee et al. used calcium 
crosslinked alginate hydrogels as a delivery matrix for poly(lactic-co-glycolic acid) 
(PLGA) microspheres loaded with heat shock protein 27 (HSP27) fused to a 
transcriptional activator (TAT) (to facilitate cell uptake of HSP27)85.  HSP27-TAT 
was encapsulated in the PLGA microspheres using water/oil/water emulsions, a 
frequently used method for preparing microspheres containing proteins, and 
these loaded microspheres were embedded in the alginate hydrogel during 
calcium crosslinking upon injection.  Loading HSP27-TAT in the densely 
crosslinked microspheres prevented the burst release that is typical of proteins 
encapsulated in hydrogels.  Released HSP27-TAT remained active as evidenced 
by reduced cardiomyocyte apoptosis and restored cardiomyocyte proliferation 
under ischemic conditions in vitro, although this system was not tested in the 
setting of MI. 
 
Angiogenic Factors 
Another common strategy to preserve viable myocardium following MI is 
to restore blood flow to the ischemic myocardium by stimulating neovasculature 
formation in the infarct area with localized release of pro-angiogenic growth 
factors.  Sustained release of fibroblast growth factor (FGF) from injectable 
hydrogels has been extensively explored to stimulate angiogenesis following 
MI60,86-91.  FGF is a powerful angiogenic molecule, but has a very short half-life in 
vivo.  Sakakibara et al., showed that radiolabeled FGF delivered to the 
myocardium via bolus venous injections, intracoronary injections or 
intramyocardial injections is nearly undetectable 24 hrs after administration89.  
However, by using gelatin hydrogel microspheres as a carrier matrix, effective 
concentrations of radiolabeled FGF were sustained in the peri-infarct area of the 
myocardium 24 and 72 hrs after injection (all groups injected 4 weeks after 
induced MI in rats).  To assess the therapeutic effects of sustaining FGF levels in 
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the myocardium with this hydrogel system, FGF loaded microspheres were 
injected 4 weeks after induced MI in swine.  Upon evaluation at 4 weeks after 
injection, LV remodeling was significantly attenuated (echocardiography) and 
neovasculature was significantly increased (capillary density) compared to a 
control MI group.  Other groups have also reported the efficacy of using gelatin 
microspheres to deliver FGF in the setting of MI89,90.  In addition to gelatin 
microspheres, injectable chitosan hydrogels have been used to deliver FGF86.  
Wang et al. encapsulated FGF in thermoresponsive chitosan hydrogels upon 
injection into the myocardium by mixing FGF with the chitosan solution.  This 
system significantly improved heart function compared to injecting FGF alone in 
a rat model of chronic MI (hydrogels injected 1 week post-MI).   
While the sustained delivery of pro-angiogenic factors to ischemic tissue 
has stimulated neovasculature formation, as evidenced by increases in capillary 
densities, the stability and connectivity of these newly formed vessels has been a 
concern92.  In order to form more stable vessels with supporting smooth muscles 
cells, dual delivery of angiogenic growth factors using injectable hydrogels has 
been explored to treat MI.  Hao et al., encapsulated vascular endothelial growth 
factor (VEGF) and platelet derived growth factor (PDGF) in alginate hydrogels by 
mixing a solution of purified alginate and growth factors with a calcium sulfate 
solution upon injection into the myocardium93.  The rationale for choosing these 
two molecules was to first stimulate endothelial vessel formation with VEGF 
delivery, followed by smooth muscle cell recruitment with PDGF delivery to 
support the immature vessels.  To this end, VEGF release preceded PDGF 
release from the alginate hydrogels and release of both molecules was sustained 
for over 30 days in vitro as the hydrogel degraded.  When applied 1 week 
following induced MI in rats, the dual growth factor releasing hydrogels 
significantly increased the number of !-SMA containing blood vessels around the 
injection site 4 weeks after injection compared to hydrogels loaded with each 
growth factor alone.   
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To further control VEGF delivery in the setting of MI, Wu et al. conjugated 
VEGF to N-hydroxysuccinimide (NHS) terminated PVL-b-PEG-b-PVL block 
copolymers (NHS reacts with primary amines on the protein)94.  The block 
copolymers were designed to form a hydrogel at 37°C for injectability and 
completely degraded after 42 days when implanted subcutaneously in rats.  
When injected into the myocardium 1 week following induced MI in rats, the 
VEGF conjugated hydrogels showed significant improvements in heart function 
(FS, EF, LV EDV and ESV, dP/dt max, dP/dt min) and structure (scar area, 
capillary density) 4 weeks after injection compared to VEGF alone and VEGF 
injected with the hydrogel but not conjugated (Figure 3.6).   
 
Figure 3.6. Tissue response to delivered growth factors.  Representative heart slices 
obtained at 35 days after post-MI injection of PBS, hydrogel (HG), hydrogel with soluble VEGF 
(HG+VEGF), or hydrogel with VEGF tethered through covalent linkage (HG-VEGF). Arrows 
indicate the location of the infarct in individual slices. Figure adapted from94. 
 
Finally, plasmid DNA encoding angiogenic molecules has been delivered 
with injectable hydrogels.  Kwon et al. synthesized multiblock copolymers with 
acid-labile acetal linkages (for controlled degradation) that form hydrogels at 
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37°C for VEGF plasmid delivery following MI95.  The injectable hydrogels 
significantly enhanced the efficacy of the VEGF plasmid over injecting the naked 
plasmid, as confirmed by VEGF expression in the infarct area 2 weeks after 
injection.  This enhanced expression was correlated with increases in capillary 
density and a more preserved myocardium in the infarct area.  To further 
enhance angiogenesis, injectable hydrogels with adhesive sites can be used as a 
carrier of angiogenic plasmids to provide a matrix that facilitates cell migration.  
The combination of plasmid and adhesive matrix (termed gene-activated matrix) 
enhances gene transfection by localizing the plasmid until endogenous cells 
migrate into the implanted scaffold and become transfected to express the 
encoded protein48,96,97.  For example, Christman et al. used an injectable fibrin 
glue that forms upon mixing fibrinogen and thrombin to localize a plasmid 
encoding the angiogenic molecule pleiotrophin (PTN) in the infarct myocardium48.  
Injecting the PTN plasmid in fibrin glue 1 week following induced MI in rats 
increased the formation of arterioles (!-SMA staining) that were functionally 
connected to existent coronary vasculature (confirmed with fluorescent 
microbead perfusion) 5 weeks after injection. 
 
Chemoattractants  
For control of endogenous cell recruitment, chemokines that selectively 
recruit stem/progenitor cells have been delivered from injectable hydrogels.  For 
example, stromal derived factor-1 alpha (SDF-1!) has been locally delivered in 
the setting of MI using the injectable peptide hydrogels described in the previous 
section98.  Release of SDF-1! was controlled by tethering the protein to the 
oligopeptide scaffold through a peptide sequence that is cleaved by endogenous 
proteases.  The amino acid sequence of SDF-1! was engineered to resist 
protease degradation to ensure that active SDF-1! was released from the 
scaffold in the presence of proteases.  Released SDF-1! was detectable for up 
to 7 days around the injection site in vivo and led to significant increases in cells 
expressing the receptor for SDF-1! in the MI region, which co-expressed 
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markers of stem/progenitor cells and endothelial cells.  In addition, capillary 
(isolectin) and arteriole (!-SMA) densities increased significantly 4 weeks after 
injecting the SDF-1! containing hydrogels compared to MI controls in rats.  
These tissue-level observations were correlated with significant improvements in 
LV function.   
 
3.4. Summary 
Although only in its infancy, it is clear that the field of injectable hydrogels 
to treat cardiac tissue post-MI has high potential as a translatable therapy.  The 
lack of a cell source needed for transplantation will only accelerate development 
of percutaneous delivered hydrogels, whether they act as tissue bulking agents 
or for the controlled delivery of therapeutic molecules.  A wide range of both 
natural and synthetic materials have been investigated and each has unique 
properties, including mechanics, degradation, and cellular interactions.  Future 
work should further investigate the various mechanisms in which these materials 
act, both biologically and mechanically, and focus on clinically relevant 
parameters, such as the animal model and mode of delivery.  This information 
will lead to a clear understanding and illustration of the efficacy of injectable 
hydrogels to treat patients that have experienced an MI and to prevent the LV 
remodeling events that can lead to heart failure. 
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CHAPTER 4 
 
Synergy of SDF-1! and degradable hyaluronic acid hydrogels in directing 
bone marrow derived cell homing to the remodeling heart 
 
(Adapted from: B.P. Purcell, J.A. Elser, A. Mu, K.B. Margulies, J.A. Burdick, 
Biomaterials, 2012, 33:7849-7857) 
 
4.1. Introduction  
 Nearly 1 million Americans suffer a myocardial infarction (MI) each year 
and many patients progress to heart failure due to limited treatment options to 
attenuate the remodeling response post-MI1.  Following MI, a dynamic tissue 
remodeling process, characterized by cell death and the formation of avascular 
scar tissue, induces global changes to ventricle geometry (i.e., wall thinning and 
chamber dilation), which ultimately compromise heart function2.  In order to 
attenuate the progression to heart failure, therapeutics using bone marrow-
derived cells (BMCs) are being widely explored to promote repair in the 
remodeling myocardium.  In particular, autologous BMC transplantation has 
received the greatest attention in a clinical setting; yet, only modest 
improvements in ventricular function have been demonstrated after intracoronary 
BMC delivery, potentially due to limited cell engraftment in the myocardium3.  
Inconsistencies in cell isolation and storage procedures4, the timing of BMC 
administration following MI5, and the location of BMC administration6 complicate 
outcomes by altering the delicate signaling mechanisms that are critical for cell 
engraftment.    
BMC engraftment in the bone marrow microenvironment (i.e., BMC 
homing) is regulated by the expression of chemokines and extracellular matrix 
(ECM) molecules under steady state conditions.   In response to injury or under 
pathological conditions, elevated concentrations of these regulatory molecules in 
the peripheral circulation mobilize BMCs and direct their engraftment in 
remodeling tissues to mediate repair.  In particular, stromal-derived factor-1 
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alpha (SDF-1!), along with its receptor (CXCR4), are critical regulators of BMC 
homing to the bone marrow, but also orchestrate BMC mobilization into the 
peripheral circulation and local engraftment in the heart following MI7.  
Myocardial SDF-1! expression post MI is accompanied by a concomitant 
increase in bone marrow derived CXCR4+ circulating cells, suggesting that these 
cells are mobilized and respond to the myocardial SDF-1! signal8.   
Despite evidence that the mobilized BMCs home to the myocardium via 
SDF-1! and contribute to tissue repair, the extent of this endogenous response 
is insufficient to prevent the eventual onset of heart failure following MI.  
Enhancing endogenous BMC homing (and therefore repair) through myocardial 
delivery of SDF-1! increases progenitor cell markers in the heart, stimulates 
angiogenesis, and attenuates global ventricular remodeling9.  However, due to its 
very low molecular weight (8kDa) and proteolytic susceptibility, SDF-1! delivery 
to the myocardium following MI is challenging.  Researchers have addressed this 
challenge by covalently linking recombinant SDF-1! (rSDF-1!)10 or SDF-1! 
peptide analogs11 to scaffolds that incorporate sites for integrin mediated 
adhesion.  Beyond integrin mediated interactions, there are other components of 
the bone marrow niche, such as interactions with glycosaminoglycans (GAGs) 
that might aid in SDF-1! delivery and BMC engraftment with improved efficacy.   
 Naturally, local concentrations of small, cationic chemokines like SDF-1! 
are regulated by GAGs in the ECM12.   SDF-1! binds to GAGs through ionic 
interactions between basic amino acid residues and acidic groups along the 
disaccharide backbone13.  The affinity between SDF-1! and GAGs plays an 
important role in localizing SDF-1! on the endothelium to direct cell homing14 
and sustaining SDF-1! activity in the presence of proteases15.   In addition to 
their roles in chemokine presentation, some GAGs play a more direct role in 
BMC homing through receptor interactions.  For example, hyaluronic acid (HA) is 
abundant in the bone marrow, where it serves as an anchoring molecule for BMC 
homing through binding to the CD44 receptor16.  Interestingly, HA is localized to 
regions of SDF-1! expression in the bone marrow and HA and CD44 mediate 
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cell responsiveness to SDF-1! during cell migration in vitro and cell homing in 
vivo17.  
 In this work, we exploit the cooperative roles of SDF-1! and HA in order to 
enhance endogenous BMC homing to the heart following MI.  Specifically, 
recombinant SDF-1! was encapsulated in degradable HA hydrogels that form in 
situ on the heart, in order to localize SDF-1! and HA homing cues to the 
remodeling heart for enhanced engraftment of circulating BMCs in the 
myocardium.  
 
4.2. Materials and Methods 
Animals 
Adult BALB/CAnNHsd mice (Charles River, Production) were housed in a 
dedicated vivarium under conventional conditions.  Mice received a standard diet 
(LabDiet 5010) and water ad libitum.  All experimental procedure were performed 
according to the NIH Guide for Care and Use of Laboratory Animals and 
approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Pennsylvania. 
 
Macromer synthesis  
A degradable HA macromer with methacrylate functionality was 
synthesized through hydroxyethyl methacrylate (HEMA) modification of the HA 
backbone in a three step process. (1) Sodium hyaluronate (74 kDa, Lifecore) was 
converted to a tetrabutylammonium (TBA) salt by acidic ion exchange with 
Dowex resin (50W×8–200, Sigma), followed by neutralization with TBA-OH, and 
lyophilization.  (2) 2-hydroxyethyl methacrylate was reacted with succinic 
anhydride in dichloroethane (DCE) via a ring opening reaction (65°C, 16hrs) in 
the presence of N-methylimidazole to obtain HEMA-COOH.  HEMA-COOH was 
purified via hydrochloric acid wash, DI H2O wash, and DCE evaporation with a 
rotary evaporator. (3) HEMA-COOH was coupled to HA-TBA in anhydrous 
dimethyl sulfoxide through an esterification reaction in the presence of 4-
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dimethylaminopyridine (DMAP) and di-tert-butyl dicarbonate (BOC2O) activating 
agents (45°C, 20hrs).   The following molar ratios of reactants were used: HA-
TBA (1), HEMA-COOH (1.4), BOC2O (1.2), DMAP (0.1).  The modified HEMA-HA 
macromer was purified via overnight dialysis in DI H2O at 4°C, acetone 
precipitation, another 5 days of dialysis in DI H2O at 4°C, followed by 
lyophilization.  1H NMR was used to determine the degree of modification and 
purity of the HEMA-HA. 
 
SDF-1! electrostatics 
Electrostatic surface potentials of SDF-1! were visualized with Adaptive 
Poisson-Boltzmann Solver (APBS) software18.  The PDB file for SDF-1! 
(2KEC19) was first converted to a PQR file with PDB2PQR software20 using a 
PARSE forcefield and PROPKA software21 to assign protonation states at pH = 
7.4.  All calculations were performed on a web server hosted by the National 
Biomedical Computation Resource and surface potentials were visualized with 
Jmol22. 
 
Macromer binding affinity 
Binding affinity between rSDF-1! and HEMA-HA was quantified using an 
intrinsic protein fluorescence quenching technique23. Fluorescence titration 
experiments were performed on a Tecan infinite m200 plate reader (Grödig, 
Austria) at 25°C.  The fluorescence of a 2 µM rSDF-1! (460-SD, R&D Systems) 
solution in 100 mM HEPES buffer (pH 7.4) was recorded at 280/350nm 
excitation/emission.  Fluorescence quenching was monitored by increasing the 
concentration of HEMA-HA in rSDF-1! solution in 13.5 µM increments.  Dry 
macromer was dissolved in the rSDF-1! solution, mixed, and incubated for a 2 
min equilibration period before measuring fluorescence.  The normalized 
changes in fluorescence with each HEMA-HA titration were plotted against 
HEMA-HA concentration and resulting binding isotherms were fit by nonlinear 
regression (Mathematica, Wolfram Research, Inc.) to the equation describing 
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bimolecular association:  
 
 
where F is the change in fluorescence over initial fluorescence (-!F/Fo), Fi is the 
initial value for (-!F/Fo), Ff is the final value for (-!F/Fo), and Kd is the dissociation 
constant 23. 
 
Hydrogel formation   
Hydrogels were formed upon visible light exposure using a previously 
established initiator system consisting of eosin Y, triethanolamine (TEOA), 1-
vinyl-2-pyrrolidinone (VP), and a halogen curing light (Elipar 2500, 3M)24.  50 µL 
hydrogel precursor solutions were prepared by mixing HEMA-HA and initiators in 
PBS at final concentrations of: 6 wt% HEMA-HA, 0.02 wt% eosin Y, 225 mM 
TEOA, and 37 mM VP.  200 ng rSDF-1α was mixed into the 50 µL hydrogel 
precursor solution for HA Gel/rSDF-1α groups.  Hydrogels were formed in 
cylindrical molds upon light exposure for 90 seconds.  For release studies, gels 
were incubated in 1 mL of chemically defined (CD) media comprised of α-MEM 
media (Invitrogen) supplemented with 20 mM L-glutamine, 100 U/mL penicillin, 
100 μg/mL streptomycin, and 0.1% bovine serum albumin (BSA).  Gels were 
moved to fresh media at the indicated time points and media containing eluted 
molecules were stored at -20°C.  rSDF-1α was quantified with ELISA (DY350, 
R&D Systems) and HA was quantified with a previously established uronic acid 
assay25.   
 
Enzyme-linked Immunosorbent Competition Assay 
An ELISA kit (DY350, R&D Systems) was used to quantify rSDF-1! (460-
SD, R&D Systems) as summarized in the General ELISA protocol from R&D 
Systems.  Prior to loading samples, 0.5 ng/mL rSDF-1! was preincubated in 
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serial dilutions of a 5 mg/mL HEMA-HA solution in PBS for 90 min at 25°C.  
Percent inhibition of monoclonal antibody binding to rSDF-1! due to the added 
HEMA-HA was calculated after quantifying rSDF-1! in each sample. 
 
 
BMC isolation 
Adult BALB/CAnNHsd mice (10–12 weeks old, 22-26 g) were 
anesthetized with 100 mg/kg ketamine and 20 mg/kg xylazine.  Unfractionated 
BMCs were obtained by removing the femurs, and flushing the marrow cavity 
with sterile PBS over a 40 µm filter.  The cells were pelleted by centrifugation and 
resuspended in lysis buffer (BD Biosciences) for 1 min to lyse red blood cells. 
Cells were again pelleted and resuspended in 1 mL PBS to remove remaining 
lysis buffer.  To visualize the cells in vitro and in vivo, PKH fluorescent linker kits 
were employed (Sigma).   
 
In vitro BMC chemotaxis  
The chemotactic activities of rSDF-1! and HEMA-HA were quantified 
using freshly isolated BMCs in microchemotaxis chambers (NeuroProbe) 
following a modified boyden chamber assay26.  Briefly, BMCs (2x106 cells/mL) in 
CD media were separated from active molecules in CD media by a porous 
polycarbonate membrane (5 µm pores) coated with type 1 collagen (PureCol, 
Advanced BioMatrix).  After 4 hrs at 37°C, non-migrated cells on the top side of 
the membrane were scraped away, while migrated cells on the bottom side were 
fixed in 4% formalin and imaged.  PKH67GL fluorescence was used to visualize 
cells and Image J Particle Analysis software was used to quantify cells as 
follows. For each well containing fluorescently tagged cells, a circle was drawn to 
denote the well area using Image J.  The same well area was used for all wells in 
each experiment.  After converting fluorescent images to 8-bit, the images were 
threshold to eliminate background without excluding cells.  Total cell counts in 
each well were quantified using the “Analyze Particles” function in Image J.  Cells 
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were counted manually to validate threshold levels, and the same threshold was 
used for all wells in each experiment.  For each experiment, the average number 
of migrated cells per well for each condition were normalized to the average 
number of migrated cells per well for control wells containing only CD media (n=6 
wells per condition).  A monoclonal antibody to CD44 (ab25064, abcam) was 
used for HA specific blocking at 3 µg/mL, while a CXCR4 antagonist (AMD3100, 
Calbiochem) was used for SDF-1! specific blocking at 0.5 µg/mL.   
 
hMSC culture and chemotaxis 
Human mesenchymal stem cells (hMSCs) were obtained from Lonza 
Corporation (Walkersville, MD) and expanded in growth media (!-MEM, 16.7% 
(v/v) fetal bovine serum, 20 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL 
streptomycin).  hMSCs were used at passage 4 after thawing from liquid N2 
storage and culturing overnight on tissue culture polystyrene (TCPS) in growth 
media under anaerobic conditions (GasPak EZ, Becton Deckinson).  hMSCs 
were removed from TCPS with TrypLE Express (Invitrogen), washed with CD 
media, and resuspended in CD media for chemotaxis experiments.  Cells were 
seeded at 2x105 cells/mL in upper wells of chemotaxis chambers using collagen-
coated membranes with 8 µm pores, and DAPI stained after formalin fixing to 
visualize cells.  Recombinant human SDF-1! (350-NS, R&D systems), 3 µg/mL 
mouse monocolonal antibody for CD44 (ab6124, abcam) and 0.5 µg/mL 
AMD3100 (Calbiochem) were used for hMSC chemotaxis experiments.  
 
Experimental MI 
A cryoinjury model of MI was used to initiate MI remodeling27.  Adult 
BALB/CAnNHsd mice (10–12 weeks old, 22-26 g) were anesthetized with 20 
mg/kg ketamine and 4 mg/kg xylazine, shaved and disinfected with alcohol.  The 
mice were kept under anesthesia (1.5% isoflurane), incubated and ventilated with 
95% O2 using a mechanical ventilator (MiniVent, Harvard Apparatus).  The heart 
was exposed through a left lateral thoracotomy and cryoinjury was introduced by 
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applying a round 2 mm diameter stainless steel probe frozen with liquid nitrogen 
to the epicardial surface of the ventricle for 10 sec.  After removing the probe, the 
cryoinjured area was confirmed by a white disk-shaped region.  For mice 
receiving hydrogels, 25 µL of the liquid hydrogel precursor solutions were applied 
to the surface of the injured ventricle through a 27G syringe in the presence of 
curing lamp exposure.  For mice receiving SDF-1! only, 10 µL of a 10 µg/mL 
rSDF-1! solution was injected into the ventricle wall using a 30G syringe.  The 
order of therapeutic intervention was rotated from animal to animal.  Following 
manipulations to the heart, the intercostal space and skin were closed with 
sutures. Mice received 100% oxygen until responding to interdigital pinch, after 
which the endotracheal tube was withdrawn.  Mice were kept warm with a 
heating blanket during recovery.  Meloxicam (5 mg/kg) was administered via 
intraperitoneal injection 1 hr after surgery and once a day for 1 week following 
surgery to minimize pain.  
 
In vivo BMC homing  
After a recovery period of 3 hrs following MI induction, mice were 
anesthetized with 20 mg/kg ketamine and 5 mg/kg xylazine.  Freshly isolated 
BMCs from a donor mouse were fluorescently tagged with PKH linker kit, 
counted on a Vi-CELL (Beckman Coulter, Inc.), and 9x106 cells in 300 µL sterile 
PBS was injected into the femoral vein of the MI mouse.  Blood samples were 
collected 1 day after BMC injection via retro orbital bleed, treated for RBC lysis, 
and analyzed for PKH+ cells using flow cytometry.  Briefly, cells were gated for 
viability using 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen), size and 
granularity using characteristic BMC distributions of forward scatter (FSC) and 
size scatter (SSC), respectively, and fluorescent intensity using appropriate 
controls (Figure 4.1)28.  PKH+ cells in the blood were reported as a percentage of 
total cells in the blood within the characteristic BMC size distribution.  Mice were 
anesthetized 7 days after experimental MI with 100 mg/mL ketamine and 
xylazine, blood samples were collected from the abdomen, and hearts were 
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excised and either perfusion digested with collagenase (150 U/mL type 2 
collagenase in Krebs buffer, Worthington) for PKH+ cell quantification using flow 
cytometry28 or flash frozen in embedding medium for PKH+ cell visualization 
using histology.  Quantified PKH+ cells in the blood were again reported as a 
percentage of total BMCs in the blood, while quantified PKH+ cells in the heart 
were reported as a total number of cells/heart.  Embedded hearts were sectioned 
at a 12 µm thickness and imaged immediately upon thawing at room 
temperature.  
 
 
 
Figure 4.1. PKH- BMC negative controls for flow cytometry gating.  After gating for viability with 
DAPI, BMCs in the blood (A) and the heart (C) were gated based on the typical size of freshly 
isolated BMCs (A, inset).  The cells within this size range were then analyzed for PKH 
fluorescence (C and D).  This gating strategy minimized PKH false-positive counts in the blood 
and heart to less than 1 per 106 events (D). Abbreviations: SSC – side scatter, FSC – forward 
scatter.     
 
Statistical analysis 
Values are reported as mean ± standard error of the mean.  Statistical 
differences between groups were determined using ANOVA in conjunction with a 
student’s two-tailed t-test (Microsoft Excel), with P < *0.05, **0.01, and ***0.001 
considered as significant. 
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Heart 
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4.3. Results  
HEMA-HA synthesis 
HA macromers were synthesized to facilitate photoinitiated crosslinking 
into hydrogels through a terminal methacrylate group and degradation through 
hydrolysis of ester groups between the methacrylate and the HA backbone 
(Figure 4.2 A).  The extent of HEMA modification was determined to be ~25% of 
disaccharide repeat units along the HA backbone via 1H NMR (Figure 4.3).  This 
percent can be easily tuned with the molar ratio of HEMA-COOH to BOC2O in the 
coupling reaction29.   
 
 
Figure 4.2. Electrostatic interactions between HEMA-HA and rSDF-1!. (A) Repeat unit of HEMA-
HA macromer synthesized with reactive methacrylate group and hydrolyzable ester groups (black 
arrows) between the methacrylate functionality and HA backbone.  The macromer carries a 
negative charge due to carboxylic acid groups along the HA backbone. (B) SDF-1! surface 
potentials visualized using APBS software package (left) that correspond to the beta sheet rich in 
basic amino acids (right).  Scale for surface potentials is in units of kT/e where k is Boltzman’s 
constant, T is temperature, and e is the charge of an electron. (C) Fluorescence quenching of 
rSDF-1! with HEMA-HA titration.  Data fit to bimolecular association equation to calculate KD 23 (n 
= 3 independent experiments). 
 
 
 
Figure 4.3. 1H NMR of purified HEMA-HA macromer. Approximately 25% of the disaccharide 
repeat units were modified with HEMA.  The 1H peaks from the methacrylate group on HEMA (A) 
were normalized to the 1H peaks from the methyl groups on N-acetylglucosamine (B) to 
determine percent modification. 
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HEMA-HA and SDF-1! binding  
To investigate ionic interactions between the HEMA-HA macromer and 
rSDF-1!, the electrostatic surface potentials of SDF-1! were visualized and 
binding association constants were experimentally determined.  Visualization of 
SDF-1! using APBS revealed an overall positive surface charge with the most 
positive charges of nearly +10 kT/e concentrated along the beta sheet of the 
protein structure (Figure 4.2 B).  This charge distribution is attributed to an 
abundance of basic amino acids (i.e., arginine and lysine residues) in the beta 
sheet, which have important roles in SDF-1! binding to negatively charged 
GAGs13.  Indeed, binding between rSDF-1! and the purified HEMA-HA 
macromer was observed with a dissociation constant (KD) of 36 ± 5 µM (Figure 
4.2 C).  This interaction was significantly stronger than the measured interaction 
between HEMA-HA and BSA (KD = 157 ± 4 µM, data not shown), illustrating the 
specificity of small, positively charged chemokines for negatively charged GAGs 
(i.e., HA) in the ECM.   
 
BMC chemotaxis to rSDF-1! and HEMA-HA 
In order to model endogenous BMC homing, unfractionated BMCs were 
isolated from mouse femurs, fluorescently tagged with PKH linker dyes, and used 
to assess the activity of rSDF-1! and HEMA-HA in vitro and in vivo.  In vitro, both 
rSDF-1! and HEMA-HA stimulated chemotaxis of BMCs in a dose dependent 
manner, nearly 4-fold at the highest concentrations investigated (Figure 4.4, ***P 
= 0.0001 and ***P = 0.0008, respectively).  The observed chemotaxis was 
specific to cell surface receptors for SDF-1! (CXCR4) and HA (CD44) as 
evidenced by antagonist and antibody blocking, respectively.  Specifically, the 
introduction of the antagonist or antibody completely diminished any increased 
migration in response to the molecule and was indistinguishable from control 
groups.  The chemotactic activity of rSDF-1! and HEMA-HA was also observed 
using a purified population of bone marrow derived stem cells, human 
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mesenchymal stem cells (hMSCs) (Figure 4.5).  The hMSC response to rSDF-1! 
and HEMA-HA was also diminished in response to the introduction of a CXCR4 
antagonist and CD44 antibody blocking, respectively. 
 
Figure 4.4. Chemotactic activity of rSDF-1! and HEMA-HA. (A) rSDF-1! stimulated significant 
dose-dependent chemotaxis of unfractionated BMCs and was blocked with a CXCR4 antagonist, 
AMD3100. (B) HEMA-HA stimulated similar dose-dependent chemotaxis of BMCs and was 
blocked with a monoclonal antibody to CD44.  For each experiment, the average number of 
migrated cells per well for each condition was normalized to the average number of migrated cells 
per well for negative control wells containing only chemically defined media (mean ± SEM, n = 6 
wells per condition). (C) Representative negative control well with migrated PKH+ BMCs. (D) 
Representative 100 ng/mL rSDF-1! well containing migrated PKH+ BMCs. E) Fluorescent 
visualization of migrated PKH+ BMCs. Scale bars: C-D = 500 µm; E = 50 µm. 
 
Figure 4.5. hMSC chemotaxis to rSDF-1! and HEMA-HA.  (A) rSDF-1! stimulated chemotaxis of 
hMSCs in a dose-dependent manner and was blocked with a CXCR4 antagonist, AMD3100.  (B) 
HEMA-HA stimulated chemotaxis of hMSCs in a dose dependent manner and was blocked with a 
monoclonal antibody to CD44.  The average number of migrated cells per well for each condition 
was normalized to the average number of migrated cells per well for negative control wells 
containing only chemically defined media (n = 6 wells per condition).  (C) Representative wells 
containing migrated cells for negative control (upper) and 100 ng/mL rSDF-1! (lower) conditions. 
Scale bars: C = 500 µm. 
Molecule release from HEMA-HA hydrogels 
To sustain release of rSDF-1! and HEMA-HA in the setting of MI, a visible 
light initiator system was used to crosslink the HEMA-HA macromer into 
hydrogels from a liquid precursor solution (containing rSDF-1!, HEMA-HA, and 
photoinitiator) upon blue light exposure.  Photocrosslinked HEMA-HA 
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hydrogels sustained the release of rSDF-1! and HA, measured over 7 days in 
vitro (Figure 4.6 A-B).  HEMA-HA hydrogels exhibit hydrolytic degradation of 
ester groups in the HEMA side groups, releasing HA,  
 
entrapped rSDF-1!, and poly(methacrylic acid) kinetic chains with time.  
Generally, the release of rSDF-1! and HA was rapid in the first few days, due to 
diffusion of peripheral rSDF-1! and uncrosslinked HEMA-HA, and then slowed 
as release of encapsulated molecules was mediated by hydrogel degradation.  
Gels were still intact after 7 days in buffer at 37°C, while little additional rSDF-1! 
release was measured.  While the ELISA kit provides a low limit of detection for 
rSDF-1!, this antibody “sandwich” technique was unable to detect rSDF-1! in the 
presence of soluble HEMA-HA, which acted as a binding competitor to the 
Figure 4.6. Molecule release from 
photocrosslinked HA Gels. (A) 
Cumulative release of encapsulated 
rSDF-1! was sustained for 7 days in 
vitro as determined by ELISA. (B) 
Cumulative release of uncrosslinked 
HEMA-HA and degradation products of 
the hydrogel was sustained for 7 days in 
vitro as determined by uronic acid 
analysis. Quantity of rSDF-1! and HA 
was measured from buffer collected and 
replaced at specified time points.  Gels 
remained intact after the 7-day 
incubation.  Insets indicate quantity of 
molecules in each sample (n = 3 gels, 
mean ± SEM).  (C) The HA Gel 
significantly enhanced BMC chemotaxis 
for up to 7 days, which was further 
enhanced with release of encapsulated 
rSDF-1!. For each experiment, the 
average number of migrated cells per 
well for each condition was normalized 
to the average number of migrated cells 
per well for negative control wells 
containing only chemically defined 
media (mean ± SEM, n = 6 wells per 
condition). !
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monoclonal antibodies with 44% inhibition at 0.08 mg/mL HEMA-HA (Figure 4.7).  
Therefore, we suspect that reported concentrations of released rSDF-1! are for 
the free, unbound protein in solution, and that rSDF-1!/HEMA-HA complexes are 
also present in the release samples.  Importantly, released molecules from HA 
hydrogels and HA hydrogels containing rSDF-1! both stimulated chemotaxis of 
BMCs over 7 days (Figure 4.6 C), indicating the influence of both HA and rSDF-
1! components on BMC chemotaxis.     
 
Figure 4.7. ELISA inhibition by soluble HEMA-HA.  Incubating rSDF-1! in serial dilutions of 
HEMA-HA inhibited ELISA detection of rSDF-1!.  
 
BMC homing to the remodeling heart 
In order to quantify BMC homing in vivo, fluorescently tagged BMCs were 
infused into the circulation following experimental MI in mice and tracked in the 
blood and the heart using flow cytometry (Figure 4.8 A).  Myocardial delivery of 
homing factors (HA and rSDF-1!) from hydrogels (formed on heart using blue 
light, Figure 4.8 B) was assessed for the ability to enhance BMC homing to the 
heart and compared to controls of MI only and MI with intramyocardial injection of 
rSDF-1!.  Hydrogels were localized to the injury site and adhered to the 
myocardium for sustained delivery of homing molecules (Figure 4.8 C-D).   
The circulating PKH+ BMCs were readily quantified in the blood and heart 
using flow cytometry (Figure 4.8 E).  The fluorescence intensity of the cells varied 
over a wide range, so a PKH+/PKH- threshold was chosen to quantify PKH+ 
BMCs while minimizing PKH- false-positive events in the blood and the heart 
(Figure 4.1).  Using this threshold, we observed a decrease in fluorescence 
intensity of the PKH+ BMCs in the blood from day 1 to day 7 (Figure 4.8 E).   
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Figure 4.8. In vivo model to quantify BMC homing. (A) HA Gels were applied to the heart 
immediately following experimental MI.  Freshly isolated BMCs were fluorescently tagged with 
PKH linker dyes and infused into the circulation via a femoral vein injection 3 hrs after MI.  Blood 
samples were collected 1 and 7 days following MI and hearts were digested 7 days following MI 
to quantify PKH+ BMCs. (B) Hydrogels formed in situ by applying a liquid precursor solution to 
the epicardial surface of the ventricle upon blue light exposure. (C) This technique allowed the 
hydrogels to be localized on the injured myocardium for localized molecule delivery. (D) The 
hydrogels adhered to the myocardium while processing the tissue for histology and H&E staining. 
(E) Representative flow cytometry with constant threshold to quantify PKH+ BMCs in the blood 
and heart. Scale bars: B-10 mm; C-5 mm; D-100 µm.  
 
Considering that the PKH linker dyes are stable in vivo for weeks, the decrease 
in fluorescent intensity could be due to cell proliferation, or simply due to 
preferential retaining of cell types in the blood that do not uptake PKH dyes as 
effectively as others30.  Interestingly, BMCs quantified in the blood on day 1 were 
primarily larger cells around the size and granularity of granulocytes, while the 
BMCs quantified in the blood on day 7 were primarily smaller cells around the 
size and granularity of lymphocytes (Figure 4.9); however, both size phenotypes 
show similar ranges of PKH staining intensity immediately after exposure to the 
PKH linker dye.  
 
Figure 4.9. Size of PKH+ BMCs in the blood.  Circulating PKH+ BMCs exhibited a larger 
phenotype characteristic of granulocytes 1 day after infusion (A), while PKH+ BMCs exhibited a 
smaller phenotype characteristic of lymphocytes/monocytes 7 days after infusion (B).  Both cell 
phenotypes were increased to the same extent in the blood after rSDF-1! delivery to the heart. 
Abbreviations: SSC – side scatter, FSC – forward scatter. 
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Delivery of the HA Gel with encapsulated rSDF-1! and delivery of rSDF-
1! as a bolus injection significantly increased the number of infused BMCs 
circulating in the blood 1 day after infusion (Figure 4.10 A, ***P < 0.001 and *P = 
0.01, respectively).  Both rSDF-1! delivery groups more than doubled the 
number of circulating BMCs on day 1 from 1% to 2% of native BMCs; however, 
this effect was only apparent in the HA Gel/ rSDF-1! group on day 7, although 
not statistically significant (Figure 4.10 B).  All intervention groups significantly 
increased the number of BMCs engrafted in the heart compared to MI only, and 
the HA Gel with encapsulated rSDF-1! significantly increased BMC engraftment 
compared to rSDF-1! alone and the HA Gel alone (Figure 4.10 C, #P = 0.01 and 
0.047, respectively), indicating synergy between the released molecules. 
 
Figure 4.10. Quantification of BMC homing with molecule delivery to the heart. A) rSDF-1! 
delivery to the heart significantly increased the number of circulating PKH+ BMCs 1 day after 
infusion.  B) This effect was sustained, although not statistically significant, 7 days after infusion 
when rSDF-1! was delivered from the HA Gel. PKH+ BMCs in the blood are reported as a 
percentage of total cells in the blood within the BMC size and granularity gating. C) 
Intramyocardial injection of rSDF-1! and application of the HA Gel alone following MI significantly 
enhanced the number of PKH+ BMCs in the heart compared to MI only 7 days after MI and cell 
infusion. Application of the HA Gel with encapsulated rSDF-1! further enhanced PKH+ BMC 
engraftment in the heart compared to delivering rSDF-1! or the HA gel individually. D) When 
normalized to the percent of PKH+ BMCs in the blood 1 day after infusion, the HA Gel enhances 
engraftment of circulating PKH+ BMC with a constant efficiency.  (mean ± SEM, n = 7 animals for 
all groups except for MI only, n = 6). 
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When normalized to the percentage of BMCs circulating in the blood, the 
HA Gel (with and without rSDF-1!) enhanced myocardial engraftment of 
circulating BMCs at a significantly improved rate, over 3-fold greater than the 
bolus rSDF-1! injection and MI control, which showed the same engraftment rate 
(Figure 4.10 D).  While both the HA Gel/rSDF-1! and bolus rSDF-1! injection 
groups had the same effect on circulating BMCs 1 day after infusion (2.2 ± 0.2 
and 2.2 ± 0.3% native BMCs, respectively), they had significantly different effects 
on enhancing BMC engraftment in hearts 7 days after infusion, 570 ± 130 and 
170 ± 40 BMCs per heart, respectively.    
Engrafted BMCs localized to the infarct region (IR) and border region (BR) 
in the heart following MI (Figure 4.11), while PKH+ BMCs in other regions of the 
myocardium were very rare.  The infarct region was characterized by dense 
collagen staining with Masson’s Trichrome (Figure 4.11 A-B).  This collagen scar 
tissue autofluoresced, allowing the infarct region to be easily identified for 
characterizing engrafted BMC locations within the heart, and PKH+ BMC 
fluorescence was bright enough to distinguish the BMCs against the tissue 
background as indicated by white arrows (Figure 4.11 C). PKH+ BMCs were 
identified in the infarct region in all groups, but were rare in the border region for 
all groups except for the HA Gel/rSDF-1! group.  Border region BMCs in this 
group were commonly localized within and around vascular structures (Figure 
4.11 D).  Some cells also appeared to integrate into the tissue and align with the 
native tissue morphology (Figure 4.11 E). 
 
4.4. Discussion 
The objective of this study was to develop a biomaterial system to 
enhance BMC homing to the remodeling myocardium through exogenous 
delivery of the chemokine rSDF-1!.  To accomplish this, we synthesized an in 
situ crosslinkable and degradable hydrogel system based on the molecule HA to 
encapsulate and sustain the local release of rSDF-1! to the myocardium. 
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Figure 4.11. Visualization of PKH+ BMCs in the myocardium 7 days after systemic infusion. A) 
The cryoinjury resulted in the formation of a nontransmural collagen rich scar tissue (blue region) 
7 days following MI as visualized with Masson’s Trichrome. An infarct region (IR) and border 
region (BR) were defined to assess PKH+ BMC locations within the heart.  B) Vasculature in the 
IR and BR remained intact following the cryoinjury. C) PKH+ BMCs were identified in the IR of all 
groups, while PKH+ BMCs in the BR were rare except in the HA Gel/rSDF-1! group.  PKH+ 
BMCs were not found in remote regions of the myocardium for all groups. White arrowheads 
indicate PKH+ BMCs. D) PKH+ BMCs in the BR were often localized in and around vascular 
structures.  E) In addition, cells in the BR appeared to align with the myocardial tissue structure. 
Scale bars: A-500 µm; B-50 µm; C-100 µm; D and E-50 µm. 
 
 Our rationale for choosing HA as our biomaterial was two-fold: (1) HA is a 
negatively charged GAG that naturally regulates chemokines in tissues, and (2) 
HA is the major ligand for CD44, which mediates cell motility processes that 
govern BMC homing.  
GAGs are linear polysaccharides with an abundance of acidic groups that 
are negatively charged under physiologic conditions.  Chemokines, on the 
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other hand, are characterized by an abundance of basic amino acid residues that 
are positively charged under the same conditions.  These complimentary charges 
induce binding between GAGs and chemokines with an affinity that is dependent 
on the specific GAG chemistry, the size of the GAG molecule, and the net charge 
of the chemokine12.  In particular, heparin sulfate (HS) has been shown to bind 
SDF-1! with high affinity (KD~30 nM)13.  Binding between SDF-1! and HS in the 
glycocalyx of the cell surface is important to localize SDF-1! and facilitate 
binding to CXCR413; however, soluble HS has been shown to inhibit the 
chemotactic activity of SDF-1! in a dose dependent manner (0.1 to 100 µg/mL 
HS)31.  Since the CXCR4 binding domain remains exposed after HS binding13, 
the soluble HS is likely acting as a binding competitor to glycocalyx HS, 
preventing SDF-1! from achieving close contact with CXCR4 on the cell surface.  
Therefore, GAG chemistries with less affinity for SDF-1! may be optimal as a 
carrier matrix to allow glycocaylx sequestration of released SDF-1! in the 
presence of the degraded matrix.  HA has 1 carboxylic acid per repeat unit 
compared to 3 sulfate groups per repeat unit of HS; therefore, we expected HA to 
bind SDF-1! with much less affinity (higher KD) than HS.  Indeed, we measured a 
KD of 36 µM between our HA macromer and SDF-1! (Figure 4.2 C), which was 
selective to the positively charged SDF-1! (KD,BSA=157 µM).  This micromolar 
affinity was sufficient to slow SDF-1! diffusion within the HA Gels where the 
concentration of HA is very high (~100 mg/mL), without inhibiting cell chemotaxis 
to released SDF-1! in the presence of HA released from the gels (10 to 100 
µg/mL HA) (Figure 4.6 B-C).  
HA also interacts cooperatively with SDF-1! in directing cell motility 
through CD44 and CXCR4 receptor signaling crosstalk17. SDF-1!-CXCR4 
binding on hematopoetic progenitor cells stimulated cell spreading on HA coated 
substrates through CD44 binding and CD44 polarized to the leading edge of cells 
migrating towards gradients of SDF-1! in vitro17.  HA-CD44 binding initiates G-
protein-dependent signal transduction that stimulates cell motility through Rho-
ROCK signaling32, as well as cell adhesion through integrin expression33.  These 
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signaling pathways are important regulators of BMC homing processes in the 
bone marrow17, as well as in peripheral tissues during inflammation34.  For 
example, intravenously injected MSCs home to the injured kidney in a CD44 
dependent process35.  The role of HA in this process was corroborated in vitro as 
the MSCs exhibited CD44 dependent chemotaxis to HA.  
In line with these studies, we showed that our modified HA macromer 
stimulates chemotaxis of BMCs through CD44 (Figures 4.4, 4.5).  When 
delivered to the myocardium as an epicardial hydrogel immediately following 
experimental MI, the HA Gel enhanced engraftment of circulating BMCs in the 
myocardium (Figure 4.10 C).  BMC engraftment was further enhanced by 
encapsulating rSDF-1! in the HA Gel (Figure 4.10 C).   To form the hydrogels in 
situ, a photo-initiated crosslinking mechanism was utilized in order to localize 
molecule release to the myocardium while avoiding biomaterial injections that 
could cause further damage due to the small thickness of a mouse ventricle wall.  
In experimental models with larger ventricle wall thicknesses, a redox-initiated 
crosslinking mechanism can be used to form these hydrogels upon injection 
through a syringe29.   
Interestingly, delivering rSDF-1! to the heart had systemic effects in 
significantly increasing the number of PKH+ BMCs circulating in the blood, and 
sustained release of rSDF-1! from the HA Gel prolonged this effect (Figure 4.10 
A-B).  Separate studies have shown that an increase in circulating CXCR4+ cells 
coincides with the temporal expression of rSDF-1! in the heart following MI8,9.  In 
addition, elevating SDF-1! concentrations in the blood has been shown to 
mobilize BMCs into the circulation36.  Since we report the number of PKH+ BMCs 
in the blood as a percentage of total BMCs in the blood, an increase in this 
percentage may indicate that systemic concentrations of SDF-1! are high 
enough to prevent circulating PKH+ BMCs from homing to other organs, such as 
the bone marrow or spleen37,38, but not high enough to mobilize native BMCs 
from SDF-1! gradients in the bone marrow.  Indeed, mobilizing agents have 
been administered systemically following MI in order to mobilize CXCR4+ BMCs 
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into the circulation and therefore enhance the response to SDF-1! signals in the 
heart39.   
To model BMCs mobilized from the bone marrow, unfractionated BMCs 
were injected directly into the systemic circulation.  These cells were used with 
minimal manipulations to include all CXCR4+ and CD44+ BMC populations that 
are present in vivo, and avoid culture conditions that are known to affect cell 
responsiveness to chemokines40.  Using this model system, we were able to 
definitively quantify BMC homing with molecule delivery to the heart; however, 
investigation of how homed BMCs contribute to myocardial repair is beyond the 
scope of the model.  Nevertheless, a growing body of literature suggests that 
delivery of SDF-1! and HA would promote a beneficial healing response 
following MI.  For example, CXCR4 is expressed on selective populations of 
BMCs that have been implicated in myocardial tissue repair, including 
hematopoetic progenitor cells41, mesenchymal stem cells42, dendritic cells43, T 
lymphocytes44, and even committed tissue-specific stem cells45.  Furthermore, 
SDF-1! delivery has been shown to largely promote neovascularization in 
ischemic tissues through BMC homing9-11.  While enhancing CXCR4 positive 
cells in the heart has been shown to significantly attenuate post-MI remodeling, 
this approach seems to require complimentary growth factor and cell adhesion 
molecule expression that occurs in the early stages of post MI remodeling46.  
Therefore, early therapeutic intervention may be a limiting factor in translating 
SDF-1!-based therapies to the clinic. 
Like SDF-1!/CXCR4, HA/CD44 interactions have important roles in 
regenerative processes during tissue remodeling including cell migration, 
proliferation, and differentiation47.  In the setting of MI, CD44 expression is 
abundant on infiltrating leukocytes, myofibroblasts and endothelial cells that 
contribute to tissue repair48.  CD44 knockout animals showed a prolonged 
maldaptive inflammatory response and diminished collagen synthesis, causing 
further ventricle dilation following MI48.  Here, we report that dual delivery of SDF-
1! and HA from in situ forming hydrogels enhances BMC homing to the 
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remodeling myocardium.  This finding highlights the importance of using 
materials that mimic components of the bone marrow niche to provide BMC 
specific cell adhesion ligands that act synergistically with SDF-1!/CXCR.  
However, applying these systems beyond the early stages of post MI remodeling 
remains to be investigated.  
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CHAPTER 5 
 
Sustained release of SDF-1! polypeptide analogue from injectable 
hyaluronic acid hydrogels attenuates post MI remodeling 
 
(Adapted from: J.W. MacArthur Jr., B.P. Purcell, P.F. Hsiao, A.S. Fairman, E.C. 
Yang, A. Trubelja, W. Hiesinger, Y. Shudo, P. Atluri, J.A. Burdick, J.Y. Woo, 
Circulation, in press) 
 
5.1. Introduction 
 Heart disease is the cause of significant morbidity and mortality in the US 
with estimates of nearly 800,000 new acute coronary events each year, a 
disease accounting for a substantial proportion of the national health care 
expenditure1, 2.  On a cellular level, the events following a myocardial infarction 
include a change in composition of the extracellular matrix with a shift towards 
collagen deposition, hypocontractile scar formation, myocyte apoptosis, and 
progressive ventricular dilatation3"  The deleterious remodeling that occurs over 
time leads to augmentation in the stress-strain relationship of ventricular 
myocytes, inefficient contractility, and ultimately heart failure.  When current 
treatments for coronary artery disease fail, they usually do so because 
microvascular perfusion is not adequately restored – a critical, independent 
predictor of ventricular remodeling, reinfarction, heart failure, and death4"   
 In an effort to restore microvascular perfusion, various cytokines have 
been used to stimulate angiogenesis, with moderate success.  One such 
cytokine, stromal cell-derived factor 1-alpha (SDF-1), is a key regulator in 
hematopoietic stem cell trafficking between the bone marrow and peripheral 
circulation and effectively localizes endothelial progenitor cells to areas of 
ischemia5, 6.  It has been shown by our group and others to increase 
vasculogenesis, decrease cardiac myocyte apoptosis, increase cardiac myocyte 
survival, and preserve ventricular geometry7-10"  The functional and regenerative 
benefits of SDF-1 treatment are directly related to its ability to bind its receptor, 
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CXCR4.  However, there is a temporal mismatch between peak expression of 
SDF-1 and upregulation of CXCR4 on bone marrow and cardiac stem cells.  
Within an hour of ischemia, cardiac SDF-1 expression is rapidly upregulated in 
the heart, while CXCR4 peaks at 96 hours, by which time SDF-1 is nearly 
absent5, 11, 12.  Contributing to this mismatch is that SDF-1 is rapidly cleared from 
the circulation and cleaved by matrix metalloproteinase-2 and CD-2613-16"  
 In order to address the temporal mismatch in the SDF-1:CXCR4 axis, 
SDF-1 concentration within cardiac tissue must be maintained over the course of 
several weeks to prolong its trophic effects on CXCR4+ cells, thereby optimizing 
angiogenesis, cardiac myocyte preservation, and ventricular performance.  In the 
current study, we hypothesized that a hyaluronic acid based hydrogel could 
sustain the release of our previously reported engineered SDF-1 analog (ESA) 
over several weeks, resulting in the temporal realignment of the SDF:CXCR4 
axis and consequently improved angiogenesis, limited ventricular remodeling, 
and preserved cardiac function in a rat model of myocardial infarction. 
 
5.2. Methods 
Custom Peptide Synthesis 
We have previously reported on the design and synthesis of an 
engineered SDF-1! peptide analogue (ESA)17, 18.  Briefly, the CXCR4 receptor 
binding N-terminus and the molecular stabilizing C-terminus were preserved 
while the central beta pleated sheet was deleted and replaced with 2 proline 
“linker” residues.   Using mathematical modeling, this modified sequence was 
predicted to retain as similar a three-dimensional protein configuration to the 
native SDF-1! as possible.  The designed protein was synthesized using solid 
phase peptide synthesis, where the N !-amino acids are incorporated into the 
peptide in a step-wise fashion while one end is attached to a solid support matrix.  
Additionally, we added HiLyte Fluor TR (AnaSpec, San Jose, California) during 
the synthesis process as a fluorophore tag for use in the in vitro studies, and 
HiLytefluor 750 (AnaSpec, San Jose, California) was added for the in vivo study. 
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Macromer Synthesis 
Sodium hyaluronate (74kDa, Lifecore) was chemically modified with h 
ydroxyethyl methacrylate (HEMA) to incorporate a terminal methacrylate 
group for free-radical initiated crosslinking and ester bonds to introduce hydrolytic 
degradation19"  Briefly, HEMA was reacted with succinic anhydride via a ring 
opening polymerization in the presence of N-methylimidazole to obtain HEMA-
COOH, which was then coupled to a tetrabutylammonium salt of HA in the 
presence of 4-dimethylaminopyridine.  The resulting HA macromer with HEMA 
group modification (HEMA-HA) was purified via dialysis, lyophilized, and the 
percentage of HA disaccharides modified with a HEMA group was determined to 
be ~15% using 1H NMR.   
 
Hydrogel Crosslinking 
To form hydrogels rapidly upon injection into the myocardium, a two-
component redox initiator system consisting of ammonium persulfate (APS) and 
N,N,N!,N!-tetramethylethylenediamine (TEMED) was utilized. APS and TEMED 
were added to a final concentration of 10mM in a 4% (w/v) HEMA-HA solution 
and kept on ice.  The kinetics of gel formation were characterized with rheometry 
at 37°C by monitoring the storage (G’) and loss (G”) modulus with time, while 
applying oscillatory strain (20mm 1o cone geometry, 1% strain, 1Hz, Texas 
Instruments AR 2000ex). For in vitro release kinetics, 25µg ESA was added per 
50µL gel precursor solution, and 50uL gels were formed in cylindrical molds for 
30 min at 37°C.  Gels were incubated in 1mL PBS supplemented with 1% BSA at 
37°C and buffers were refreshed every 2 days.  Fluorescence of eluted ESA from 
each 2 day sample, extending over a 4 week period, was quantified on a 
microplate reader (TECAN, Austria), while HA content was quantified with a 
uronic acid assay20"  After 28 days, hydrogels were enzymatically degraded with 
hyaluronidase (800 units/mL, Sigma) and evaluated for remaining ESA and HA. 
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Endothelial Progenitor Cell Chemotaxis 
 Bone marrow mononuclear cells were isolated from the long bones of 
syngeneic adult male Wistar rats (Charles River) by density centrifugation with 
Histopaque 1083 (Sigma-Aldrich), plated on vitronectin coated dishes, and 
cultured in endothelial basal medium-2 supplemented with EGM-2 SingleQuot 
(Lonza) containing human epidermal growth factor, FBS, vascular endothelial 
growth factor, basic human fibroblast growth factor, recombinant human long R3 
insulin-like growth factor-1, ascorbic acid, heparin, gentamicin, and amphotericin-
B.  Media was changed on culture day 4 and non-adherent bone marrow 
mononuclear cells were discarded, enriching for the EPC phenotype. 
 A modified transwell migration assay (Neuro Probe, Gaithersburg, MD) 
was used to assess EPC migration.  Briefly, 8-!m filters were loaded into control 
and experimental chambers.  Seven-day EPCs cultured in endothelial-specific 
media on vitronectin-coated plates were trypsinized, counted, and brought to a 
concentration of 90 cells/!l in Dulbecco’s phosphate buffered saline (DPBS).  
The bottom chamber was loaded with either DPBS or the eluted ESA from the 
hydrogel at each respective 2 day time point.  DPBS from hydrogel without ESA 
served as a control.  A 560!l cell suspension was added to the top chamber of 
each.  All chambers were incubated at 37ºC, 5% CO2 for 3.5 hours.  The cells 
remaining in the top chamber were wiped clean with a cotton swab and the filter 
was removed, placed on a glass slide, and mounted with Vectashield w/ DAPI 
(Vector Laboratories).  Slides were visualized on a DF5000B Leica fluorescent 
microscope and analyzed via LASAF version 2.0.2 (Leica) software.  Boyden 
chamber analyses were performed in triplicate. 
 
Animal Care and Biosafety 
 Male Wistar rats weighing 250-300g were obtained from Charles River 
Labs (Wilmington, Massachusetts).  Food and water were provided ad lib.  All 
experiments pertaining to this investigation conformed to the “Guide for the Care 
and Use of Laboratory Animals,” published by the US National Institutes of 
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Health (Eighth Edition, 2011).  The protocol was approved by the Institutional 
Animal Use and Care Committee of the University of Pennsylvania (protocol 
number 803394). 
 
Animal Model 
 Myocardial infarction was induced in 33 male Wistar rats using an 
established and highly reproducible model.  Briefly, the rats were anesthetized in 
a 2L induction chamber (VetEquip, Pleasantville, CA) and 3% isofluorane was 
continuously delivered.  A 16-gauge angiocatheter was used for endotracheal 
intubation and connected to mechanical ventilation (Hallowedl EMC, Pittsfield 
Mass) where 1% isofluorane was maintained throughout the operation.  A 
thoracotomy was performed through the left 4th intercostal space, the heart was 
exposed, and a 7-0 polypropylene suture was placed around the left anterior 
descending artery 2mm below the left atrium.  The suture was briefly snared to 
verify the size and location of myocardial ischemia based on color change, and 
permanently tied down to produce a large anterolateral MI8-10, 17, 18.  The animals 
were then randomized into 3 groups and received 4 separate peri-infarct 
intramyocardial injections of either saline (100!l, n=8) hydrogel alone (100!l, 
n=10), or hydrogel/25!g ESA (100!l, n=9).  The thoracotomy was closed in 
multiple layers and tissue adhesive (VetBond, 3M, Minneapolis, MN) was applied 
over the incision.  All rats were implanted with subcutaneous microchips 
(BioMedic Data Systems, Boise, ID), and recovered from anesthesia.  
Buprenorphine (0.5mg/kg) was administered for post-operative pain control. 
 
Echocardiographic and Hemodynamic Assessment 
 LV geometry and function were evaluated pre-operatively and at 4 weeks 
in all animals21"  A Phillips Sonos 5500 revD ultrasound system (Philips Medical 
Systems, Amsterdam ND) was used, utilizing a 12-MHz transducer at an image 
depth of 2cm.  Left ventricular parasternal short axis 2D and M-mode images at 
the level of the papillary muscle were used to obtain echocardiographic data.  All 
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analyses were performed by a single investigator who was blinded to the 
treatment groups. 
 Four weeks after LAD ligation, all three groups of animals underwent 
invasive hemodynamic measurements with a pressure-volume (P-V) 
conductance catheter (SPR-869; Millar Instruments, Inc.).  The catheter was 
calibrated via 5 point cuvette linear interpolation with parallel conductance 
subtraction by the hypertonic saline method.  Rats were anesthetized as above, 
and the catheter was introduced into the LV utilizing a closed-chest approach via 
the right carotid artery.  Measurements were obtained before and during inferior 
vena cava occlusion to produce static and dynamic P-V loops under varying load 
conditions.  Data were recorded and analyzed with LabChart version 6 software 
(AD instruments) and ARIA Pressure Volume Analysis software (Millar 
Instruments, Inc).  Finally, cardiac output was assessed by placing a 2.5mm peri-
aortic Doppler flow probe (Transonic Systems, Ithaca, NY) around the ascending 
aorta. 
 
In-vivo ESA release 
 In a subset of 6 animals from the hydrogel/ESA group, in vivo 
fluorescence of ESA was quantified using a Pearl Impulse small animal imaging 
system (LI-COR) on post injection day 1, and every 4 days thereafter through the 
4 week time point in order to visualize intramyocardial ESA.  Animals were 
anesthetized with 1% isoflurane via nose cone, the left chest was shaved, and 
the animals were placed in the right lateral decubitus position on the imaging 
platform with the left chest closest to the camera.  Dynamic images were 
obtained using the 800nm channel of the instrument (785/820nm 
excitation/emission), with standardized parameter settings scaled to the same 
maximum values.  Estimates of the fluorescence of ESA were determined by 
fixed regions of interest (ROI) over the heart, and signal intensity was calculated 
using the manufacturer’s software.  Signal intensity for each time point was 
normalized to the peak signal observed for each animal, and the ratio for each 
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time point was averaged for all 6 animals.  Animals from the saline group (n=3) 
served as negative controls.  
 
Histologic Analysis and Immunohistochemistry 
In order to assess ventricular geometry, infarct size, and microvascular 
angiogenesis, hearts were explanted in a subset of 11 animals after the invasive 
hemodynamic assessment was performed (saline, n=3; hydrogel, n=4; 
hydrogel/ESA, n=4) and flushed with PBS, then injected retrograde with Tissue 
Tek OCT compound (Sekura, Netherlands) through the aorta and pulmonary 
artery.  Hearts were submerged in OCT, frozen, and stored in a -80ºC freezer.  
Orientation of hearts during freezing was standardized so as to result in 
consistent positioning during the sectioning process.  Eight, 10!m thick sections 
were prepared from each heart at the level of the papillary muscles and stained 
with hematoxylin and eosin or Masson’s Trichrome.  Standardized digital 
photographs were taken with a Nikon D5100 SLR camera (Nikon, Tokyo, Japan).  
Photographs were uploaded to ImageJ (v1.46b) and the size of the infarct 
assessed with digital planimetry. 
Two, 10!m thick sections from each animal were co-stained with 
antibodies directed against von Willebrand Factor (vWF) in order to quantify 
capillary density.  Sections were fixed with HistoChoice (Amresco, Solon, OH), 
blocked in 10% FBS, and incubated with sheep anti-VWF (conjugated to FITC, 
1:100 dilution, Abcam) for 2 hours.  Slides were washed and mounted with 
Vectashield (Vector Laboratories).  Quantitative analysis of capillary density 
within the borderzone was conducted under the 20x objective of a Zeiss LSM 
710 confocal microscope (Zeiss, Germany).  Group blinded counts were 
averaged over 4 fields per specimen.  Sections were also stained with antibodies 
directed towards CXCR4.  Sections were fixed with ice cold acetone, blocked in 
10% FBS, and incubated with goat anti-CXCR4 (Abcam 1671, 1:300) for 2 hours.  
Donkey anti-goat antibody-FITC (Abcam 7121, 1:1000) was used as a secondary 
reagent, and sections were counterstained with DAPI to visualize nuclei.  
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Immunofluorescent images were acquired and analyzed as above. 
 
Statistical Analysis 
Continuous variables were reported as means ± standard deviation.  The 
Student’s t-test was used to compare continuous variables.  Statistical 
significance was set at p < 0.05.  Analyses were preformed with STATA 
(StataCorp, College Station, TX) statistical software package, version 12.1.  
 
5.3. Results 
Hydrogel Formation 
 HEMA-HA gels formed rapidly through the mixing of two solutions that 
each contain components of the APS/TEMED free-radical initiator system (Figure 
5.1).  Gelation occurred within 1 minute and the crosslinking reaction reached a 
plateau within 30 minutes.  By using this crosslinking route, we are able to inject 
the liquid precursor solution through a syringe and form solid gels under 
physiologic conditions. 
 
 
Figure 5.1. Hydrogel formation.  (A) HEMA modified HA macromers synthesized with terminal 
vinyl double bonds for free-radical initiated crosslinking into gels and ester groups to introduce 
hydrolytic degradation of the gels. (B) Monitoring storage (G’, elastic component) and loss (G’’, 
viscous component) moduli over time with rheometry shows that solid gels form from an 
injectable liquid solution within minutes upon addition of APS/TEMED initiators.  
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Hydrogel Degradation and ESA Release Kinetics 
 ESA release was sustained for over 28 days in vitro when encapsulated in 
degradable HEMA-HA hydrogels (Figure 5.2 A).  An initial burst release of ESA 
was observed during the first few days due to ESA that was not encapsulated 
during gel formation or encapsulated in the periphery of the gels.  Similarly, an 
initial burst release of HA was observed due to HEMA-HA polymers that were not 
incorporated into the gels during the crosslinking reaction.  After this initial period, 
ESA release was steady for approximately 20 days while the gels remained 
intact. The retention of ESA within the hydrogels was surprising considering the 
small size of ESA (~4kDa).  Upon closer examination, microscale ESA 
aggregates were observed within the gel (purple due to the fluorescent tag) 
which would account for the reduced diffusion of the peptide within the hydrated 
gel (Figure 5.2 C).  As the gels began to hydrolyze and HA was released, the 
rate of ESA release increased due to less restricted diffusion of the particles 
within the gels (Figure 5.2 D). 
 
 Hydrogel Release of ESA Remains Functional 
 Using a transwell migration assay, EPCs showed significant chemotaxis 
towards ESA released from the gels, indicating that the peptide remains active 
after gel encapsulation and release (Figure 5.2 B).  Importantly, the ESA 
remained active throughout the entire 28 day in vitro study.  Significant increases 
in EPC chemotaxis were also observed in samples from the hydrogel alone when 
compared to PBS, which is attributed to the HA degradation products being 
released from the material.  
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Figure 5.2. Molecule release from hydrogels.  (A) ESA release from the gels was sustained for 
28 days in vitro and correlated with gel stability (n=3 gels, mean±SD).  (B) Released ESA and HA 
stimulated EPC chemotaxis throughout the 28 day study (n=5-6 wells/condition, mean±SD, 
*p<0.05 compared to saline control. Dotted line represents saline control).  (C) Representative 
bright field images of ESA aggregates (purple due to fluorescent tag) encapsulated in the 
hydrogel at Days 1, 5, 14, and 23 (scale bar = 200 µm).  (D) Schematic of diffusion controlled 
release of encapsulated ESA from degradable HA gels.        
 
Tracking ESA within the Heart post MI 
 By utilizing ESA that had been conjugated with a near IR wavelength 
fluorophore (i.e., HiLyte Fluor 750, 753/778nm excitation/emission), we were able 
to image ESA in the heart to quantify the dynamics of ESA release from 
hydrogels.  Rats treated with the fluorescently tagged ESA encapsulated in 
hydrogels manifested a strong fluorescent signal for the first 10 days, followed by 
a steady decline in signal until a plateau at day 24, when there was no difference 
in signal compared to the saline control group (Figure 5.3). The quantitative data 
for ESA localized to the heart is shown in Figure 5.3 and demonstrates that ESA 
is released over a 24 day time period in-vivo. 
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Figure 5.3. In vivo ESA tracking.  After undergoing LAD ligation and injection with 
hydrogel/ESA, animals underwent in vivo imaging to visualize ESA fluorescence.  Animals 
receiving saline injections served as a negative control.  (A) Representative images of 
hydrogel/ESA injection group.  (B) Quantitative analysis of fluorescent images showed a 
fluorescent ESA signal in the heart out to day 24, after which fluorescence was not different than 
background (dotted line denotes fluorescence of saline control) (Saline n=3; hydrogel/ESA, n=6; 
mean±SD). 
 
Hydrogel + ESA Improves Hemodynamics post-MI 
 Echocardiographic assessment of cardiac structure and function revealed 
significant benefits with hydrogel injection and ESA delivery  (Figure 5.4 A-B).  At 
4 weeks post MI, LV inner diameter at end diastole (LVIDd) was reduced in the 
hydrogel groups compared to the saline control group; however, there was no 
statistical difference between hydrogel and hydrogel/ESA groups (Figure 5.4 A).  
LV ejection fraction was preserved and significantly greater in the hydrogel/ESA 
group compared to the saline and hydrogel alone groups (Figure 5.4 B).  
Additionally, hemodynamic assessment of LV function revealed significant 
improvements with hydrogel injection and ESA delivery (Figure 5.4 C-D).   
Cardiac output was significantly greater in the hydrogel/ESA group compared to  
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saline and hydrogel alone groups (Figure 5.4 C).   In addition, there was a 
significant increase in the LV end systolic pressure-volume relationship (ESPVR) 
in the hydrogel/ESA group compared to the saline and hydrogel alone groups 
(Figure 5.4 D).   
 
Figure 5.4.  LV functional assessment.  LV function was quantified using echocardiography (A-
B) and hemodynamic analysis (C-D) 28 days following experimental MI and injections in rats.  (A) 
Injection of hydrogels significantly reduced LV dilation as indicated by LV internal diameter and 
diastole (LVIDd).  (B) A significant improvement in LV ejection fraction was observed with 
hydrogel delivery of ESA.  (C) Significant improvements in cardiac output were observed with 
hydrogel injections, and further improvement was observed with encapsulation of ESA.  (D) 
Significant improvements in LV end systolic pressure-volume relationship (ESPVR) were 
observed with gels injection, and further improvement was observed with encapsulation of ESA. 
(Saline, n=8; HA Gel, n=10; HA Gel/ESA, n=9; mean±SD; #p<0.025 versus control, *p<0.025 
between groups, student’s t-test with Bonferonni correction). 
 
 
Hydrogel + ESA Results in Preservation of Ventricular Geometry, Smaller 
Infarcts, Greater Borderzone Capillary Density, and Upregulation of CXCR4+ 
Cells 
 Histologic analyses showed smaller LV areas in the hydrogel/ESA group 
when compared to saline control, but was statistically similar to the hydrogel 
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alone group, while the infarct fraction of theLV was significantly smaller in the 
hydrogel/ESA group compared to controls.  Representative images are shown in 
Figure 5.5.  Analysis of immunofluorescently labeled vWF showed a significant 
increase in capillary density in the hydrogel/ESA group and hydrogel alone group 
when compared to the saline group (Figure 5.6 A). Additionally, there were 
significantly more CXCR4+ cells in the hydrogel /ESA group compared to 
hydrogel and saline groups (Figure 5.6 B).   
 
Figure 5.5.  Histologic assessment of LV geometry and structure. (A) Representative 
sections from rat hearts 28 days post MI after haematoxylin and eosin (H&E) or Masson’s 
Trichrome staining. (B) ESA delivery from injected hydrogels significantly increased LV wall area 
(C) and reduced fibrosis compared to hydrogel alone and saline control groups (saline, n=3; 
hydrogel, n=4; hydrogel/ESA, n=4;! mean±SD, #p<0.025 versus control, *p<0.025 between 
groups, student’s t-test with Bonferroni correction) 
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Figure 5.6.  Immunohistochemistry of the border zone myocardium 28 days post MI.  (A) 
Representative von Willebrand factor (vWF) staining.  (B) Quantitative analysis of vWF 
expression showed a significant increase in capillary density with hydrogel injections. (C) 
Representative CXCR4 staining (SDF-1! receptor). (D) Quantitative analysis of CXCR4 showed 
a significant increase in the number of CXCR4+ cells with hydrogel injection, and a further 
increase with ESA encapsulation. (mean±SD, #p<0.025 versus control, *p<0.025 between 
groups, student’s t-test with Bonferroni correction) 
 
5.4. Discussion  
 Over the past five years, investigations into intramyocardial injection of 
bioengineered, chemically modified materials after MI have showed promising 
results, causing thicker, stiffer infarcts, limiting infarct expansion and preserving 
LV geometry22-26"  Although promising, it may be very useful to improve on these 
techniques through further biological targets, such as stimulating a robust 
angiogenic response and localizing progenitor cells to the site of infarction.  HA 
based hydrogels offer an intriguing benefit as they are able to provide both 
support to the infarcted myocardium during the acute phase and a platform for 
the delivery of potent chemokines, where release is controlled with diffusion and 
hydrolytic degradation. 
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In the present study we utilized a HA based hydrogel to encapsulate an 
engineered SDF-1 analog (ESA) to sustain release of this polypeptide over 28 
days.  The hydrogel was chemically engineered to degrade in about 28 days, 
which was confirmed in vitro by a uronic acid assay.  We were able to show that 
functional ESA can be released from the hydrogels over the entire 28 days study, 
recruiting EPCs in a transwell migration assay across all time points.  
Interestingly, the hydrogel alone group also stimulated migration of EPCs, albeit 
to a lesser extent than hydrogel/ESA, a finding that is supported by prior studies 
and likely due to the interaction of HA with the membrane protein CD44 on 
EPCs19, 27, 28.   
Our in vivo studies demonstrated that treatment with hydrogel/ESA 
resulted in smaller infarcts, stimulated angiogenesis at the borderzone, and 
preserved LV geometry and function.  Again, we observed that treatment with 
hydrogel alone stimulated a moderate amount of angiogenesis at the borderzone 
and maintained LV geometry, findings which are consistent with previous 
literature showing that injectable hydrogels can limit infarct expansion by 
providing structural support to the myocardium, resulting in improved 
hemodynamic functioning24, 25.  Lastly, we were able to successfully track ESA in 
the heart over 24 days using fluorescent imaging, confirming that our hydrogels 
sustained release of ESA in vivo as we originally proposed. 
It is noteworthy the degree to which the hydrogel alone group derived 
structural and functional benefit in this study.  Although this is not a new finding, it 
is interesting that HA hydrogels can limit infarct expansion and preserve 
ventricular geometry, causing improved hemodynamics.  It is likely that these 
benefits are multifactorial in nature, resulting from the structural properties of the 
gel itself as well as HA interaction with CD44 on bone marrow progenitor cells.  
Ultimately, however, we have shown that hydrogel/ESA has a synergistic effect 
on the heart following MI, resulting in improved structure and function of the 
myocardium and upregulation of CXCR4+ cells.  Despite the similarities in 
angiogenesis between the hydrogel and hydrogel/ESA groups, improved 
!87!
hemodynamic function was observed in the hydrogel/ESA group.  This is most 
likely due to the fact that the role of ESA is not merely to attract bone marrow 
progenitor cells, but also recruit endogenous cardiac progenitor cells to the 
infarct borderzone.  Through its interaction with CXCR4+ cardiomyocytes, ESA 
may lead to preservation of cardiac cells through reduced apoptosis via CXCR4 
pathways, leading to improved hemodynamics.  In a very eloquent knockout 
model, Dong and colleges were able to show that the SDF-1:CXCR4 axis is 
vitally important for preservation of cardiac function following MI, specifically 
showing SDF-1 binding to CXCR4+ cardiac cells leads to retention of 
cardiomyocytes, reduction in infarct size and localization of cardiac stem cells at 
the borderzone – and all without altering vascular density29" 
One limitation of this study is that it was performed in an acute model of 
MI, where the treatment was given immediately after coronary artery ligation.  
Although this satisfies our scientific search for how hydrogel encapsulated ESA 
interacts with ischemic myocardium, the positive findings reported here may not 
be generally applied to clinical situations where treatment modalities must be 
effective in the setting of chronic heart failure.  Chronic post-ischemic changes 
offer a complex problem to the investigator, where deleterious remodeling and a 
diminutive stem cell supply must be overcome.  However, as a proof of principle 
study and a starting point, we have effectively shown that sustained release of 
ESA by injectable hydrogels is possible in the heart.   
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CHAPTER 6 
 
Local hydrogel delivery of recombinant tissue inhibitor of 
metalloproteinase-3 attenuates adverse left ventricular remodeling after 
myocardial infarction 
 
(Adapted from: S.R. Eckhouse, B.P. Purcell, J.M. Oelsen, C.B. Logdon, W.F. 
Rawls, R.K. Patel, K.N. Zellars, R.E. Stroud, J.A. Jones, R. Mukherjee, R.C. 
Gorman, R.A. Black, J.A. Burdick, F.G. Spinale, Sci Trans Med, in revision) 
  
6.1. Introduction 
 A structural milestone in the progression of heart failure following a 
myocardial infarction (MI) is left ventricular (LV) remodeling, defined as changes 
in LV geometry and structure1-10.  While post MI remodeling is a multifactorial 
process, one ubiquitous event is infarct expansion4-10. Specifically, infarct 
expansion is the regional process by which continuous turnover of the 
extracellular matrix (ECM) results in the LV wall thinning and the loss of structural 
support8-13.  One biological system that is active in the post MI context is a family 
of ECM proteases, the matrix metalloproteinases (MMPs)13-25.  MMPs are a 
family of enzymes involved in proteolytic processing of interstitial structural 
proteins, signaling molecules and growth factors13,26,27. The induction and 
release of MMPs have been demonstrated in patients post MI, and were 
associated with adverse LV remodeling and the development of heart failure22-25.  
Moreover, direct measurement of interstitial MMP activity through microdialysis 
techniques have established that MMP activation occurs within the ischemic 
myocardium21,28.  Thus, localized control of MMP activity within the MI region is a 
potential therapeutic target for the purposes of interrupting the maladaptive 
process of infarct expansion.     
The cause-effect relationship between MMP activity and adverse LV 
remodeling has been established in experimental models through 
pharmacological MMP inhibition, as well as transgenic constructs13-20.  For 
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example, continuous, systemic adminstration of pharmacologic MMP inhibitors 
reduced the extent of infarct expansion and LV dilation following experimental MI 
in adult pigs14.  However, translation of systemic pharmacologic MMP inhibition 
to clinical application has encountered problematic issues, including concerns 
surrounding dosing and potential side-effects29-32.  Under ambient physiologic 
states, endogenous MMP inhibition is achieved through the synthesis and 
release of the tissue inhibitors of MMPs (TIMPs)13,33-35.  In contradistinction to the 
induction of MMPs in the early post-MI period, a concomitant increase in relative 
TIMP levels does not occur, causing an imbalance between endogenous 
proteolytic activity and inhibition, which in turn would facilitate early adverse LV 
remodeling and infarct expansion13-15,22-25.  It is now becoming recognized that 
the biological effects of TIMPs may not be uniform, and studies have identified 
unique functionality34-38.  Of particular relevance, TIMP-3 levels are reduced in 
patients post MI22,  and transgenic deletion of TIMP-3 causes adverse 
remodeling and acceleration to heart failure39-41.  Unique biological features of 
TIMP-3 include a high affinity to bind to the ECM through interactions with 
glycoasaminoglycans34,42,43,  influences on cytokine processing41,44,  and 
alterations in fibroblast phenotype in-vitro36,45.  However, localized augmentation 
of TIMP-3 in the context of post-MI remodeling has not been examined.   
Accordingly, the central hypothesis of this study was that local delivery of 
exogenous TIMP-3 within the MI region would reduce infarct expansion and alter 
the course of post-MI remodeling.  Polymers that form solid water-swollen 
hydrogel matrices from liquid precursor solutions upon injection through a syringe 
have been applied in order to localize and sustain the release of macromolecules 
to the MI region46.  Past studies have demonstrated that composite materials 
such as hydrogels containing hydroxyapatite or fibrin-alginate can be safely 
injected into the MI region47-51.  Moreover, injectable hydrogels based on 
hyaluronic acid (HA), a glycosaminoglycan found abundantly in the ECM, have 
been deployed in large animal models of MI47.  Thus, the first aim of the present 
study was to develop a method by which to incorporate a recombinant TIMP-3 
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(rTIMP-3) within a degradable HA hydrogel construct for localized myocardial 
delivery in a large animal model of MI.  The second aim of the present study was 
to locally place the Hydrogel/rTIMP-3 system within the MI region and quantify 
the effects on regional interstitial MMP activity, infarct expansion, and LV 
geometry and structure within the early post MI period. 
 
6.2. Methods 
Animals 
All animals were treated and cared for in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals (Eighth 
Edition. Washington, DC: 2011), and all protocols were approved by the Medical 
University of South Carolina’s Institutional Animal Care and Use Committee. 
 
rTIMP-3 Synthesis 
 A stable human TIMP-3 poly-His (rTIMP-3) expressing Chinese hamster 
ovary cell line was established using a vector with a Cytomegalovirus promoter, 
whereby 60 L of conditioned medium were concentrated to 8 L via Tangential 
Flow Filtration (TFF) (Millipore, 10kD MWCO). The full length human TIMP-3 
sequence was utilized52.  The concentrated supernatant was filtered and applied 
to Fractogel EMD SO3 (Merck KGaA, Darmstadt, Germany), and protein was 
eluted with a 0.1 M sodium chloride (NaCl) gradient. The TIMP-3 containing 
fractions were applied to Ni-NTA resin (Qiagen, Valencia, CA), and poly-His 
tagged protein was eluted with 300 mM Imidizol.  To further remove 
contaminants, the protein was then subjected to size-exclusion chromatography. 
TIMP-3 containing fractions were concentrated by TFF and buffer exchanged to 
10 mM Na Acetate pH 5.2, 9% Sucrose. The material was then lyophilized for 
later reconstitution. Using a previously validated global MMP fluorogenic peptide 
assay, 10 µM of the MMP substrate (Cat no. ES001, R&D Systems) and 4 nM of 
a recombinant active MMP-2 (Cat no. 902-MP R&D Systems) were incubated in 
the presence and absence of increasing concentrations of rTIMP-3.   
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Fluorescence of the cleaved substrate was measured at an emission/excitation 
wavelength of 320/405 nm. An exponential decay in MMP activity occurred with 
increasing concentrations of rTIMP-3, with a computed half maximal inhibitory 
concentration of approximately 26 ng/mL (Figure 6.1 A).  
 
Hydrogel Synthesis 
A degradable hydrogel was fabricated by synthesizing HA macromers as 
described previously48-49.  Briefly, HA (74kDa, Lifecore) was modified with 
hydroxyethyl methacrylate (HEMA) to incorporate a terminal methacrylate group 
for free-radical initiated crosslinking as well as ester bonds to introduce hydrolytic 
degradation (Figure 6.1 B). Briefly, HEMA was reacted with succinic anhydride 
via a ring opening polymerization in the presence of N-methylimidazole to obtain 
HEMA-COOH, which was then coupled to a tetrabutylammonium salt of HA in 
the presence of 4-dimethylaminopyridine.  The resulting HA macromer with 
HEMA group modification (HEMA-HA) was purified with dialysis, lyophilized and 
characterized by 1H NMR.  For hydrogel formation upon injection, a redox 
initiator system consisting of ammonium persulfate (APS) and N,N,N!,N!-
tetramethylethylenediamine (TEMED) was utilized.  10 mM APS and 10 mM 
TEMED were mixed with a 4 wt% (w/v) HEMA-HA solution in phosphate buffered 
saline (PBS) to form hydrogels.  Kinetics of hydrogel formation were 
characterized with rheometry by monitoring the storage (G’) and loss (G”) with 
time (20mm 1o cone geometry, 1% strain, 1Hz, Texas Instruments AR 2000ex). 
 
rTIMP-3 Binding Affinity to HEMA-HA 
Binding affinity between rTIMP-3 and HEMA-HA was quantified using an 
intrinsic protein fluorescence quenching technique. Fluorescence titration 
experiments were performed on a Tecan infinite m200 plate reader (Grödig, 
Austria) at 25°C.  The fluorescence of a 2 µM rTIMP-3 solution in 100 mM 
HEPES buffer (pH 7.4) was recorded at 280/350nm excitation/emission.  
Fluorescence quenching was monitored by increasing the concentration of 
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HEMA-HA in rTIMP-3 solution in 0.64 µM increments. 2 µL of concentrated 
polymer solution in HEPES was added to 1 mL rTIMP-3 solution for each 
titration, mixed, equilibrated for 2 min and fluorescence was measured.  The 
normalized changes in fluorescence with each HEMA-HA titration were plotted 
against HEMA-HA concentration and resulting binding isotherms were fit by 
nonlinear regression to the equation describing bimolecular association: 
 
 
where F is the change in fluorescence over initial fluorescence (-!F/Fo), Fi is the 
initial value for (-!F/Fo), Ff is the final value for (-!F/Fo), and Kd is the dissociation 
constant. 
 
Hydrogel Encapsulation of rTIMP-3 and in vitro Release Kinetics 
rTIMP-3 was mixed with a 4 wt% HEMA-HA macromer solution in PBS, 
and hydrogels were formed upon mixing 10mM APS/TEMED initiators as 
described above. 50 µL hydrogels containing 10 µg rTIMP-3 were crosslinked in 
cylindrical molds for 30 minutes at 37°C and then transferred to eppendorf tubes 
containing 1mL PBS supplemented with 1% (w/v) bovine serum albumin (BSA). 
Hydrogels were incubated in buffer at 37oC, and samples were collected for up to 
14 days.  At each time point, buffer was collected and replaced and analyzed for 
released molecules. rTIMP-3 was quantified with a His ELISA (QUAexpress, Ni-
NTA HisSorb, Quiagen Inc) using rTIMP-3 standards (0.7-25 ng) and HA 
degradation products were quantified using a uronic acid assay47,48. After 14 
days, hydrogels were enzymatically degraded by overnight incubation with 
hyaluronidase (800 units/mL, Sigma Aldrich), and evaluated for remaining rTIMP-
3 and HA.  
 
In vivo Validation of rTIMP-3 Releasing Hydrogel 
 Hydrogel/rTIMP-3 injections were performed within the LV free wall of 
Yorkshire pigs (n=3, 25 kg, Hambone Farms, Orangeburg, SC).  The pigs were 
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anesthetized with isoflurane (2%), and through a left thoracotomy, the LV free 
wall was exposed.  A 2 cm square calibrated grid was sutured below the origin of 
the first two obtuse marginal arteries of the circumflex artery (OM1 and OM2)14,50, 
which provided for a total of 9 distinct injection sites within a targeted 2X2 cm 
region of myocardium (Figure 6.1 E).  The hydrogel precursors containing 
initiators and rTIMP-3 (20 µg rTIMP-3/100 µL hydrogel) were mixed in a sterile 
fashion, drawn into micro-syringes, and injected into the mid-myocardium of each 
target site. This volume of hydrogel and concentration of rTIMP-3 was 
determined during initial titration studies, which provided the optimal ratio of 
volume and concentration.  The duration of time from final polymer mixing to 
completion of the 9 injections was 3 minutes.  Successful injections were 
confirmed by visualization of an opacification of the epicardial surface at the point 
of myocardial injection.  The perimeter of the injection grid was marked at each 
corner with radiopaque markers (1.6mm diameter, VNUS Medical Systems, 
Sunnyvale, CA) and the grid removed14.  At 7 days post injection, the pigs were 
again anesthetized, the LV harvested, the myocardial tissue isolated and 
sectioned into 9 regions, and immediately processed.  The LV samples were 
prepared in an ice cold extraction/homogenization buffer (QUAexpress, Ni-NTA 
HisSorb, Quiagen Inc) and subjected to the His ELISA technique described in the 
previous section.   
 
MI Induction and Hydrogel Injection Protocol 
Pigs were randomized to one of three different groups: MI and no 
injections (MI only, n=6), MI and hydrogel injections (MI/Hydrogel, n=8), and MI 
and hydrogel with rTIMP-3 injections (MI/Hydrogel/rTIMP-3, n=8).  Non-
instrumented pigs were used as referent, non-MI controls (n=8). The pigs were 
anesthetized and markers placed as described in the previous section.  OM1 and 
OM2 were ligated to induce an MI, and characteristic ECG changes occurred, but 
electrical cardioversion and/or defibrillation were not required, and past studies 
demonstrated that this technique creates a uniform and consistent MI involving 
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22% of the LV free wall14,50.  For pigs assigned to either hydrogel groups, nine 
injections were performed as described in the previous section.    
 
 Measurements of Infarct Expansion, LV Geometry and Function, In-vivo MMP 
Activity 
Two weeks after chronic instrumentation, the animals were sedated and 
two-dimensional echocardiographic studies (ATL Ultramark VI, 2.25MHz 
transducer, Bothell, WA) were performed to calculate LV volume and 
dimensions14,22,50.  In addition, LV short-axis images gated to end-diastole were 
digitized and used to compute regional wall stress as previously described14,50.  
Following which, fluoroscopic images of the myocardial markers were recorded 
with a high-speed cinefluoroscopy (Philips Cardiac-Diagnostic) and were 
digitized (ATI Radeon).  Using projections of the markers from two orthogonal 
planes, intermarker distances were computed in three-dimensional spaces and 
used to determine the area circumscribed by the markers14. 
 Following imaging studies, the pigs were anesthetized with sufentanyl (2 
µg/kg IV, Baxter Healthcare), morphine sulfate (3 mg/kg/h IV, Elkin-Sinn), and 
isoflurane (1%, 3 L/min O2, Baxter Healthcare), and mechanically ventilated.  The 
LV was exposed through a sternotomy, a microdialysis probe (20 kDA, outer 
diameter of probe shaft 0.77 mm; CMA/Microdialysis, North Chelmsford, MA) 
placed within the MI region, and infused with the MMP fluorescent substrate (5 
µL/min) described in the previous section and validated previously21,28.  The 
dialysate was then subjected to fluorometry which reflected interstitial MMP 
activity.  Following these measurements, the LV was harvested, separated into 
MI and remote regions (area served by left anterior descending artery), and 
prepared for biochemical and histological measurements. 
 
Ex vivo Measurements of TIMP-3, LV Histology, and Cytokine Assay 
Immunoblotting. Immunoblotting was performed for total myocardial TIMP-
3 levels using approaches described in detail previously14,15,28,50,51.  LV extracts 
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(80 µg of total protein) underwent electrophoretic separation, transferred to a 
nitrocellulose, incubated with anti-TIMP-3 (1:2000, Cat#AB6000, Millipore, 
Billerica, MA, overnight 4°C), the immune-positive signal detected by 
chemiluminescence (Western Lighting, Perkin Elmer), and digitally quantified 
(Gel-Pro Analyzer, v3.1.14, Media Cybernetics Inc., Silver Spring, MD).  In order 
to confirm the presence and absence of rTIMP-3 within the LV targeted regions, 
immunoblotting was performed using anti-polyHis (1:1000, Cat#ab27025, 
Abcam, Cambridge, MA, overnight 4°C). 
 Histomorphometry.  The formalin fixed full thickness LV samples were 
embedded, sectioned (7 µm), and stained with picrosirius red for fibrillar collagen, 
and the percent area of collagen within the remote and MI regions were 
computed using computer assisted morphometry14-16,51,53.  Immunostaining was 
used to colocalize with cells that stained positive for !-smooth muscle actin 
(1:100; !-smooth muscle actin: Sigma A5228), a marker for actin present in 
vascular smooth muscle cells as well as myofibroblasts, using approaches 
described previously53.  Additional LV sections were stained with hematoxylin 
and eosin, and histopathological examination was performed. 
Cytokine Assay. LV myocardial homogenates were subjected to cytokine 
analysis using a 2-laser flow cytometric detection system (Bio-Plex 200, BioRad 
Laboratories) and a previously validated platform (Cat. no. 
MPXHCYT060KPMX39, Millipore, Billerica, MA)21.  Using pre-calibrated 
standards and regression modeling, the fluorescence emission was converted to 
an absolute cytokine concentration.  
 
Computation and Data Analysis 
 Statistical analyses were performed using STATA statistical software 
(STATA Corp, College Station, TX).  LV geometry, function, and area within the 
markers were compared between the control and MI groups using a one-way 
analysis of variance (ANOVA).  Post-hoc separation following ANOVA was 
performed using pairwise comparisons with a Bonferroni analysis (prcomp 
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module, STATA).  The interstitial global MMP activity was evaluated by ANOVA 
and subsequently compared against the control values of 100% by a Student’s t-
test.  For TIMP-3 levels and myocardial cytokine concentrations, values from 
each group were first evaluated by ANOVA, and then a post-hoc separation 
following ANOVA was performed using pairwise comparisons with a Bonferroni 
analysis. For morphometric measurements, a multi-way ANOVA (MANOVA) was 
performed, evaluating for treatment dependent, MI dependent, and region 
dependent effects.  Post-hoc separation following MANOVA was performed 
using pairwise comparisons with a Bonferroni analysis.  Results are presented as 
a mean ± standard error of the mean (SEM), and values of p<0.05 were 
considered to be statistically significant. 
 
6.3. Results 
Hydrogel Formation and rTIMP-3 Release 
 HEMA-HA macromers were synthesized with a modification of ~20% as 
determined by 1H NMR analysis.  The negatively charged HEMA-HA macromers 
bound rTIMP-3 with a dissociation constant (KD) of 3.8±0.03µM (Figure 6.1 B).  
Solutions of the HEMA-HA macromer and APS/TEMED initiators (4 wt% HEMA-
HA, 10 mM APS/TEMED) were mixed together for hydrogel formation, with 
gelation occurring approximately 1 minute after mixing, and a plateau of 
crosslinking reached within 30 minutes (Figure 6.1 C).  Upon mixing APS and 
TEMED, a free-radical is generated, which initiates the growth of kinetic chains 
between methacrylate groups on the HEMA-HA macromers, covalently 
crosslinking the hydrogel.  The crosslinked hydrogels steadily degraded in 
aqueous solution throughout the 14 day period, as determined by release of 
uronic acid, although the gels remained intact at day 14 (Figure 6.1 D).  rTIMP-3 
was successfully encapsulated in the hydrogel and released at a nearly uniform 
rate throughout the 14 day period (Figure 6.1 D).  A significant amount of rTIMP-
3 remained in the hydrogels after the 14 day study.  When injected into the 
myocardium, the hydrogels maintained the levels of rTIMP-3 above remote 
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background levels over a 7 day period. Specifically, a consistent signal for 
rTIMP-3 was detected at each of the targeted injection sites, but no signal was 
obtained in non-targeted injection sites (Figure 6.1 F). 
 
LV Geometry, Infarct Expansion, and Wall Stress 
 LV end-diastolic volume, ejection fraction, and regional infarct expansion, 
defined as the area of myocardium within the markers (MI marker area), are 
summarized in Figure 6.2.  At 14 days post MI, LV volumes increased in all three 
MI groups but were reduced in the MI/rTIMP-3/Hydrogel group.  LV ejection 
fraction fell in all MI groups but was higher in the MI/rTIMP-3/Hydrogel group 
when compared to the MI only group.  Regional infarct expansion increased in 
the MI only and MI/Hydrogel groups at 14 days post-MI, whereas this index of MI 
expansion was significantly attenuated in the MI /Hydrogel/rTIMP-3 group.  In 
light of the changes in LV global geometry and MI expansion, LV regional wall 
stress was computed in all groups (Figure 6.3 A).  LV regional wall stress 
increased in all MI groups when compared to referent controls but was reduced 
in both the MI/Hydrogel and the MI/Hydrogel/rTIMP-3 groups when compared to 
MI only values.  However, the greatest reduction in LV regional wall stress 
occurred in the MI/Hydrogel/rTIMP-3 group. 
 
In vivo interstitial MMP activity and ex-vivo TIMP-3 levels 
 Myocardial interstitial MMP activity was quantified within the MI region at 
14 days post-MI using a validated microdialysis-fluorogenic approach21,28,53, and 
the results are summarized in Figure 6.3. Interstitial MMP activity was higher in 
the MI only and the MI/Hydrogel groups, and was significantly reduced in the 
MI/Hydrogel/rTIMP-3 group. LV myocardial extracts were subjected to anti-
polyHis immunoblotting, whereby only apositive signal corresponding to rTIMP-3 
could be identified within the MI region at 14 days post-MI (Figure 6.4 A). 
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Figure 6.1. Hydrogel fabrication for targeted rTIMP-3 delivery. (A) rTIMP-3 inhibits rMMP-2 
activity in a dose-dependent manner with a half maximal inhibitory concentration, IC50=26±2 
ng/mL. (B) Synthesized HA macromer with reactive methacrylate group for gel crosslinking and 
hydrolytically unstable ester groups for gel degradation.  This negatively charged macromer binds 
to rTIMP-3 with a KD=3.8±0.3µM through electrostatic interaction. (C) Gel crosslinking was 
quantified with rheometry by measuring the storage (G’) and loss (G’’) moduli over time. 
Crosslinking of 4wt% macromer (20% HEMA modification) reaches a gel point within 1 min after 
adding 10mM APS/TEMED free-radical initiators and plateaus by 30 min. (D) Encapsulated 
rTIMP-3 (10µg/gel) diffuses from the gels in a steady fashion for 14 days as the gels degrade in 
aqueous buffer. A significant amount of rTIMP-3 remained in the gels after the 14-day study. (E) 
Gels containing rTIMP-3 (20µg/100µL gel) were delivered to the MI region through a syringe 
immediately following ligation of obtuse marginal arteries 1 and 2 (OM1 and OM2) in pigs. (F) 
rTIMP-3 was quantified locally at the 9 injections sites 1 week after MI with no spillover to remote 
sites.  
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Figure 6.2.  LV end-diastolic volumes and ejection fraction were computed by echocardiography 
and the area within the radiopaque markers (MI marker area) by fluoroscopy at 14 days post MI.  
LV dilation, as measured by LV end-diastolic volume, increased in all 3 groups post MI when 
compared to referent control values. However, the degree of LV dilation was significantly reduced 
in the MI/Hydrogel/rTIMP-3 group. LV ejection fraction significantly fell in all 3 groups at 14 days 
post-MI. However, LV ejection fraction was significantly higher in the MI/Hydrogel/rTIMP-3 group 
when compared to the MI only group.  MI marker area, indicative of infarct expansion, increased 
in the MI only and MI/Hydrogel groups, but was significantly reduced to control values in the 
MI/Hydrogel/rTIMP-3 group. (*p<0.05 vs referent control, +p<0.05 vs MI only, #p<0.05 vs 
MI/Hydrogel). 
 
 
 
Figure 6.3. (A) Regional peak systolic wall stress at the LV anterior wall (targeted MI region) was 
computed using LV short axis dimensions, and wall thickness measurements as described in the 
Methods section. LV regional wall stress increased within the targeted MI region in all 3 groups at 
14 days post-MI when compared to referent controls. However, LV regional wall stress was 
reduced in the MI/Hydrogel group when compared to MI only values. Moreover, LV regional wall 
stress was reduced even further in the MI/Hydrogel/rTIMP-3 group. (B) Interstitial MMP activity 
within the MI region was determined using microdialysis and a fluorogenic peptide, as described 
in the Methods section, and normalized to referent control values (dashed line). Interstitial MMP 
activity increased in the MI only and MI/Hydrogel groups at 14 days post MI and was reduced in 
the MI/rTIMP-3/Hydrogel group. (*p<0.05 versus referent control, +p<0.05 versus MI only, 
#p<0.05 versus MI/Hydrogel) 
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Using anti-TIMP-3 targeted against both native TIMP-3 and rTIMP-3, quantitative 
immunoblotting was performed and summarized in Figure 6.4 B. Total TIMP-3 
levels fell within the MI region in both the MI only and MI/Hydrogel groups, but 
increased in a robust fashion within the MI region of M/Hydrogel/rTIMP-3 group. 
Total myocardial TIMP-3 levels were similar across groups in the LV remote 
region.  
 
 
 
 
 
Cytokine levels relative to referent control values are summarized in Figure 6.5. 
LV myocardial levels of interleukin-6, -9, and -12 increased in both the MI only 
group and the MI/Hydrogel group.  Interestingly, the myocardial concentrations of 
IL-6, -9, -12 were significantly reduced in the MI/Hydrogel/rTIMP-3 group. 
Monocyte chemoattractant protein-1 (MCP-1) concentrations were similar in 
!""""""#$%&'()"
"""*+,-#+." ""&%"/,.0" "&%1203#+45." &%1203#+45.1"
#$%&'()"
'+67895"
*+,-#+."
:;"&0+<=#37>?"
@"@"
@"
A"
B"
&%"+,.0" &%1"
203#+45."
&%1"
203#+45.1"
#$%&'()"
$+
-=
."$
%&
'(
)"
CDDD"
EDDD"
FDDD"
GDDD"
HDDDD"
HCDDD"
I5?+-5"I547+,"
&%"I547+,"
J""""""$+-=."$%&'()"
KCG""
LM="
KCG""
LM="
""""""""""""""""""I5?+-5"""""""""""&%""""""""""""I5?+-5""""""""""""&%"""""""""""I5?+-5""""""""""""&%"
" ""
*+,-#+.""""""""""""""""&%"/,.0""""""""""""""""""""""&%1203#+45."""""""""""""&%1"203#+45."1#$%&'()"""""""""""
" " ""
" " ""
Figure 6.4. (A) Representative 
immunoblot for the His-tagged 
rTIMP-3 within the targeted MI region 
at 14 days post MI. A strong positive 
signal was identified within the 
MI/rTIMP-3/Hydrogel samples and 
was absent in the referent control, MI 
only, and MI/Hydgrogel groups. (B-
Top Panel) A representative 
immunoblot for TIMP-3, using an 
antibody which reacted against both 
rTIMP-3 and native TIMP-3. The 
signal for total TIMP-3 was reduced 
within the MI region in the MI only 
and MI/Hydrogel groups. (B-Bottom 
Panel) Quantitative immunoblotting 
for total LV myocardial TIMP-3 levels 
within the MI and remote regions was 
performed at 14 days post MI as well 
as in referent control samples (the 
mean is represented by the solid line, 
and the SEM is represented by the 
dashed lines). Within the MI region, 
total TIMP-3 was reduced in the MI 
only and MI/Hydrogel groups, and 
was significantly increased from both 
MI groups and referent control values 
in the MI/Hydrogel/rTIMP-3 group. 
(*p<0.05 versus referent control, 
+p<0.05 versus MI only, #p<0.05 
versus MI/Hydrogel)  
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the MI only and MI//Hydrogel groups, and actually fell below referent control 
values in the MI/Hydrogel/rTIMP-3 group. 
 
 
Figure 6.5.  Significant changes in specific inflammatory cytokines were detected within the MI 
region at 14 days post MI, which included interleukin-6,-9,-12, and monocyte chemoattractant 
protein-1 (MCP-1) when compared to referent control values. Interleukin-6, -9, and -12 increased 
significantly in the MI only and MI/Hydrogel groups, whereas these cytokine levels were 
significantly reduced in the MI/Hydrogel/ rTIMP-3 group. MCP-1 were similarly increased in the MI 
and MI/Hydrogel groups and actually fell below referent control values in MI/Hydrogel/rTIMP-3 
group. (*p<0.05 versus referent control, +p<0.05 versus MI only, #p<0.05 versus MI/Hydrogel) 
 
Myocardial Histology and Fibrillar Collagen Content 
Histological examination of LV sections taken from the referent control and 
MI region revealed significant myofibrillar loss and an influx of inflammatory cells 
(Figure 6.6 B-D).  The presence of remnant hydrogel was observed within the 
MI/Hydrogel and MI/Hydrogel/rTIMP-3 groups.  Collagen content increased in all 
MI groups when compared to controls (Figure 6.6 E).  Collagen content was 
further increased in the MI/Hydrogel and MI/Hydrogel/rTIMP-3 groups when 
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compared to the MI only group. LV mid-myocardial sections devoid of large blood 
vessels were examined with respect to immunolocalization for smooth muscle 
actin (SMA), and representative photomicrographs are shown in Figure 6.6 F. 
While in the referent control and remote regions, SMA staining predominated 
around arterioles and venules. The predominant staining pattern within the MI 
region was that of interstitial cells, consistent with myofibroblasts. This 
myofibroblast positive staining was increased in the MI/Hydrogel group and 
increased further in the MI/Hydrogel/rTIMP-3 group (Figure 6.6 F). 
  
6.4. Discussion 
Targeting Myocardial Infarct Expansion 
While a number of pathophysiological events contribute to adverse 
remodeling following MI, the myocardial process generically termed as infarct 
expansion is a significant contributing factor5-10.  In the early post MI period 
(hours-days), an influx of inflammatory cells, cytokine release, and activation of 
multiple signaling pathways occurs, and results in heightened MMP activation 
and matrix degradation12,13.  While this early MMP induction may be an adaptive 
biological response to myocardial injury, the persistently elevated MMP activation 
which can occur in the later post MI period (days-weeks) can result in matrix 
instability and abnormalities in stress-strain patterns, which in turn cause thinning 
of the MI region as well as jeopardize the cellular and extracellular structure and 
function of the viable border zone9-13.  In contrast to the robust MMP induction 
and activation in the post MI period, animal and clinical studies have 
demonstrated that there is not a parallel increase in TIMPs, which in turn would 
further potentiate interstitial MMP proteolytic activity14,15,22,24,25,51,53..  Moreover, 
transgenic models have underscored the importance of TIMPs in terms of the 
adverse LV remodeling process16.  Thus, targeting MMPs remains an area of 
active therapeutic investigation and development29-32 and would be particularly 
relevant in terms of the infarct expansion process.  
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Figure 6.6.  (A-D) Representative photomicrographs of LV sections taken from the MI region 
stained with hematoxylin and eosin: (A) a referent control and 14 days post-MI for (B) MI only, (C) 
MI/Hydrogel, and (D) MI/Hydrogel/rTIMP-3. In contrast to the organized distribution of myofibrils 
within the referent control LV myocardium, an influx of inflammatory cells and myofibril disruption 
could be appreciated within the MI region, but to a lesser extent in the MI/Hydrogel/rTIMP-3 
sections. Histological features consistent with islands of remnant Hydrogel were observed within 
the MI region of the MI/Hydrogel group and the MI /Hydrogel/rTIMP-3 (black arrows). Scale bars 
are 50 µm. (E) Computer assisted morphometric measurements of picro-sirius stained sections 
from referent controls and the MI region were used to compute relative fibrillar collagen content. 
Collagen content was increased in all MI groups when compared to referent control values 
(F=3.07, p=0.04).  Collagen content was further increased in the MI/Hydrogel group and the 
MI/Hydrogel/rTIMP-3 group when compared to the MI only group. (F) Top Panels- Representative 
smooth muscle actin staining within the referent control and MI sections. In the referent control as 
well as the remote sections, smooth muscle actin staining was primarily associated with small 
vascular structures (arterioles/venules), whereas in the MI region the staining pattern was 
primarily associated with interstitial cells – i.e. myofibroblasts. Quantification using densitometry 
revealed a substantial increase in this pattern of smooth muscle actin staining within the MI 
region of the MI/ Hydrogel/rTIMP-3 group.  (*p<0.05 versus control group, +p<0.05 versus MI only 
group, #p<0.05 versus MI/Hydrogel)   
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The present study was built upon these past clinical observational studies, 
transgenic model systems, and broad based systemic pharmacological inhibitors, 
through directly targeting the region of the LV myocardium where a clear 
imbalance exists between MMPs and TIMPs.  Using a clinically relevant model of 
post MI remodeling54, the present study demonstrated that targeted TIMP 
delivery is feasible and effective in interrupting the infarct expansion process. 
These findings underscore the importance of developing therapeutic strategies 
focused upon restoring the balance between MMP/TIMPs following MI.  
Specifically, the new and unique findings from the present study were three-fold: 
(1) regional Hydrogel/rTIMP-3 injections abrogates infarct expansion, reduces LV 
dilation and regional wall stress, and improves systolic function in the early post-
MI period; (2) local Hydrogel/rTIMP-3 delivery augments total TIMP-3 levels 
within the MI region and reduces myocardial interstitial MMP activity without 
causing significant collagen accumulation over and above that of hydrogel 
delivery alone; and (3) rTIMP-3 delivery within the MI region reduces local pro-
inflammatory cytokine levels and increases myofibroblast density. This unique 
translational study provides the first proof of concept that local and sustained 
delivery of a recombinant TIMP effectively interrupts infarct expansion and 
improves LV geometry, likely through modifying biological mediators of the 
adverse post MI remodeling process. 
 
LV Remodeling and Function: Effects of rTIMP-3 
LV remodeling following MI invariably includes LV dilation, whereby the 
progression and extent of post MI LV dilation is an independent risk factor for 
morbidity and mortality1-7.  In the present study, regional injection of rTIMP-3 into 
the MI region reduced the degree of LV dilation when compared to MI only 
values as well as to that of Hydrogel injection alone. It is important to note that a 
range of hydrogels have been investigated to alter local tissue bulking and to 
reduce stress profiles in the myocardium, leading to changes in LV dilation, 
without the delivery of biological molecules47.  Here, there is a clear improvement 
 108 
in outcomes with the addition of rTIMP-3.  Also, LV ejection fraction increased in 
the rTIMP-3 group in the post MI period. LV ejection fraction, as with any index of 
LV pump function, is influenced by loading conditions and intrinsic contractile 
performance.  
In the present study, rTIMP-3 injection resulted in increased MI thickness, 
and when considered in conjunction with the changes in chamber radius, caused 
a net reduction in regional LV peak wall stress. Since LV peak wall stress is a 
fundamental measure of LV afterload and is inversely related to LV ejection 
performance, one likely mechanism for the improved LV ejection fraction with 
rTIMP-3 injection was favorable effects on regional LV afterload. However, it 
must be recognized that these measures of LV global and regional geometry 
were taken at only one time point post MI, and whether these improvements with 
rTIMP-3 are due to changes in the trajectory of adverse post-MI remodeling, or 
actually represent a complete cessation of this process, will require future serial 
studies. Significantly increased collagen accumulation within the LV myocardium 
can contribute to increased myocardial stiffness properties13.  One critical 
observation was that while rTIMP-3 release into the MI region, while significantly 
reducing interstitial MMP activity, was not associated with excessive collagen 
accumulation. These findings would suggest that localized rTIMP-3 augmentation 
did not disproportionally alter ECM turnover and accelerate fibrosis.   
 
Potential Biological Effects and Mechanisms of rTIMP-3 Delivery Post-MI 
In the present study, interstitial MMP activity was reduced within the MI 
region with rTIMP-3 delivery, demonstrating a localized MMP inhibitory effect, 
and therefore, the hydrogel mediated delivery strategy released an active protein. 
However, multiple substrates and biological pathways are influenced by 
MMPs58,59, and therefore, it would be an oversimplification to assume that rTIMP-
3 delivery merely inhibited matrix proteolysis. In addition, it has been 
demonstrated that TIMP-3 can induce direct biological effects, which include 
influencing fibroblast growth and function, cell survival, and cytokine 
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processing36,42,44.  The present study provides evidence to suggest that the 
reduction in MI wall thinning and infarct expansion that occurred with rTIMP-3 
delivery was likely due to a summation of these biological effects.  
One unique finding from the present study was that rTIMP-3 delivery 
resulted in a significant reduction in pro-inflammatory cytokines within the MI 
region. This effect may have been due to several factors, which include 
interference of MMP matrix proteolysis and egress of inflammatory cells, MMP 
mediated cytokine processing, and/or direct effects of TIMP-3 on cytokine 
induction.  Nevertheless, it is likely that the attenuation of cytokine signaling 
within the MI region with rTIMP-3 delivery influenced the post MI remodeling 
process. Another observation from the present study was that rTIMP-3 caused a 
significant increase in !-smooth muscle actin, predominantly in interstitial cells 
(i.e. myofibroblasts)58,59.  Since myofibroblasts are critical in the wound healing 
context and provide significant contractile force across the ECM13,58,59, it is likely 
that the increase in this fibroblast phenotype with rTIMP-3 delivery influenced 
regional tissue geometry and structure within the MI region. While this potential 
contributory mechanism for the effects of rTIMP-3 remains associative, what is 
clear from the present study is that regional TIMP-3 delivery within the MI region 
likely altered biological signaling pathways as well as fibroblast phenotype.  
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CHAPTER 7 
 
Incorporation of sulfated hyaluronic acid macromers into degradable 
hydrogels for controlled presentation of proteins through electrostatic 
interactions 
 
 
7.1. Introduction 
Hyaluronic acid (HA) based hydrogels have been used widely in recent 
years for applications in drug delivery and tissue engineering1.  HA is a 
ubiquitous biological polymer composed of repeating D-glucuronic acid [!-1-3] 
and N-acetyl-D-glucosamine [!-1-4] disaccharides and is found abundantly in the 
extracellular matrix (ECM) of tissues.  During endogenous tissue remodeling, HA 
plays a critical role in regulating cell motility through CD44 receptor interactions 
and provides a hydrated microenvironment for growth factor and cytokine stability 
and diffusion2.   
HA is unique among glycosaminoglycans (GAGs) in that it is produced 
and secreted from cells as a linear polymer unattached to a polypeptide.  This 
feature makes HA production amendable to typical genetic engineering 
approaches using microbial fermentation3.  These recombinant HAs are 
nonimmunogenic, available in a wide range of well-defined molecular weights, 
and have been used in numerous biomedical applications.  Further, due to the 
abundance of hydroxyl and carboxylic acid groups, HA is readily modified with 
reactive groups to form hydrogels1.  In particular, modification of HA with vinyl 
groups permits gel formation through free-radical initiated crosslinking.  This 
approach has allowed spatiotemporal control of network architectures to direct 
stem cell differentiation in vitro4,5, as well as in situ gelation to localize therapeutic 
protein delivery in vivo6. 
While protein binding to vinyl modified HA macromers has been 
observed6, HA lacks the sulfate groups typically associated with high protein-
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ECM binding affinities.  For example, heparin has been shown to bind, stabilize, 
and in some cases enhance the activity of hundreds of heparin binding proteins 
(HBPs) through electrostatic interaction between sulfates and basic amino acid 
residues7.  These interactions are critical to regulating tissue remodeling 
processes by localizing HBP activity in a temporally controlled fashion (i.e., HBP 
presentation)8,9.  A variety of conjugation techniques have been developed to 
covalently incorporate heparin into scaffolds, and these systems have been used 
to control HBP presentation and subsequent cellular processes10-12. However, 
since heparin is normally present in tissues attached to a core protein (i.e., 
proteoglycan), production of heparin is limited to crude isolation from animal 
tissues.   As a result, commercially available heparin is a heterogeneous 
distribution of polysaccharides with diverse protein binding specificities and some 
polysaccharide contaminants found in heparin have caused a sudden increase of 
severe side effects in patients undergoing antithrombotic treatment13.   
To minimize contaminants and provide a higher level of HBP specificity, 
there has been a growing interest in producing well-defined heparin mimetics 
through synthetic routes14.  Heparin mimetics are highly sulfated polymers that 
are structurally distinct from naturally occurring GAGs, but perform some of the 
same functions as heparin (e.g., HBP binding)7.  These sulfated polymers have 
been shown to bind HBPs with high affinity and when delivered in vivo they 
significantly enhance tissue repair, presumably by replacing degraded heparin 
and increasing the bioavailability of HBPs15.  While HA is unique among GAGs in 
that it lacks sulfate groups, researchers have demonstrated synthetic sulfation of 
HA through nucleophilic substitution of primary hydroxyl hydrogens on HA with 
SO3 by simply reacting SO3 complexes with HA in an organic solvent16-18.  
Reaction of an SO3/DMF complex with HA results in a specific sulfation pattern 
that binds HBPs with a high affinity17,19.  Further, sulfated HA polymers exhibit 
good cytocompatibility and enhance HBP presentation to cells in vitro20.  Also, 
sulfated HA polymers themselves have been shown to influence cell activity in 
vitro including stimulating Wnt and Notch signaling16, as well as increasing cell-
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cell junctions18.  However, sulfated HA has not previously been modified for 
covalent incorporation into hydrogels to alter features such as protein interactions 
and diffusion. 
Here, we synthesized sulfated and vinyl modified HA macromers to 
incorporate protein-binding features into radically crosslinked HA hydrogels.  
Further, we incorporated hydrolytically unstable ester groups between the 
reactive vinyl group and the sulfated HA backbone to liberate bound proteins in a 
controlled fashion.  We show that these macromers bind a HBP with an affinity 
comparable to heparin, can be readily incorporated into unsulfated HA hydrogels 
without significantly altering hydrogel crosslinking, and therefore can be used to 
control the presentation of HBPs for drug delivery and tissue engineering 
applications.      
 
7.2. Methods 
Materials.  
Sodium hyaluronate (NaHy) was purchased from Lifecore (100 and 440 
kDa, as measured with GPC).  ELISA kit and reagents were purchased from 
R&D Systems.  Recombinant human TIMP-3 with a 6x His tag was provided as a 
gift from Amgen, Inc.  Anti-6x His antibodies were purchased from Abcam.  
Heparin binding plates were purchased from BD Biosciences.  Polyethylene 
glycol standards were purchased from Waters.  All other materials and chemicals 
were purchased from Sigma Aldrich.   
 
Macromer Synthesis.   
NaHy (100kDa) was chemically modified with a hydroxyethyl methacrylate 
(HEMA) group to incorporate methacrylate reactivity for free-radical initiated 
crosslinking, as well as hydrolytic degradation through ester group hydrolysis as 
previously described6.  Briefly, HEMA was reacted with succinic anhydride via a 
ring opening polymerization in the presence of N-methylimidazole to obtain 
HEMA-COOH, which was then coupled to a tetrabutylammonium (TBA) salt of 
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HA in the presence of 4-dimethylaminopyridine (DMAP) and di-tert-butyl 
dicarbonate (BOC2O).  The resulting HA macromer with HEMA group 
modification (HEMA-HA) was purified with dialysis and characterized by 1H NMR.   
For HEMA-SHA synthesis, a 440kDa NaHy was first synthesized to 
HEMA-HA as described above and then converted to a TBA salt through resin 
exchange (Dowex 50x8w hydrogen form) and TBA-OH titration to pH 7.02 to 
permit polymer solubility in DMF for the sulfation reaction.  HEMA-HA TBA was 
then frozen and lyophilized.  Dry HEMA-HA TBA was dissolved in N,N-
dimethylformimide (DMF) at 0.25% (w/v) under N2 at room temperature (RT).  
SO3/DMF complex in DMF solution (10% (w/v)) was added to the reaction at a 
20:1 (mol/mol) SO3/DMF:HA repeat unit ratio and reacted for 1 hr at RT under 
N2.  The reaction solution was then dialyzed against DI H2O for 14 days at 4°C to 
remove solvent and TBA salts, frozen and lyophilized. 
 
Gel Permeation Chromatography.   
Molecular weights were determined with gel permeation chromatography 
(GPC) analysis using a Waters 1525 Binary HPLC Pump, Waters 2414 
Refractive Index (RI) Detector, and Waters Ultrahydrogel 1000 columns.  The 
eluent was PBS buffer and the flow rate was 0.5 mL/min.  Size calibrations for 
molecule weight determination were made with polyethylene glycol standards 
(Polymer Standard Services USA, Inc). 
 
Zeta Potential Measurements.   
Polymers were dissolved in MilliQ H2O at 3.5wt% for HEMA-HA and 4wt% 
for HEMA-SHA and loaded into folded capillary cells (Malvern).   Zeta Potential 
measurements were made on a ZetaSizer Nano ZS (Malvern).   
 
Dimethylmethylene Blue Assay.   
Serial dilutions of each polymer were prepared in MilliQ H2O 
(50µg/mL!0µg/mL) and assayed for the presence of sulfate groups using a 
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previously developed dimethylmethylene blue (DMMB) assay21.  Absorbance at 
520 nm was measured using a cuvette reader (Tecan).  To visualize sulfate 
groups, 50µL hydrogels were formed (see subsequent methods), washed for 2 
days in PBS, incubated in DMMB solution overnight at 37°C, rinsed and 
photographed. 
 
Solid-phase Binding Assay.  
HEMA-HA, HEMA-SHA and heparin at 2.5µM in PBS were coated 
overnight at 25°C onto heparin binding plates (BD Life Sciences)22.  Wells were 
washed in TNC buffer (50 mM Tris/HCl, 150 mM NaCl, 10 mM CaCl2, 0.05 % 
Brij-35 and 0.02 % sodium azide) containing 0.1 % Tween 20 between each 
subsequent incubation. Wells were blocked with 0.2% gelatin in TNC buffer and 
then incubated with rTIMP-3-His (0.02-3µg/mL in blocking solution for 3 h at 
37°C). Bound rTIMP-3-His was detected using a biotin labeled antibody against 
the 6xHis tag on rTIMP-3 (Abcam, ab27025, 3 hr incubation at 37!C), followed by 
streptavidin coupled to horseradish peroxidase (R&D Systems) for 1h at 37°C. 
Hydrolysis of a 1:1 mixture of H2O2 and tetramethylbenzidine (R&D Systems) 
was measured at 450 nm using a microplate reader (Tecan infinite m200). 
 
Hydrogel Formation.   
For crosslinking, a redox initiator system consisting of ammonium 
persulfate (APS) and N,N,N",N"-tetramethylethylenediamine (TEMED) was 
utilized.  APS and TEMED were mixed with polymers dissolved in phosphate 
buffered saline (PBS) to initiate crosslinking at final concentrations of 10mM 
APS, 10mM TEMED, and 4wt% (w/v) polymer.  HEMA-HA/HEMA-SHA blends 
were formed by mixing different volumetric ratios of the respective polymers 
dissolved at the same concentrations in PBS.  Kinetics of the crosslinking 
reaction were characterized with rheometry by monitoring the storage (G’) and 
loss (G”) moduli with time (20mm 1° cone geometry, 1% strain, 1Hz, TA 
Instruments AR 2000ex).  
!
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Hydrogel Swelling.   
50µL hydrogels (4wt% polymer, 10mM APS/TEMED) were formed in 
cylindrical molds at 37°C for 30 min after mixing APS/TEMED initiators.  
Hydrogels were then incubated in PBS for 2 days at 37°C.  Gel diameters were 
measured after 30 min crosslinking and again after 2 days in PBS.  Swelling 
ratios were reported as a percent change in diameter after 2 days in PBS. 
 
Protein Release Studies.   
rTIMP-3 or FITC-BSA were dissolved in the polymer solutions at 10µg of 
protein/50µL gel.  50µL hydrogels (4wt% polymer, 10mM APS/TEMED) were 
formed in cylindrical molds at 37°C for 30 min after mixing APS/TEMED initiators.  
After a wash in PBS, hydrogels were incubated in PBS supplemented with 1% 
BSA (R&D Systems) at 37°C.  Hydrogels were moved to fresh buffer every 2 
days and samples were stored at -20°C until the end of the study.  After the final 
time point, hydrogels were degraded in 0.3 mg/mL hyaluronidase to release 
remaining protein.  FITC-BSA was quantified using fluorescence while rTIMP-3 
was quantified using ELISA (R&D Systems). 
 
Statistical Analysis.   
Statistical comparisons between groups were performed with a two-tailed 
student’s t-test, followed by a Bonferroni correction for multiple comparisons; 
p<0.05 were considered statistically significant for comparison between two 
groups, while p<0.025 were considered statistically significant for comparison 
between three groups.  The results are reported as mean values ± standard 
deviations. 
 
7.3. Results and Discussion 
Sulfation of HEMA Modified HA.   
HA has been previously modified with sulfate groups through nucleophilic 
substitution of primary hydroxyls along the HA backbone17.  When the reaction 
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was performed with the SO3/DMF complex at a 20:1 SO3/DMF:HA ratio, a high 
degree of sulfation was observed, estimated at 2.8 sulfate groups per HA 
disaccharide, in a specific pattern that resulted in high protein binding affinities.  
We applied this sulfation reaction to our previously developed 
hydroxyethylmethacrylate (HEMA) modified HA (HEMA-HA) in order to 
incorporate protein-binding features into a degradable, radically crosslinked 
hydrogel.  Using this strategy, sulfated HEMA-HA macromers (HEMA-SHA) 
could be blended with non-sulfated HEMA-HA macromers at any desired ratio 
and crosslinked using a variety of free-radical initiator systems (Figure 7.1).  
Further, the degradation kinetics of the system can be controlled through HEMA 
group modification to release bound proteins in a temporally controlled fashion. 
 HEMA-HA was synthesized as previously reported by first converting 
sodium hyaluronate (NaHy, 100kDa) to a tetrabutylammonium (TBA) salt and 
then coupling HEMA succinate to primary hydroxyls on HA through an 
esterification reaction6 (Figure 7.2 A).  The modification process decreased the 
number average molecular weight (Mn) of the HA polymer by 20% and slightly 
increased the HA polydispersity, as determined by GPC (Figure 7.2 B).  The 
decrease in Mn is likely due to acid hydrolysis  
 
 
Figure 7.1.  Incorporation of sulfated hyaluronic acid (HA) macromers into hydrogels 
through free-radical initiated crosslinking.  Hydroxyethylmethacrylate (HEMA) modified HA 
macromers were synthesized with or without sulfate groups to control sulfated polymer 
concentration in hydrogels by simply blending the two macromers together and crosslinking with 
free-radical initiators.  Release of encapsulated proteins in these networks is controlled by 
electrostatic interactions with the negatively charged polymers and by gel degradation through 
ester group hydrolysis of the HEMA crosslinks.  
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of the polysaccharide backbone during HA-TBA synthesis as a proton-rich 
exchange resin was used for protonation of NaHy.  The final HEMA-HA had a Mn 
of ~80kDa and a HEMA modification of ~16%. 
To synthesize HEMA-SHA, HEMA-HA was synthesized starting with NaHy 
of 440kDa and converted to a TBA salt through a protonated resin exchange.  
This step did not affect the HEMA modification as indicated by peak integration of 
vinyl protons on the methacrylate group (approximately 5.8 and 6.2 ppm) via 1H 
NMR (Figure 7.3 A).  Next, the TBA salt of HEMA-HA was reacted with SO3 in 
DMF, which also did not affect HEMA modification as indicated by the vinyl 
proton integrations before and after the reaction (Figure 7.3 A).  Also, there was 
an obvious shift in hydroxyl proton peaks along the HA backbone (approximately 
3 to 4 ppm) following the sulfation reaction as expected due to substitution of 
these protons with sulfate groups (Figure 7.3 A).   
 
 
Figure 7.2.  Synthesis of HEMA modified HA.  (A) Sodium hyaluronate (NaHy) was converted 
to a tertbutylammonium (TBA) salt and reacted with HEMA-succinate in dimethyl sulfoxide using 
dimethylaminopyridine (DMAP)/di-tert-butyl dicarbonate (BOC2O) catalyzed esterification.  HEMA 
modification was quantified by methacrylate group 1H NMR peaks (green circle).  (B) This 
modification slightly reduced the number average molecular weight (Mn) and increased the 
polydispersity index (PDI) as measured with GPC when compared to unmodified NaHy. 
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Figure 7.3.  Synthesis of sulfated HEMA-HA.  (A) HEMA-HA was converted to a TBA salt and 
reacted with SO3/dimethylformamide (DMF) complex in DMF.  This reaction altered hydroxyl 
group 1H NMR peaks as expected, but did not affect methacrylate 1H NMR peaks (green circles).  
(B) Sulfation reduced the Mn of HEMA-HA by almost 80% as measured by GPC, so a larger 
440kDa NaHy was used to generate HEMA-SHA macromers with comparable Mn to HEMA-HA 
macromers (80kDa).  
 
Although there was no change in HEMA modification (~16%) there was an 
expected and significant reduction of the macromer Mn following the sulfation 
reaction, which is likely due to acid hydrolysis of HA from H2SO4 formed from 
reaction of SO3/DMF and water vapor, or from non-specific nucleophilic 
substitution (Figure 7.3 B).  By starting with a 440kDa NaHy, the final Mn of 
HEMA-SHA was maintained at ~80kDa so that HEMA-HA and HEMA-SHA could 
be blended at approximately the same molecular weight and modification.  
Naturally sulfated GAGs are typically much smaller than 80kDa; therefore, our 
approach allows generation of sulfated and crosslinkable polymers with larger 
molecular weights for covalent incorporation into hydrogels.  Using this approach, 
the sulfate group content within hydrogels can be easily controlled by blending 
sulfated and non-sulfated polymers at the desired ratios. 
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Sulfating HEMA-HA Alters Polymer Charge and Increases Binding to a HBP.   
Heparin has been shown to bind hundreds of proteins through 
electrostatic interaction between negatively charged sulfate groups on heparin 
and positively charged amino acid residues on proteins7.  While intermolecular 
forces such as hydrogen bonding and van der Waals interactions involving other 
chemistries on heparin have been shown to contribute to some highly specific 
binding events23, charge interactions from sulfate groups are the major force 
driving heparin-protein binding24.  Similarly, the addition of sulfate groups to HA 
has been shown to dramatically increase binding of proteins that are rich in basic 
amino acid residues17,19.  While the degree of sulfation of HA was shown to 
directly correlate with protein binding affinity, oversulfation of polysaccharides 
can inhibit protein binding 25 and the distribution of sulfate groups along the 
polysaccharide is important in protein binding affinity17,19.   
 The sulfate content on HEMA-SHA macromers was compared to HEMA-
HA and heparin using a modified dimethylmethylene blue (DMMB) assay21.  
Using this assay, a significant increase in sulfate content was observed on 
HEMA-SHA compared to HEMA-HA, confirming success of the sulfation reaction 
(Figure 7.3 A).  Further, the sulfate content on HEMA-SHA was comparable to 
that of heparin.  To quantify the effect of the sulfate groups on polymer charge, 
an important contributor to protein binding affinity, zeta potentials of the polymers 
were measured from pH 2 to 10.  HEMA-SHA polymers possessed a more 
negative charge when compared to HEMA-HA polymers across all pHs (Figure 
7.3 B).  Further, a clear difference was observed in the protonation states 
characteristic of sulfate groups on HEMA-SHA polymers compared to 
carboxylate groups on HEMA-HA polymers.  The sulfate groups remained 
deprotonated across all pHs, while the carboxylate groups were protonated at 
lower pH.   
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Figure 7.4.  Characterization of HEMA-SHA macromers.  (A) Sulfate content was significantly 
increased in HEMA-SHA macromers when compared to HEMA-HA macromers, as determined by 
dimethylmethylene blue assay.  Sulfate content of HEMA-SHA macromers was comparable to 
that of heparin.  (B) Addition of sulfate groups significantly enhanced the negative charge of 
carboxylic acid-containing HEMA-HA macromers via zeta potential measurements, and (C) 
significantly enhanced binding to the heparin binding TIMP-3 protein.  TIMP-3 binding of HEMA-
SHA macromers was comparable to that of heparin, though with a significantly different binding 
profile. (n=3 replicates per group, mean±SD, *p<0.025 compared to HEMA-HA, #p<0.025 
compared to heparin).   
 
 To assess the protein-binding characteristics of the polymers, a 
recombinant tissue inhibitor of matrix metalloproteinases (TIMP-3) was used as a 
model HBP.  TIMP-3 is unique among the four known TIMPs in that it binds 
sulfated polymers with a high affinity26, 27.  It naturally associates with sulfated 
GAGs in the ECM, so matrix presentation is thought to be important in controlling 
TIMP-3 activity28.  TIMP-3 was incubated in wells with polymers adsorbed to the 
surface and TIMP-3 bound to the polymer-coated wells was quantified using 
ELISA.  Using this technique, a significant increase in TIMP-3 binding was 
observed with HEMA-SHA polymers compared to non-sulfated HEMA-HA 
polymers (Figure 7.3 C).  Further, HEMA-SHA polymers had comparable TIMP-3 
binding to heparin, although more TIMP-3 was bound to HEMA-SHA at higher 
TIMP-3 concentrations.  This observation could be explained by the greater Mn of 
HEMA-SHA compared to heparin (80kDa vs. 20kDa by GPC) as both polymers 
were adsorbed to the wells at the same molar concentration.  In addition, 
differences in the sulfation pattern could affect HBP binding.  For example, 
Hintze and coworkers showed that sulfated HA binds human transforming growth 
factor beta-1 (TGF-!1) with a stronger affinity than synthetically sulfated  
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chondroitin sulfate, despite having the same degree of sulfation19.  Further, 
sulfated HA was shown to have different binding specificities for human plasma 
proteins than heparin29.  Therefore, while HEMA-SHA was shown to bind a HBP 
(TIMP-3) in this study, further investigation into protein binding specificity of 
HEMA-SHA polymers is warranted for specific HBPs. 
 
HEMA-SHA Incorporates into Radically Crosslinked Hydrogels and Alters HBP 
Presentation.   
 While a number of heparin mimetics have been developed as 
antithrombotic therapeutics, very few have been crosslinked into hydrogels for 
application in drug delivery or tissue engineering30-32.  After demonstrating 
successful synthesis of a methacrylate modified and sulfated HA macromer and 
its ability to bind a HBP, we crosslinked these polymers into hydrogels to 
encapsulate and localize HBPs.  HEMA-SHA polymers were blended with 
HEMA-HA polymers at 10% HEMA-SHA, 90% HEMA-HA with a total polymer 
concentration of 4 wt% (w/v), then crosslinking was initiated with APS and 
TEMED redox initiators.  Rheometry was used to quantify gelation, and HEMA-
SHA blended hydrogels were compared to 100% HEMA-HA hydrogels.  
Incorporation of 10% HEMA-SHA did not significantly alter gelation, as both 
groups had similar storage modulus (G’) profiles over time and crosslinking 
reached the same G’ plateau after 30 min (Figure 7.5 A-B).  Other ratios were 
also investigated (higher HEMA-SHA content); however, they led to hydrogels 
with statistically different mechanical properties, likely due to extensive sulfate 
charge repulsion and were not pursued further (results now shown).   
To visualize incorporation of sulfate groups into the HEMA-SHA blended 
hydrogels, they were incubated with DMMB after a 2-day wash in PBS.  HEMA-
SHA blended hydrogels exhibited a purple color compared to blue HEMA-HA 
hydrogels, indicating the presence of sulfate groups (Figure 7.5 C).  Further, 
HEMA-SHA blended hydrogels swelled significantly more than HEMA-HA 
hydrogels, likely due to charge repulsion within the sulfate rich hydrogels or 
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increased water content due to sulfate hydrophilicity (Figure 7.5 D).   
  
 
Figure 7.5.  Crosslinking of HEMA-HA/HEMA-SHA hydrogels.  HEMA-HA/HEMA-SHA 
hydrogels were crosslinked using APS/TEMED initiators and 4wt% macromers in PBS at 100/0 or 
90/10 HEMA-HA/HEMA-SHA compositions (wt/wt).  (A) Storage (G’) and loss (G’’) moduli profiles 
over time with and without 10% HEMA-SHA incorporation.  (B) Incorporation of 10% HEMA-SHA 
did not significantly affect G’ after crosslinking had reached a plateau at 30 min.  (C) Incorporation 
of sulfate groups in the hydrogels was visualized using dimethylmethylene blue with purple 
indicative of sulfate groups (scale bar = 5mm).  (D) Incorporation of sulfate groups slightly 
increased swelling of the hydrogels after 2 days in PBS.  (n=3 replicates per group, mean±SD, 
*p<0.05 between groups). 
 
Finally, to illustrate the influence of sulfate group incorporation on HBP 
presentation within the hydrogels, networks were formed that encapsulated either 
a model HBP, TIMP-3, or bovine serum albumin (BSA) and protein release and 
hydrogel degradation were monitored over 12 days.  HEMA-SHA blended 
hydrogels degraded in a slightly more rapid fashion compared to HEMA-HA 
hydrogels (Figure 7.6 A).  This observation is likely due to the increased water 
content of the hydrogels which enhances ester group hydrolysis of the HEMA 
groups.  BSA release from HEMA-SHA blended hydrogels was significantly 
reduced from HEMA-HA hydrogel release; however, both release profiles were 
quite similar (~70% within 12 days), indicating little influence of sulfate groups on 
BSA presentation and release (Figure 7.6 B).  This is not surprising as previous 
studies also found that albumin does not bind to sulfated HA with a high affinity29.  
However, TIMP-3 release was drastically reduced with incorporation of HEMA-
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SHA polymers into the network (Figure 7.6 C).  Less than 15% of the 
encapsulated TIMP-3 was released from HEMA-SHA blended hydrogels, 
whereas almost 60% was released from HEMA-HA alone hydrogels.  This 
reduced release of TIMP-3 with the incorporation of HEMA-SHA polymers 
demonstrates our ability to control HBP presentation within covalently crosslinked 
and degradable hydrogels, simply through chemical modification of the gel 
precursors.  This approach can be used with a variety of radically crosslinked 
scaffolds for drug delivery and tissue engineering applications.   
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Figure 7.6.  Gel degradation and 
encapsulated protein release.  (A) 
Gel mass loss as determined by 
uronic acid content.  Incorporation of 
HEMA-SHA macromers significantly 
enhanced hydrolytic degradation of 
the hydrogels over 2 weeks.  
Encapsulated FITC-BSA (B) and 
heparin-binding TIMP-3 (C) release 
from hydrogels of HEMA-HA alone or 
incorporating HEMA-SHA 
macromers.  Encapsulated TIMP-3 
release was reduced by over 40% 
with incorporation of HEMA-SHA 
macromers. (n=3 replicates per 
group, mean±SD, *p<0.05 between 
groups). !
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CHAPTER 8 
 
On-demand delivery of TIMP-3 from matrix metalloproteinase degradable 
hydrogels attenuates post myocardial infarction remodeling 
 
8.1. Introduction  
Excessive extracellular matrix (ECM) proteolysis by matrix 
metalloproteinases (MMPs) is a hallmark of many human disease states 
including chronic inflammation, tumor progression, and cardiovascular disease1.  
MMPs hydrolyze peptide bonds with a high level of amino acid specificity and 
regulation.  Under normal physiological conditions, MMP activity is precisely 
controlled to maintain a low level of structural protein, cell receptor, and growth 
factor turnover.  However, following a stimulus such as an injury, there is a loss 
of control over MMP activity which causes maladaptive changes to tissue 
architectures and functions, often resulting in the progression of disease2.   For 
example, MMP levels are elevated in patients following a myocardial infarction 
(MI) and are associated with adverse left ventricle (LV) remodeling3.  Increased 
MMP activity was directly measured within the human myocardium following 
myocardial arrest and reperfusion4.  Further, experimental models involving 
transgenic deletion of specific MMPs and systemic administration of 
pharmacologic MMP inhibitors have demonstrated that MMPs are important 
contributors to multiple aspects of adverse global LV remodeling including LV 
wall thinning, volume dilation, and ultimately dysfunction5-8.  While systemic 
administration of pharmacologic MMP inhibitors has shown efficacy in 
attenuating post MI remodeling in pre-clinical animal models of MI, off-target 
effects have limited their success in recent clinical trials9.  Therefore, strategies 
that localize physiological concentrations of MMP inhibitors to regions of MMP 
overexpression and limit spill over into the systemic circulation would provide a 
safe and effective strategy to attenuate post MI remodeling by targeting MMP 
activity.  !
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Wilson and colleagues recently showed that MMP elevation is highly 
localized to ischemic tissue within the MI region following experimental MI in 
pigs10.  While MMP levels increased dramatically, levels of their inhibitors, tissue 
inhibitors of MMPs (TIMPs), decreased significantly within the MI region.  TIMPs 
inhibit MMP activity by forming non-covalent complexes with MMPs in a 1:1 
stoichiometry, blocking the MMP catalytic domain and preventing proteolysis.  
With the exception of TIMP-1, TIMPs are known to inhibit all of the 25 known 
MMPs, and studies have identified unique roles and functionalities of each of the 
four TIMPs11.  In the context of post MI remodeling, TIMP-3 has been shown to 
play a particularly important role.  For example, myocardial TIMP-3 levels were 
significantly reduced in contradistinction to elevated myocardial MMP levels in 
patients with end-stage heart failure12.  In addition, transgenic TIMP-3 deletion in 
experimental animal models caused adverse LV remodeling and accelerated 
progression to heart failure following MI13-15.  
We therefore chose to evaluate the ability of a recombinant TIMP-3 to 
attenuate adverse LV remodeling through local MMP inhibition in a large animal 
model of MI.  Critical to the success of this approach is a safe and flexible 
delivery platform that locally releases TIMP-3 to the MI region while minimizing 
systemic off-target effects.  Injectable hydrogels have recently been developed 
for the therapeutic delivery of molecules to the heart following MI16.  In these 
systems, therapeutic molecules are encapsulated in a polymer matrix and 
released locally over time to sustain target levels of a molecule in the 
myocardium.  Polymer concentration, polymer-molecule interactions, 
hydrophobic effects, and gel degradation collectively determine molecule 
diffusion from the gel.  While these parameters can be controlled to engineer a 
gel formulation with a desired TIMP-3 release profile, studies have shown that 
post MI MMP expression profiles are dynamic and vary from patient to patient.  In 
some patients, MMP expression was endogenously restored from day 1 to day 5 
following MI, while in others a persistent or elevated MMP-9 signal from day 1 to 
day 5 was accompanied by a 3-fold end-diastolic volume increase at day 283.  
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Therefore, while MMP overexpression is an important target towards attenuating 
post MI remodeling, it is difficult to choose a single TIMP-3 release profile 
suitable for every patient.  One way to overcome these limitations is to design 
responsive gels that alter molecule release rates in response to external stimuli.  
Specifically, hydrogels with MMP-cleavable crosslinks allow encapsulated 
molecules to be released in response to local MMP activity17,18.  Utilizing this 
approach would effectively dose TIMP-3 release in response to MMP activity.  
One challenge towards realizing on-demand TIMP-3 delivery is to 
minimize passive TIMP-3 release from the gels (i.e., in the absence of MMP 
activity). TIMP-3 is unique among the TIMPs in that it is found bound to the ECM 
of tissues while the other three TIMPs are presented as soluble proteins19.  
Specifically, TIMP-3 binds to sulfated glyocosaminoglycans with a high affinity 
through an abundance of positively charged lysine and arginine residues 
exposed on the protein surface20,21.  TIMP-3 binding to the ECM is thought to 
facilitate local MMP inhibition in tissues, and recent studies have shown that 
sulfated polymers enhance TIMP-3 binding affinity for specific MMPs22.  
Therefore, we developed injectable gels with a negatively charged 
polysaccharide backbone to mimic native TIMP-3-ECM interactions and minimize 
passive diffusion of TIMP-3 from the gels.  MMP-cleavable crosslinks were 
incorporated to liberate bound TIMP-3 in the presence of local MMP activity.  
Further, we utilized conjugation and crosslinking chemistries to form gels rapidly 
upon injection into the myocardium that are stable in the absence of MMP activity 
to further prevent the passive release of TIMP-3 from the injection site.  We 
demonstrate that this TIMP-3 delivery strategy effectively inhibits MMP activity 
within the MI region without further damaging the myocardium or raising systemic 
TIMP-3 levels.  Finally, we show attenuated post MI LV remodeling through 
significant increases in LV wall thickness and ejection fraction in a large animal 
model of MI.  
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8.2. Methods 
HA-maleimide synthesis.    
74kDa sodium hyaluronate (NaHy, Lifecore) was first converted to a 
tetrabutylammonium (TBA) salt of HA (HA-TBA) by mixing NaHy with an ion 
exchange resin in DI water for 8hrs at RT.  The resin was then filtered from the 
aqueous solution and the solution was pH’d to 7.02 with TBAOH, frozen and 
lyophilized.   HA-TBA was dissolved in DMSO and then reacted with N-(2-
aminoethyl)maleimide trifluoroacetate salt (Sigma) in the presence of 
benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate for 
2hrs at RT.  The reaction solution was then dialyzed against DI water for 14 
days, frozen and lyophilized.  Percent maleimide modification of HA was 
determined to be 35% of the HA repeat units by normalizing the area under the 
maleimide 1H peak to the aminomethyl protons on the HA backbone.  
 
Solid-phase peptide synthesis.  
Peptides were synthesized with the MMP-cleavable sequence 
GCNSGGRMSMPVSNGG-Hyd where C is the cysteine used for coupling to a 
maleimide functionalized HA and Hyd is the hydrazide for gel crosslinking with an 
aldehyde functionalized HA.  The solid-phase resin (Rink Amide MBHA resin, 
100-200 mesh, Novabiochem) was deprotected with 20% (v/v) piperidine in N,N-
dimethylformamide (DMF) solution and Fmoc protected amino acids 
(Novabiochem) were activated with HBTU (Novabiochem) in 0.4 M N-
methylmorpholine in DMF prior to reaction with deprotected resin.  Amino acids 
were reacted at 4x excess to solid-phase resin using an automated solid phase 
peptide synthesizer (PS 3, Protein Technologies, Inc.).  After completion, the 
polypeptide was cleaved from the resin with a 90% trifluoroacetic acid, 5% tri-
isopropylsilane, 5% water solution for 3 hrs at room temperature.  The 
polypeptide was then precipitated in ethyl ether solution at -80°C for 2 hrs, spun 
down and dried against vacuum pump pressure overnight.  Matrix-assisted laser 
desorption/ionization-Time of Flight (MALDI-TOF) mass spectroscopy was used 
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to verify successful polypeptide mass based on theoretical calculation. 
 
Synthesis and characterization of polymers.  
HA-peptide-hydrazide polymers were synthesized by coupling a cysteine 
terminated peptide to HA-maleimide by mixing at a 4:1 molar ratio, 
cysteine:maleimide in PBS for 4hrs at 4°C.  The polymer was purified by dialysis 
against a 20 mM NaCl solution for 4 days, then DI water for 3 days, frozen and 
lyophilized.   HA-aldehyde was synthesized by mixing NaHy (350kDa, Lifecore) 
at 1 % (w/v) and sodium periodate (IO4) in DI water at a molar ratio of 1:2 HA:IO4 
for 2hrs at RT.  The reaction was stopped by adding 10% (v/v) ethylene glycol to 
the reaction, dialyzing against DI water for 5 days, freezing and lyophilizing.  DS-
ald was synthesized in a similar fashion except DS (Sigma) was reacted with IO4 
at a molar ratio of 2:1 DS:IO4 for 5hrs at RT.  Percent aldehyde modification was 
quantified using a TNBS colorimetric assay as previously described24. 
 
Rheometry.  
To form gels, ALD (2.4% HA-ald, 1.4% DS-ald (w/v)) and HYD (3.2% (w/v) 
HA-peptide-hyd) modified polymers were dissolved in PBS, mixed 1:1 and 
gelation characteristics were quantified by monitoring the storage (G’) and loss 
(G’’) moduli with time using an AR2000ex Rheometer (TA Instruments) at 37°C 
under 1% strain and 1 Hz. 
 
Gel degradation and molecule release studies.   
FITC-BSA or rTIMP-3 was mixed with the ALD precursor solution and gels 
were formed as described above in cylindrical molds for 30 min at 37°C.  Gels 
were incubated in PBS supplemented with 1% BSA for FITC-BSA studies or TTC 
buffer (50mM Tris-HCl, 1mM CaCl2, 0.05% triton x-100, pH 7.5) for rTIMP-3 
studies at 37°C.  After a wash, enzymes (collagenase type 4, Worthington or 
rMMP-2, R&D Systems) were added every 2 days and buffers were collected 
and stored at -20°C prior to analysis.  Uronic acid content was analyzed to 
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calculate gel mass loss25, FITC-BSA fluorescence was analyzed to measure 
release, and an ELISA was used to measure rTIMP-3 content (R&D Systems).  
 
rTIMP-3 activity and binding assays.   
rTIMP-3-His (Amgen, Inc.) activity was quantified by its ability to inhibit 
rMMP-2 (R&D Systems) activity using an MMP cleavable fluorogenic substrate 
(R&D Systems).  Serial dilutions of rTIMP-3 were added to 4nM activated rMMP-
2 in TTC buffer, incubated for 2hrs at 37°C, then the fluorogenic substrate was 
added and fluorescence kinetics were measured over 5 min with a microplate 
reader (Tecan).  rTIMP-3 binding to polysaccharide polymers was evaluated with 
a solid-phase binding assay. HA-ald, DS-ald, and heparin (Sigma) at 2.5µM in 
PBS were coated overnight at 25°C on to heparin binding plates (BD Life 
Sciences)26.  Wells were washed in TNC buffer (50 mM Tris/HCl, 150 mM NaCl, 
10 mM CaCl2, 0.05 % Brij-35 and 0.02 % sodium azide) containing 0.1 % Tween 
20 between each subsequent incubation. Wells were blocked with 0.2% gelatin in 
TNC buffer and then incubated with rTIMP-3-His (0.02-3µg/mL in blocking 
solution for 3 h at 37°C). Bound rTIMP-3-His was detected using a biotin labeled 
antibody against the 6xHis tag on rTIMP-3 (Abcam, catalogue number ab27025, 
for 3 h at 37!C), followed by streptavidin coupled to horseradish peroxidase (R&D 
Systems) for 1h at 37°C. Hydrolysis of a 1:1 mixture of H2O2 and 
tetramethylbenzidine was measured at 450 nm using a microplate reader 
(Tecan). 
 
MI induction and gel injections.   
Yorkshire pigs (n=7, 25kg, Hambone Farms, Orangeburg, SC) were 
anesthetized with isoflurane (2%), and through a left thoracotomy, the LV free 
wall was exposed.  A 2 cm square calibrated grid was sutured below the origin of 
the first two obtuse marginal arteries of the circumflex artery (OM1 and OM2), 
which provided for a total of 9 distinct injection sites within a targeted 2X2 cm 
region of myocardium. OM1 and OM2 were ligated to induce an MI, and 
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characteristic ECG changes occurred, but electrical cardioversion and/or 
defibrillation were not required, and past studies demonstrated that this 
technique creates a uniform and consistent MI8.  Referent controls were 
instrumented in a similar fashion with the exception of coronary artery ligation.  
Pigs were randomized to receive injections of saline (MI only), gel alone (gel), or 
gel with rTIMP-3 (gel/rTIMP-3). For gel injections, the ALD (2.4% HA-ald, 1.4% 
DS-ald (w/v)) and HYD (3.2% (w/v) HA-GCNSGGRMSMPVSNGG-hyd) 
precursors solutions were mixed in a sterile fashion, drawn into separate 1mL 
syringes, and injected into the mid-myocardium of each target site using a 
FibriJet blending connector (Nordson Micromedics, SA-3670) with a 27G needle.  
For gel/rTIMP-3 group, rTIMP-3 was mixed into the ALD precursor (20µg rTIMP-
3/100µL ALD). Successful injections were confirmed by visualization of an 
opacification of the epicardial surface at the point of myocardial injection. 
 
Blood analysis.   
Pigs were instrumented as described in the preceding section with the 
addition of a vascular access catheter placed in the descending aorta and 
connected to a subcutaneous port (6 Fr., SlimPort,Bard Access Systems, Salt 
Lake City). Blood samples (5 mL) were collected from the subcutaneous port 1, 
3, 7 and 14 days post-MI. The referent controls were again instrumented in an 
identical manner with the exception of MI induction.  The collected blood samples 
were centrifuged and the decanted plasma subjected to ELISA for troponin-I (Pig 
Cardiac Troponin-I, KT-474, Kamiya Biomedical Co) and C-reactive protein 
(CRP; Porcine CRP ELISA, IPGCRPKT, Innovative Research Inc.). 
 
LV assessment with echocardiography.   
Animals were sedated (20 mg valium, PO, Elkin-Sinn) and two-
dimensional echocardiographic studies (GE VIVID 7 Dimension Ultrasound 
System: M4S 1.5-4.3 MHz active matrix array sector transducer probe) were 
performed to calculate LV dimensions and ejection fraction.  Echocardiography 
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measurements were taken 1 day prior to MI induction, and then again 1, 3, 7 and 
14 days following MI. 
 
Interstitial MMP activity.   
After 14 days post MI, the pigs were anesthetized with sufentanyl (2µg/kg 
IV, Baxter Healthcare), morphine sulfate (3mg/kg/h IV, Elkin-Sinn), and isoflurane 
(1%, 3 L/min O2, Baxter Healthcare), and mechanically ventilated.  The LV was 
exposed through a sternotomy, a microdialysis probe (20 kDa, outer diameter of 
probe shaft 0.77mm; CMA/Microdialysis, North Chelmsford, MA) placed within the 
MI region, and infused with the MMP fluorescent substrate (5 µL/min) as 
previously validated3,4.  The dialysate was then subjected to fluorometry, which 
reflected interstitial MMP activity, and these values were normalized to referent 
control values and expressed as a percent.  Following these measurements, the 
LV was harvested, separated into MI and remote regions (area served by left 
anterior descending artery), and prepared for biochemical analysis. 
 
Data and statistical analysis.   
Statistical analyses were performed using STATA statistical software.  LV 
geometry, function, and area within the markers were compared between the 
control and MI groups using a one-way analysis of variance (ANOVA).  Post-hoc 
separation following ANOVA was performed using pairwise comparisons with a 
Bonferroni analysis (prcomp module, STATA).  The interstitial global MMP 
activity was evaluated by ANOVA and subsequently compared against the 
control values of 100% by a Student’s t-test.  For TIMP-3 levels and plasma 
troponin and CRP concentrations, values from each group were first evaluated 
by ANOVA, and then a post-hoc separation following ANOVA was performed 
using pairwise comparisons with a Bonferroni analysis.  For PCR measurements, 
a multi-way ANOVA (MANOVA) was performed, evaluating for treatment 
dependent, MI dependent, and region dependent effects.  Post-hoc separation 
following MANOVA was performed using pairwise comparisons with a Bonferroni 
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analysis.  Results are presented as a mean ± standard error of the mean (SEM), 
and values of p<0.05 were considered to be statistically significant. 
 
8.3. Results and Discussion 
Gel design for MMP-responsive rTIMP-3 delivery  
The main criteria used in designing a gel formulation for rTIMP-3 delivery 
were 1) a gel that crosslinks  upon injection through a syringe, 2) stable gels that 
degrade only in the presence of MMP activity, and 3) minimal passive release of 
encapsulated rTIMP-3 (i.e., in the absence of MMP activity).  To this end, we 
developed a three-macromer system that utilizes the chemical versatility of 
polysaccharide backbones (Figure 8.1 a).  Polysaccharides were chemically 
modified to contain either aldehyde (ALD) or hydrazide (HYD) functional groups 
to form gels in a one-step condensation reaction, with water as the only 
byproduct (Figure 8.1 b).  Hyaluronic acid (HA) was used as a template for both 
ALD and HYD modifications due to the well-defined size ranges of commercially 
available HA, the previous use of HA in biomedical applications, and the 
abundance of diol and carboxylic acid groups necessary for ALD and HYD 
modifications, respectively.  Dextran sulfate (DS) was also incorporated into the 
gels through ALD modification of its diol groups to act as a heparin mimetic to 
immobilize encapsulated heparin-binding proteins23.  ALD modification of HA and 
DS were evaluated separately as each polysaccharide contains a different 
number of diol groups amendable to aldehyde modification (Figure 8.2).   
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Figure 8.1. Injectable hydrogels with peptide crosslinks. (a-b) HA and DS polymers were 
modified with aldehyde (ALD) groups and HA polymers were modified with a peptide containing 
an hydrazide (HYD) group to form hydrogels through stable hydrazone bond formation. (c) Upon 
mixing ALD and HYD polymers, robust hydrogels formed rapidly as evidenced by development of 
storage (G’) and loss (G’’) moduli over time. 
 
 
 
Figure 8.2. Aldehyde modifications. Aldehyde groups were synthesized on HA (a) and DS (b) 
polymers using sodium periodate (NaIO4) oxidation of diols. Different reaction conditions were 
chosen for each polymer due to differences in the amount of diol groups per polymer.   
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Further, converting diols to aldehydes through periodate oxidation is known to 
degrade polysaccharides, so a large molecular weight (MW) HA (~350kDa) was 
chosen to provide sufficient HA-ald MW to allow formation of robust gels for 
rTIMP-3 encapsulation.  Reaction conditions for HA-ald were chosen to balance 
aldehyde modification and macromer MW as periodate concentration both 
increased aldehyde modification and decreased HA MW in a dose-dependent 
manner (Figure 8.3).  Reaction conditions for DS-ald were chosen to provide 
sufficient aldehyde modification to crosslink DS-ald into the gel.  
 
 
Figure 8.3. Periodate polymer degradation. HA polymers degraded due to non-specific 
reactions during the oxidation reaction. Values reported are number-averaged molecular weights 
(Mn) as determined by gel permeation chromatography.    
 
MMP-specificity was incorporated into the gels by generating MMP-
cleavable peptides with a terminal HYD functional group using solid phase 
peptide synthesis.  In addition, a thiol containing cysteine was incorporated into 
the MMP-cleavable peptides, opposite of the HYD group to facilitate thioether 
linkage to a maleimide functionalized HA (MAHA) in a one-step click reaction 
(Figure 8.1).  Finally, hydrophilic serine (S) and asparagine (N) spacers were 
incorporated between the reactive groups (cysteine and hydrazide) and the 
MMP-cleavable peptides to improve solubility for passage through a syringe.  
Successful synthesis of the designed peptide was verified with MALDI (Figure 
8.4 a) and peptide coupling to MAHA was verified by complete consumption of 
the characteristic maleimide peak from 1H NMR (Figure 8.4 b).  Percent 
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maleimide modification of HA (and therefore HYD modification) was controlled 
through the concentration of N-(2-Aminoethyl)maleimide during MAHA synthesis.  
The thioether coupling chemistry was chosen for its stability in water to prevent 
non-specific hydrolysis of the gels.  The designed formulation enabled rapid 
crosslinking of gels upon mixing ALD and HYD modified macromers as 
evidenced by development of the elastic component (G’) of the complex modulus 
using rheometry (Figure 8.1 c).  The gels reached a plateau G’ of approximately 
1.5 kPa, at which point the gels are robust, nearly elastic solids.  
 
 
Figure 8.4. Peptide synthesis and coupling. (a) Peptide synthesized through solid-phase 
peptide synthesis was analyzed using MALDI-TOF mass spectroscopy to verify mass. (b) Peptide 
coupling to maleimide functionalized HA was verified by loss of peak characteristic of maleimide 
protons using 1H NMR. 
 
To demonstrate MMP-sensitivity, gels containing a peptide sequence that 
is cleaved by MMPs (GGRMSMPV) were incubated in buffer with varying 
concentrations of active MMPs and uronic acid content in the buffer was 
measured over time to calculate gel mass loss.  In the absence of active MMPs, 
the gels were stable over the 12-day study (Figure 8.5 a).  In a 20 U/mL enzyme 
concentration, the gels degraded in a near-linear fashion with very little gel 
remaining after 12 days.  In 200 U/mL, the gels completely degraded in 2 days.  
To evaluate the applicability of the gels for MMP-triggered release of 
encapsulated molecules, FITC-BSA was encapsulated in the gels and release 
HA-TBA 
HA-maleimide 
HA-peptide-hydrazide 
a b 
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was quantified in buffer with varying concentrations of active MMPs.  
Encapsulated FITC-BSA release followed the gel degradation behavior in a 
similar MMP-dependent manner (Figure 8.5 b).     
 
Figure 8.5. MMP-trigged molecule release.  Hydrogels with the MMP-cleavable GGRMSMPV 
peptide in the crosslink were incubated in different concentrations of collagenase type 4. (a) 
Hydrogels were stable in the absence of enzyme activity and degraded in response to enzyme 
concentration. (b) Encapsulated FITC-BSA released in proportion to hydrogel degradation. 
(mean±SD, n=3 hydrogels per condition). 
 
rTIMP-3 delivery with MMP-cleavable gels 
TIMP-3 was chosen for local delivery post-MI in part because of its unique 
ECM-binding property.  This allowed us to design ECM mimetic gels to 
encapsulate and immobilize rTIMP-3 until they are released by MMP-mediated 
gel degradation.  To this end, DS was incorporated into the gel formulation to 
mimic sulfated GAGs, the major component of the ECM responsible for TIMP-3 
binding, due to its susceptibility to aldehyde modification through diol oxidation.  
Binding of rTIMP-3 to DS-ald was evaluated using a solid-phase binding assay.  
rTIMP-3 bound to DS-ald with a much greater capacity than to HA-ald, and 
approached the capacity of rTIMP-3 binding to heparin (Figure 8.6 a).  
Importantly, rTIMP-3 binding to DS-ald did not reduce rTIMP-3 inhibition of active 
MMPs (Figure 8.6 b).  rTIMP-3 inhibited 4nM rMMP-2 with a half maximal 
inhibitory concentration of 17±4 ng/mL (0.7±0.2 nM) with 50 µg/mL DS-ald in 
solution compared to 28±7 ng/mL (1.2±0.3 nM) without DS-ald in solution 
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(p=0.07).  Previous studies found that a stretch of basic amino acids responsible 
for TIMP-3 binding to sulfated GAGs is opposite to the TIMP-3 reactive site that 
interacts with MMPs 21.  Therefore, utilizing polysaccharides that mimic sulfated 
GAGs allows localization of TIMP-3 without altering its inhibitory properties.  
Indeed, encapsulating rTIMP-3 in the crosslinked polysaccharide gels limited 
diffusion of rTIMP-3 from the gel (Figure 8.6 c), where less than 20% of 
encapsulated rTIMP-3 was released over the 14-day study. 
 
 
Figure 8.6. Polymer binding to rTIMP-3. (a) rTIMP-3 bound to polymer coated wells detected 
with ELISA.  rTIMP-3 bound to DS-ald with a greater capacity than HA-ald, and approached 
rTIMP-3 binding to heparin. (b) rTIMP-3 activity measured by its ability to inhibit a 4 nM rMMP-2 
solution.  rTIMP-3 binding to DS-ald did not affect rMMP-2 inhibition. (c) Release of rTIMP-3 
encapsulated in ALD+HYD hydrogels was limited to less than 20% by incorporating sulfated DS-
ald.    
 
 While using MMP activity to trigger release of molecules encapsulated in 
gels has been performed previously17,18, using MMP activity to trigger release of 
MMP inhibitors, and therefore using MMP activity to trigger its own inhibition, is a 
novel concept.  To investigate this unique feedback system, gels with and without 
encapsulated rTIMP-3 were incubated in 20nM active rMMP-2.  Gels without 
rTIMP-3 degraded within 2 days in the MMP buffer, while gels with encapsulated 
rTIMP-3 degraded in a linear fashion for over 14 days (Figure 8.7a).  This 
reduction in gel degradation rate observed with rTIMP-3 encapsulation indicates 
that encapsulated rTIMP-3 remains active and is inhibiting rMMP-2 activity as 
rMMP-2 is degrading the gel (Figure 8.7 b).  Further, as rMMP-2 was refreshed 
every 2 days to account for enzyme stability (Figure 8.8), a sufficient amount of 
active rTIMP-3 remained bound in the gel for the entire 14 day study, otherwise 
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the gel would rapidly degrade in similar fashion to the gels without rTIMP-3.  
These results demonstrate a novel approach of locally delivering rTIMP-3 by 
designing injectable gels containing MMP-cleavable crosslinks, where the local 
presence of active MMPs controls the release of encapsulated rTIMP-3, and 
therefore MMP inhibition. 
 
 
 
Figure 8.7. MMP-triggered release of rTIMP-3. (a) Hydrogels with (filled symbols) and without 
(open symbols) encapsulated rTIMP-3 were incubated with (squares) or without (triangles) rMMP-
2. rMMP-2 was added every two days (indicated by green arrows). Encapsulated rTIMP-3 
attenuated MMP-2 mediated hydrogel degradation, confirming activity of rTIMP-3 across the 14-
day study. (b) In this system, rMMP-2 degrades the hydrogel crosslinks (1), liberating bound 
rTIMP-3, inhibiting rMMP-2 activity (2), and attenuating further hydrogel degradation (3).  
 
 
 
 
Effectiveness of rTIMP-3 delivery in vivo 
To assess the effectiveness of our rTIMP-3 delivery system in the setting 
of MI, a large animal model of MI was employed that allows for regional 
quantification of MMP expression and activity, along with functional outcomes of 
post MI LV remodeling10.  Following MI induction in pigs, gels were injected 
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Figure 8.8. rMMP-2 activity. Activity of 
rMMP-2 decreases to less than 10% of its 
initial level immediately after activation in 
buffer. 
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at 9 equally spaced sites within a 2cm x 2cm grid in the MI region (Figure 8.9 a).  
A dual-barreled syringe was utilized to blend ALD and HYD polymers in equal 
ratios immediately prior to entering the tissue for in situ gelation. 
   Following rTIMP-3 delivery, blood samples were taken after 1, 3, 7, and 
14 days and analyzed for TIMP-3 concentrations.  Importantly, there was no 
observed increase in systemic TIMP-3 levels with local delivery of rTIMP-3 to the 
MI region using our injectable gels compared to MI only and gel injection alone 
(Figure 8.9 b). To quantify MMP activity within the MI region, a previously 
validated microdialysis technique was utilized that perfuses the myocardial 
interstitium with an MMP cleavable substrate and measures fluorescence as the 
substrate is cleaved4.  Using this technique, MMP activity was observed to 
significantly increase in the MI region following MI induction (Figure 8.10).  
Interestingly, injection of the MMP degradable gels alone significantly reduced 
MMP activity within the MI region, potentially due to a “sink effect” where the 
cleavable peptide substrate is cleaved by active MMPs, reducing substrate 
hydrolysis elsewhere.  However, rTIMP-3 delivery from the MMP degradable gels 
further reduced MMP activity within the MI region.  
 
 
Figure 8.9. Hydrogel mediated rTIMP-3 delivery. (a) Hydrogels were formed in situ by utilizing 
a dual barrel syringe to mix the ALD and HYD polymers at the injection site. (b) Hydrogel 
mediated delivery of rTIMP-3 prevented a systemic increase in rTIMP-3 levels. (mean±SD; MI 
n=5; MI/hydrogel n=6; MI/hydrogel/rTIMP-3 n=5; p>0.05 between groups across all time points; 
horizontal lines represent non-MI control ± 95% CI, n=16;)  
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Experimental MI induction caused a gradual reduction in LV function, as 
indicated by a declining ejection fraction (EF) and a progressive increase in 
pulmonary capillary wedge pressure (PCWP) (Fig 8.11 a-b).  Coinciding with 
declining LV function were significant changes in LV geometry as indicated by 
progressive LV wall thinning and LV dilation (Fig 8.11 c-d).  rTIMP-3 delivery 
from the injectable gels significantly increased LV wall thickness compared to MI 
only and significantly reduced LV end diastolic volume (LVEDV) compared to gel 
alone.  Further, rTIMP-3 delivery significantly improved LV function as evidenced 
by significant increases in EF and decreases in PCWP compared to MI only and 
gel alone control groups.  
Our results demonstrate the utility of injectable gels to locally deliver 
TIMPs and inhibit excessive MMP activity by restoring myocardial MMP/TIMP 
balance following MI.  This is the first proof-of-concept demonstration of 
designing MMP-degradable gels to release an MMP inhibitor in the presence of 
MMP activity to limit off-target effects of MMP inhibitors, which have been 
clinically problematic.  The successful demonstration of this technology in 
attenuating post MI remodeling in a large animal model warrants further pre-
clinical investigation as it could ultimately provide a safe and effective therapy to 
treat patients in the clinical setting of acute MI. 
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Figure 8.10. Post MI MMP activity. 
Interstitial microdialysis of a fluorogenic 
MMP cleavable substrate showed a 
significant increase in MMP activity in the 
MI region of pigs. Injection of the hydrogel 
alone significantly reduced MMP activity.  
Encapsulation of rTIMP-3 further reduced 
MMP activity. (mean±SD; control n=4; MI 
n=5; MI/hydrogel n=6; MI/hydrogel/rTIMP-3 
n=4; *p<0.05 vs. control; +p<0.05 vs. MI)  
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Figure 8.11. LV  function and geometry post MI. Serial LV echocardiography measurements 
were collected over the 14 day study to assess LV function (a-b) and geometry (c-d). (a) 
Progressive decrease in ejection fraction (EF) was observed following MI induction, and rTIMP-3 
delivery from injectable hydrogels significantly attenuated this decline. (b) Progressive increase 
pulmonary capillary wedge pressure (PCWP) was observed following MI induction, which was 
significantly attenuated with rTIMP-3 delivery. (c) Progressive thinning of the LV wall posterior 
wall thickness at diastole (LVPWThd) was significantly attenuated with rTIMP-3 delivery. (d) 
Progressive dilation of the LV end diastolic volume (LVEDV) was significantly attenuated 
compared to injection of the hydrogels alone. (mean±SEM; MI n=5; MI/hydrogel n=6; 
MI/hydrogel/rTIMP-3 n=5; +p<0.05 compared to MI; #p<0.05 compared to MI/hydrogel; horizontal 
lines represent non-MI controls ± 95% CI) 
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CHAPTER 9 
 
Conclusions and Limitations 
 
The work presented in this dissertation illustrated the utility of injectable 
hydrogels based on the molecule hyaluronic acid (HA) to engineer the left 
ventricular (LV) remodeling process that occurs following a myocardial infarction 
(MI) by encapsulating and locally delivering therapeutic proteins to the MI region.  
Specifically, HA hydrogels were designed and implemented for the delivery of 
two therapeutic proteins: stromal cell-derived factor-1 alpha (SDF-1a) and tissue 
inhibitor of matrix proteinases-3 (TIMP-3), and a range of in vitro and in vivo 
studies were implemented to understand how the controlled delivery of proteins 
through electrostatic interactions and hydrogel degradation influence therapeutic 
outcomes.  The following sections summarize the conclusions and limitations of 
each Aim, as well as present a prospective on future directions for this area of 
research. 
 
9.1. Specific Aim 1: Demonstrate that local rSDF-1! delivery from HA 
hydrogels homes mobilized bone marrow derived cells (BMCs) to the heart 
following MI. 
Conclusions:  Both rSDF-1! and the crosslinkable HA macromer 
stimulated BMC chemotaxis up to 4-fold in vitro through CXCR4 and CD44 
receptor signaling, respectively.  Moreover, the HEMA-HA macromer bound 
rSDF-1! with a dissociation constant of 36±5 µM through electrostatic interaction.  
When formed into hydrogels via photo-initiated crosslinking, release of 
encapsulated rSDF-1! and crosslinked HA were sustained for over 7 days, and 
these molecules significantly increased BMC chemotaxis in vitro.  When applied 
to the heart following experimental MI in mice, the HA hydrogel containing rSDF-
1! significantly increased the number of systemically infused BMCs in the heart 
by ~8.5 fold after 7 days over untreated controls, likely through both systemic and 
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local effects of released molecules.  We conclude that sustained release of 
rSDF-1! and HA from our photo-crosslinked HA hydrogels enhances circulating 
BMC homing to the remodeling myocardium better than delivery of rSDF-1! 
alone. 
Limitations:  While our finding that SDF-1! release from HA hydrogels 
enhances BMC homing through both SDF-1! and HA activities is significant, 
several experimental variables limit the implications of this result.  First, it was 
necessary to deliver BMCs to the animals and this was completed 3 hrs following 
MI induction.  Although this was necessary to quantify homing to the heart, the 
approach here was not intended to investigate injected cell therapies, but rather 
the influence of the delivered molecule alone.  Also, during this acute stage of 
post MI remodeling, the endothelium of the coronary vasculature is activated with 
adhesion molecules to regulate cell trafficking to the remodeling myocardium1.  
While delivering SDF-1! and HA during this phase enhanced engraftment of 
BMCs, whether or not SDF-1! and HA delivery at a more chronic stage would 
have the same effect is unclear.  Therefore this therapeutic strategy may be 
limited to acute post MI remodeling.  Further, since a heterogeneous population 
of BMCs was used to model cell homing, it is unclear which populations of cells 
responded to local molecule delivery and in this Aim, we did not investigate the 
actual influence of the homed cells on LV remodeling.  Therefore, we can only 
speculate about what effect the responsive cells would have on post MI 
remodeling.  Finally, while recruiting endogenous populations of progenitor cells 
to repair the heart is an attractive strategy to avoid ex vivo cell manipulations, 
progenitor cell numbers have been shown to decline with age2-4, and therefore 
the endogenous capacity for regeneration in older patients may be a limiting 
factor in the translation of this approach.   
 
9.2. Specific Aim 2: Assess the therapeutic benefit of engineered SDF-1! 
analogue (ESA) delivery from injectable HA hydrogels post MI. 
 Conclusions: Encapsulating ESA in redox-initiated HEMA-HA hydrogels 
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sustained ESA release for over 4 weeks as the hydrogels degraded in vitro.  
Interestingly, aggregates of ESA were observed dispersed throughout the gel 
suggesting the engineered protein is less water-soluble than native SDF-1!, but 
remained active in enhancing progenitor cell chemotaxis over the 4-week in vitro 
study.  Further, endothelial progenitor cell (EPC) chemotaxis to molecules 
released from the hydrogel alone was significantly enhanced, consistent with the 
finding in Aim 1 that HA released from the degradable HA hydrogels provides a 
cue for cell migration.  When delivered to the heart within injectable hydrogels 
following MI induction in rats, near-IR tagged ESA was detected for over 3 weeks 
in the heart using transthoracic optical microscopy, consistent with in vitro 
release kinetics.  Injection of the HA hydrogels alone significantly reduced LV 
fibrosis and dilation and significantly improved cardiac output (CO) and LV end-
systolic pressure volume relationship (ESPVR).  Further, significant increases in 
CXCR4+ cell and capillary densities were observed with hydrogel injection alone.  
However, delivery of ESA from hydrogels further reduced adverse LV remodeling 
with significant reductions in LV fibrosis and wall thinning, and significant 
increases in CO, ejection fraction (EF) and ESPVR compared to gel injection 
alone.  Further, ESA delivery significantly increased CXCR4+ cell densities in the 
myocardium.  We conclude that injectable HA hydrogels allow for sustained 
delivery of ESA to the myocardium post MI, and this approach effectively 
attenuates adverse LV remodeling in a rat model of MI through both hydrogel 
bulking and SDF-1!/CXCR4 homing effects.  
 Limitations: While this study provided a strong proof-of-concept that 
injectable HA hydrogel mediated delivery of ESA significantly attenuates post MI 
remodeling in rats, several experimental variables limit the implications of this 
finding.  First, it is important to note that while a fluorescent ESA signal was 
detected in the heart for over 3 weeks following hydrogel injection, this does not 
confirm activity of delivered ESA for over 3 weeks in vivo.  The engineered ESA 
is still susceptible to protease degradation; therefore, additional studies are 
warranted to investigate duration of active ESA in vivo.  Second, the hydrogels 
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with encapsulated ESA were delivered immediately following MI.  As described in 
the limitations to Aim 1, this time period may be optimal to enhance recruitment 
of endogenous cells, and therefore the positive findings reported here may not be 
generally applied to clinical situations where treatment modalities must be 
effective in the setting of chronic heart failure.  In addition to providing a SDF-1! 
signal in the early stages of post MI remodeling, the injected hydrogels provide 
mechanical support to the ischemic myocardium and therefore may be more 
effective in attenuating LV remodeling when applied directly following MI 
induction.  Therefore, the results from this Aim must be considered in an acute 
MI context.  For both Aims 1 and 2, a further limitation exists in that each 
injection technique required direct injection either on or within the infarct tissue 
from a syringe, rather than through a percutaneous delivery approach.  This may 
limit the patient population that could undergo such a process for hydrogel 
injection. 
 
9.3. Specific Aim 3: Investigate the effect of local TIMP-3 release from 
injectable HA hydrogels on MMP activity and LV remodeling following MI 
 Conclusions: HEMA-HA macromers bound rTIMP-3 with a dissociation 
constant of 3.8±0.3 µM through electrostatic interaction.  When encapsulated in 
redox-initiated HEMA-HA hydrogels, rTIMP-3 release was sustained for over 2 
weeks in vitro.  When delivered to the myocardium following experimental MI in 
pigs, a detectable rTIMP-3 signal was still present at the injection sites after 7 
days, indicating that rTIMP-3 release was sustained for at least 7 days from 
injectable HA hydrogels in vivo.  This delivery approach effectively inhibited MMP 
activity within the MI region compared to MI only and hydrogel alone control 
groups.  By restoring the TIMP/MMP balance, infarct expansion was abrogated, 
LV dilation reduced by ~20%, and ejection fraction increased by ~20% when 
compared to MI only 14 days post MI (p<0.05).  Further, smooth muscle actin 
content indicative of myofibroblast proliferation increased and pro-inflammatory 
cytokine levels were reduced within the MI region 14 days post MI with TIMP-3 
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delivery.  These changes were not associated with a significant increase in 
collagen accumulation compared to hydrogel delivery alone.  We conclude that 
these results provide the first proof of concept that local and sustained delivery of 
a recombinant TIMP from injectable HA hydrogels can effectively attenuate the 
adverse post MI remodeling process in a large animal model of MI by normalizing 
MMP activity and pro-inflammatory cytokines, and inducing contractile 
myofibroblast proliferation.  
 Limitations:  While it is clear from this study that local delivery of rTIMP-3 
from injectable HA gels has beneficial effects on post MI remodeling, the 
mechanism for this benefit remains associative.  rTIMP-3 delivery inhibited MMP 
activity, altered fibroblast phenotype, and attenuated cytokine signaling within the 
MI region; therefore, it is difficult to speculate about which has the largest impact 
on the remodeling process.  Further, while observing these beneficial results in a 
large animal model of MI is a significant step towards translating this therapeutic 
approach to humans, the hydrogels were injected immediately following MI 
induction, which may not be possible in a clinical scenario.  However, since ECM 
turnover is important for adequate wound healing following MI5,6, early MMP 
inhibition may not necessarily be optimal.  Therefore, additional studies are 
warranted that examine the optimal window for localized modulation of TIMP 
levels within the MI region, with respect to providing maximal prevention of 
adverse remodeling and minimal interference with the necessary wound healing 
response.  Further, rTIMP-3 was chosen for its strong binding to the ECM7-9 and 
its critical role in post MI remodeling10-12, however the three other TIMPs could 
also be suitable candidates for therapeutic delivery post MI.  In addition, while 
communications with collaborating laboratory (F.G. Spinale) revealed that 
injections of rTIMP-3 alone had little effect of post MI remodeling, adding this 
treatment group would better illustrate the importance of sustaining rTIMP-3 
levels in the myocardium with injectable hydrogels.  Finally, additional dose-
titration studies will be required to determine the minimal threshold levels of 
rTIMP-3 release in order to significantly affect LV regional geometry and function 
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post MI while limiting off target effects. 
 
9.4. Specific Aim 4: Develop sulfated HA macromers to incorporate high 
TIMP-3 binding affinity into injectable HA hydrogels. 
 Conclusions:  We developed sulfated and vinyl modified HA macromers 
by first synthesizing HEMA-HA, then sulfating primary hydroxyls along the HA 
backbone through nucleophilic substitution with SO3 (HEMA-SHA).  The sulfation 
reaction did not alter HEMA group modification and therefore HEMA-SHA 
macromers could be readily incorporated into HEMA-HA gels by simply blending 
the two macromers together at a desired ratio and initiating crosslinking with free 
radical initiators.  Sulfate content of HEMA-SHA macromers was significantly 
greater than HEMA-HA, and comparable to sulfate content of heparin.  In 
addition, HEMA-SHA bound rTIMP-3 with an affinity comparable to heparin, and 
could be covalently incorporated into hydrogels without altering hydrogel 
crosslinking.  Once incorporated into the hydrogels, HEMA-SHA significantly 
reduced encapsulated rTIMP-3 release (~15% compared to 60% total release) 
over 14 days.  We conclude that these sulfated HA macromers provide a useful 
way to introduce heparin-binding features into radically crosslinked HA hydrogels 
without altering hydrogel architectures, and can therefore be applied in a wide 
range of radically crosslinked HA hydrogel systems, including injectable 
hydrogels for localized rTIMP-3 delivery. 
 Limitations:  While we showed comparable rTIMP-3 binding to sulfated 
HA macromers and heparin, the differences in sulfation pattern between the two 
polymers is likely to alter the library of proteins they bind13.  Therefore, further 
investigation into protein binding specificity of HEMA-SHA polymers is warranted.  
In addition, these hydrogels would be exposed to a wide-range of proteins in 
vivo, and binding endogenously expressed proteins could affect biological 
processes.  Therefore, demonstrating biocompatibility of injectable HEMA-SHA 
blended gels in vivo in the context of the intended therapeutic application is 
important.  Further, the high concentration of highly acidic sulfate groups on the 
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HEMA-SHA polymers could affect the viability of cells encapsulated in HEMA-
SHA blended hydrogels.  Therefore, cell viability studies in a range of HEMA-
HA/HEMA-SHA ratios is important towards cellular applications of these 
hydrogels.   
 
9.5. Specific Aim 5: Engineer injectable HA hydrogels with MMP sensitive 
degradation to allow for localized TIMP-3 delivery as a function of MMP 
expression within the MI region. 
 Conclusions:  In order to form HA hydrogels with MMP degradable 
crosslinks upon injection through a syringe, a two component, aldehyde (ALD) 
and hydrazide (HYD) macromer system was developed.  This system allowed for 
rapid crosslinking of stable hydrogels upon mixing ALD and HYD macromers, 
and limited passive rTIMP-3 release by incorporation of ALD functionalized 
dextran sulfate (DS) macromers for strong rTIMP-3 binding in the hydrogels.  In 
the presence of 20 nM rMMP-2, the hydrogels degraded over 14 days, releasing 
encapsulated rTIMP-3 in response to MMP-2.  However, hydrogels without 
encapsulated rTIMP-3 completely degraded in two days in 20 nM rMMP-2, 
indicating that the encapsulated rTIMP-3 remains active as it is bound in the 
hydrogel over the 14-day study as it attenuates MMP-mediated degradation.  
Regional injection of the hydrogel alone immediately following MI induction in 
pigs normalized MMP activity in the MI region to baseline values at 14 days post 
MI, potentially by acting as a sink for active MMPs as the MMP-degradable 
crosslinks were cleaved.  However, delivery of the hydrogel alone did not 
significantly attenuate LV remodeling as measured by LV wall thickness, LV end-
diastolic volume (LVEDV), pulmonary capillary wedge pressure (PCWP), and 
ejection fraction (EF).  Regional delivery of rTIMP-3 encapsulated in the 
hydrogels further reduced MMP activity within the MI region compared to 
hydrogel alone injections, and significantly attenuated LV remodeling as 
evidenced by significant increases in LV wall thickness, EF, and PCWP 
compared to MI only and hydrogel alone controls, and a significant decrease in 
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LVEDV compared to hydrogel alone controls.  Further, these beneficial effects on 
LV function were observed without an increase in systemic rTIMP-3 levels with 
gel/rTIMP-3 delivery to the heart.  We conclude that MMP-triggered release of 
rTIMP-3 with injectable MMP-degradable hydrogels is an effective strategy to 
attenuate adverse LV remodeling while avoiding systemic concentrations of MMP 
inhibitors.  
 Limitations:  While rTIMP-3 delivery from MMP degradable hydrogels 
significantly attenuated post MI remodeling, interstitial MMP activity was not 
significantly different with rTIMP-3 delivery compared to hydrogel delivery alone.  
Therefore additional studies are warranted to investigate other biological effects 
of rTIMP-3 as in Aim 3.  Further, as discussed in the limitations of Aim 3, 
delivering an MMP inhibitor very early following MI may prevent ECM turnover 
necessary for wound healing; therefore, additional studies are warranted to find 
an optimum window following MI for this therapeutic strategy.  In addition, 
delivery of this therapy immediately following MI may not be relevant to clinical 
scenarios of chronic MI.  Also, serial echocardiography measurements revealed 
progressive decline in LV function in all groups over the two week study, 
therefore longer term studies are warranted to see if therapeutic effects are 
maintained at later time points.  Finally, as demonstrated in Aim 3, injection of 
hydrogels alone has beneficial effects on post MI remodeling by bulking and 
mechanically supporting the myocardium.  Little effect was observed in this Aim 
with hydrogel injection alone; therefore, hydrogels that degrade to release 
encapsulated molecules may not be as optimal as they lose their mechanical 
properties over time.  
 
9.6.  Future Directions 
Based on the limitations of the studies performed in this dissertation, there 
are numerous avenues of future exploration related to HA hydrogels for the 
delivery of therapeutic proteins.   
For all Aims in which hydrogels were injected immediately following MI, 
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application of the hydrogel systems in chronic models of MI (injections weeks to 
months following MI induction) would lead to a better understanding of the 
therapeutic window available to deliver hydrogels and encapsulated proteins post 
MI.  In addition, percutaneous delivery of the hydrogels through catheter 
technologies would allow therapeutic application of the hydrogels and proteins in 
a larger population of patients where a thoracotomy is not part of the current 
clinical treatment.  Finally, different doses of encapsulated proteins (SDF-1! and 
TIMP-3) would identify optimal conditions for stimulating cell homing and MMP 
inhibition. 
  For SDF-1! delivery, animal models with labeled bone marrow would 
allow a more mechanistic understanding of the contribution of homed cells 
towards myocardial repair.  In addition, animal models with humanized bone 
marrow would better assess the therapeutic potential of sustained SDF-1! 
delivery in patients.   
For TIMP-3 delivery, longer therapeutic studies would better elucidate 
whether early MMP inhibition delays the progression of LV remodeling or 
permanently interrupts remodeling events.  Further, injectable hydrogels with 
peptide crosslinks that degrade at different rates could be explored to identify an 
optimal rate of MMP-triggered TIMP-3 release.  In addition, to maintain hydrogel 
bulking while delivering TIMP-3 on demand, inter-penetrating networks of an 
MMP degradable phase and a stable phase could be constructed. 
Finally, the hydrogels developed in this dissertation could be explored for 
the delivery of a wide range of therapeutic proteins and combinations thereof by 
simply mixing the reconstituted proteins with the hydrogel precursor solution.    
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